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KESAN VITAMIN D KE ATAS FUNGSI VASKULAR DAN TEKANAN 
OKSIDATIF SALUR DARAH KECIL DIABETES 
ABSTRAK 
 Diabetes menyumbang kepada komplikasi salur darah besar dan kecil lalu 
menyebabkan penyakit kardiovaskular. Kekurangan vitamin D berhubung kait dengan 
pembentukan komplikasi kardiovaskular diabetes. Kajian ini dibahagikan kepada dua 
bahagian, iaitu kajian haiwan dan kajian manusia. Kajian haiwan ini bertujuan untuk 
mengkaji (a) peranan kekurangan vitamin D ke atas fungsi lapisan endotelium dan otot 
licin salur darah kecil tikus normal dan diabetes; (b) kekurangan vitamin D ke atas 
perubahan dalam ekspresi enzim eNOS dan parameter tekanan oksidatif dalam tisu 
salur darah kecil; (c) sama ada pembekalan tambahan calcitriol secara oral dapat 
membaik pulih gangguan fungsi salur darah kecil tikus yang kekurangan vitamin D. 
Kajian manusia ini bertujuan untuk mengkaji peranan kekurangan vitamin D ke atas 
tahap tekanan oksidatif dalam tisu arteri subkutin pesakit kencing manis. Kajian 
haiwan: (a) Tikus normal dibahagikan kepada tiga kumpulan dengan 10 ekor tikus 
setiap kumpulan: (i) tikus normal yang dibekalkan makanan biasa selama 10 minggu 
(Kumpulan NC), (ii) tikus normal yang dibekalkan makanan yang kekurangan vitamin 
D selama 10 minggu (Kumpulan ND), (iii) tikus normal yang dibekalkan makanan 
yang kekurangan vitamin D selama 10 minggu, tambahan pula dengan pembekalan 
tambahan calcitriol secara oral selama empat minggu, bermula dari minggu ketujuh 
(Kumpulan NDS). (b) Tikus diabetes aruhan streptozotosin dibahagikan kepada tiga 
kumpulan dengan 10 ekor tikus setiap kumpulan: (i) tikus diabetes yang dibekalkan 
makanan biasa selama 10 minggu (Kumpulan DC), (ii) tikus diabetes yang dibekalkan 
makanan yang kekurangan vitamin D selama 10 minggu (Kumpulan DD), (iii) tikus 
 xx 
diabetes yang dibekalkan makanan yang kekurangan vitamin D selama 10 minggu, 
tambahan pula dengan pembekalan tambahan calcitriol secara oral selama empat 
minggu, bermula dari minggu ketujuh sejak aruhan diabetes (Kumpulan DDS). 
Selepas 10 minggu, tikus dimatikan lalu arteri mesenterika diasingkan untuk 
menjalankan kajian fungsi vaskular dengan menggunakan miograf dawai. Ekspresi 
protein eNOS dalam tisu arteri mesenterika ditentukan dengan menjalankan 
pemblotan Barat. Imunohistokimia dijalankan untuk mengesan kehadiran dan 
penempatan enzim eNOS dalam arteri mesenterika tikus. Tahap penanda biologi MDA 
dan SOD dalam tisu arteri mesenterika, gula darah berpuasa (FBG), tahap vitamin D 
dan kalsium dalam darah turut diukur. Kajian manusia: Pesakit kencing manis 
dikategorikan kepada dua kumpulan mengikut tahap vitamin D: (i) pesakit kencing 
manis yang tidak mengalami kekurangan vitamin D (Kumpulan DNP, n = 10) dan (ii) 
pesakit kencing manis yang mengalami kekurangan vitamin D (Kumpulan DDP, n = 
13). Tahap penanda biologi MDA dan SOD dalam tisu arteri subkutin pesakit diukur. 
Hasil kajian haiwan: (a) Tikus normal. Pengembangan berperantara-endotelium 
kepada acetilkolin (ACh) telah dilemahkan secara ketara dalam arteri mesenterika 
daripada Kumpulan ND. Pengurangan tahap penanda biologi SOD dan ekspresi 
protein eNOS turut dijumpai dalam Kumpulan ND. Namun begitu, pembekalan 
tambahan calcitriol tidak menunjukkan peningkatan yang ketara dalam parameter 
tersebut. Pengecutan berperantara-endotelium kepada kalsium ionofor (CaI) 
dipertingkatkan secara ketara dalam arteri mesenterika daripada Kumpulan NDS. 
Peningkatan tahap kalsium turut dijumpai dalam Kumpulan NDS. (b) Tikus diabetes. 
Pengembangan berperantara-endotelium aruhan-ACh telah dilemahkan secara ketara 
dalam arteri mesenterika daripada Kumpulan DD. Pengurangan tahap penanda biologi 
SOD dan ekspresi protein eNOS, dan peningkatan tahap penanda biologi MDA turut 
 xxi 
dijumpai dalam Kumpulan DD. Kerosakan ini telah berjaya dibaik pulih oleh 
pembekalan tambahan calcitriol. Peningkatan pengecutan berperantara-endotelium 
aruhan-CaI dan pengurangan pengembangan tidak berperantara-endotelium kepada 
natrium nitroprusid (SNP) dijumpai dalam Kumpulan DD. Namun begitu, pembekalan 
tambahan calcitriol tidak dapat membaik pulih kerosakan tersebut. Pengembangan 
tidak berperantara-endotelium kepada salbutamol (SB) dan pengecutan kepada 
phenylephrine (PE) dan juga parameter umum seperti perubahan berat badan dan tahap 
FBG tidak menunjukkan perbezaan dalam semua kumpulan kajian yang melibatkan 
tikus normal dan diabetes. Hasil kajian manusia: Peningkatan tahap MDA yang 
ketara dijumpai dalam tisu arteri subkutin daripada Kumpulan DDP. Namun begitu, 
tahap penanda biologi SOD dalam Kumpulan DDP menunjukkan trend berkurangan 
(p = 0.072) berbanding dengan Kumpulan DNP. Kesimpulannya, kajian ini 
menunjukkan keadaan kekurangan vitamin D telah melemahkan fungsi lapisan 
endotelium salur darah kecil tikus biasa dan juga tikus diabetes. Kerosakan tersebut 
berkemungkinan disebabkan oleh pengurangan penglibatan nitrik oksida yang 
berhubung kait dengan kekurangan ekspresi protein eNOS dan peningkatan tekanan 
oksidatif. Kekurangan vitamin D pada tikus diabetes turut melemahkan fungsi lapisan 
otot licin salur darah kecil. Kajian ini juga menunjukkan pembekalan tambahan 
calcitriol kepada tikus diabetes yang kekurangan vitamin D membaik pulih 
pengembangan berperantara-endotelium dengan meningkatkan ekspresi protein eNOS 
dan menambah baik status tekanan oksidatif. Pembekalan tambahan calcitriol kepada 
tikus biasa yang kekurangan vitamin D meningkatkan tahap kalsium lalu 
menyebabkan peningkatan pengecutan berperantara-endotelium. Di samping itu, 
kekurangan vitamin D pada pesakit kencing manis turut menunjukkan peningkatan 
tahap tekanan oksidatif.  
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EFFECTS OF VITAMIN D ON VASCULAR FUNCTION AND OXIDATIVE 
STRESS IN THE MICROCIRCULATION OF DIABETICS 
ABSTRACT 
Diabetes mellitus contributes to macro- and microvascular complications, 
leading to adverse cardiovascular events. Vitamin D deficiency is associated with the 
development of diabetes-related cardiovascular complications. This study was divided 
into two parts: (i) animal study and (ii) human study. This animal study aims to 
determine the effects of vitamin D deficiency on (a) microvascular endothelial and 
smooth muscle functions in normal and diabetic rats; (b) the changes to endothelial 
nitric oxide synthase (eNOS) protein expression and oxidative stress parameters in 
mesenteric arterial tissue of normal and diabetic rats; (c) to study whether oral 
calcitriol supplementation is able to ameliorate microvascular dysfunction in vitamin 
D-deficient rats. This human study aims to evaluate the effects of vitamin D deficiency 
on oxidative stress status in subcutaneous arteries of diabetic patients. Animal study: 
(a) Male Sprague-Dawley (SD) rats were subdivided into three equal groups of 10 rats 
each: (i) rats receiving 10-weeks of normal diet (Group NC), (ii) rats receiving 10-
weeks of vitamin D-deficient diet (Group ND) and (iii) rats receiving 10-weeks of 
vitamin D-deficient diet with four weeks of oral calcitriol supplementation, starting 
from week 7 (Groups NDS). (b) Streptozotocin-induced diabetic male SD rats were 
subdivided into three equal groups of 10 rats each: (i) diabetic rats receiving 10-weeks 
of normal diet (Group DC), (ii) diabetic rats receiving 10-weeks of vitamin D-deficient 
diet (Group DD) and (iii) diabetic rats receiving 10-weeks of vitamin D-deficient diet 
with four weeks of oral calcitriol supplementation, starting from week 7 of diabetes 
induction (Groups DDS). At the end of 10 weeks, all rats were sacrificed. Rats’ 
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mesenteric arteries were isolated and dissected to undergo vascular function studies 
using wire myograph. Protein expression of eNOS in mesenteric arterial tissue was 
determined using Western blot. Immunohistochemistry was used to detect the 
presence and localization of eNOS in mesenteric arteries. Superoxide dismutase 
(SOD) and malondialdehyde (MDA) levels in mesenteric arterial tissue; fasting blood 
glucose (FBG), serum 25(OH)D and calcium levels in blood were also measured. 
Human study: Diabetic patients were categorised into two groups based on serum 
25(OH)D levels: (i) vitamin D non-deficient diabetic patients (Group DNP, n = 10) 
and (ii) vitamin D-deficient diabetic patients (Group DDP, n = 13). The levels of SOD 
and MDA in subcutaneous arterial tissue were measured. Results of animal study: 
(a) Normal rats. Endothelium-dependent relaxation to acetylcholine (ACh) was 
significantly attenuated in mesenteric arteries of vitamin D-deficient rats. Reduced 
SOD levels and protein expression of eNOS were observed in vitamin D-deficient rats. 
However, calcitriol supplementation showed no significant improvement in these 
parameters. Endothelium-dependent contraction to calcium ionophore (CaI) was 
augmented in vitamin D-deficient rats receiving calcitriol supplementation. Increased 
calcium levels were also found in calcitriol-supplemented vitamin D-deficient rats. (b) 
Diabetic rats. ACh-induced endothelium-dependent relaxation was significantly 
impaired in mesenteric arteries of vitamin D-deficient diabetic rats. Reduced SOD 
levels and protein expression of eNOS and enhanced MDA levels were found in 
vitamin D-deficient diabetic rats. These impairments were successfully ameliorated by 
calcitriol supplementation. Augmented CaI-induced endothelium-dependent 
contraction and impaired sodium nitroprusside (SNP)-induced endothelium-
independent relaxation occurred in vitamin D-deficient diabetic rats. However, 
calcitriol supplementation failed to show improvement in these vascular responses. 
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There were no significant differences in endothelium-independent relaxation to 
salbutamol (SB) and contraction to phenylephrine (PE) as well as in general 
parameters such as body weight changes and FBG levels between study groups in both 
normal and diabetic rats. Results of human study: Markedly augmented MDA levels 
were found in subcutaneous arterial tissues of vitamin D-deficient diabetic patients. 
However, SOD levels in vitamin D-deficient diabetic patients showed the reduced 
trend (p = 0.072) compared to vitamin D non-deficient diabetic patients. In conclusion, 
this study demonstrated that vitamin D deficiency attenuates microvascular 
endothelial function in both normal and diabetic rats. The impairment for endothelial 
function was likely due to the diminished nitric oxide contribution, associated with 
reduced eNOS protein expression and augmented oxidative stress. Vitamin D 
deficiency in diabetic rats also impairs vascular smooth muscle function. The study 
also showed that calcitriol supplementation to diabetic rats with vitamin D deficiency 
improves endothelium-mediated vasodilation, by upregulating eNOS expression and 
improving oxidative stress status. However, calcitriol supplementation to normal rats 
with vitamin D deficiency induces hypercalcaemia, leading to augmented 
endothelium-dependent contraction. Besides that, vitamin D deficiency in diabetic 






1.1 Background of the Study 
Diabetes mellitus (DM) is characterised by chronic hyperglycaemia resulting 
from defective insulin secretion and/or insulin action (Maritim et al., 2003). In recent 
years, DM is a major threat gaining global concern for its epidemic proportion. The 
global prevalence of DM has increased tremendously for the past decade; from 285 
million (6.6%) in year 2010 to 463 million (9.3%) in year 2019. This figure is predicted 
to exceed 700 million (10.6%) by year 2045 as predicted by International Diabetes 
Federation (IDF, 2019). The national prevalence of DM in Malaysia has increased 
from 15.2% in year 2011 to 18.3% (with 3.6 million reported cases of diabetes) in year 
2019 (Ministry of Health Malaysia, 2011; Ministry of Health Malaysia, 2019). 
National Health and Morbidity Survey (NHMS) has predicted that diabetic patients in 
Malaysia would increase to 7 million (31.3%) by year 2025 (Ministry of Health 
Malaysia, 2019). 
The chronic nature of DM requires long-term monitoring to minimise related 
secondary complications. Hence, the management of DM constitutes an ever-
increasing proportion of global as well as Malaysia national healthcare budgets. In 
year 2019, the global annual diabetes treatment cost constituted USD 760 billion, 
which was equivalent to 10% of global health expenditure. The cost is expected to 
reach USD 845 billion by year 2045 (IDF, 2019). In Malaysia, the annual expenditure 




Health Malaysia, 2015). The economic burden brought by this pandemic disease could 
undermine the development and advancement of the nation worldwide. 
In year 2017, World Health Organization reported that DM ranks seventh in 
the world top ten leading causes of death (WHO, 2017). IDF also indicated that DM 
constitutes 11.3% of global all-cause mortality, causing 4.2 million deaths globally in 
year 2019 (IDF, 2019). Cardiovascular diseases (CVD) were reported to be the major 
contributor to morbidity and mortality in diabetic patients (Bate and Jerums, 2003); 
approximately 65-75% of diabetic deaths were attributed to CVD (Moss et al., 1991; 
Geiss et al., 1995; Shi and Vanhoutte, 2009). The condition of elevated blood glucose 
levels over a prolonged period exposes diabetic individuals to a significant risk of 
secondary cardiovascular complications, leading to a two to four-fold increased risk 
of developing CVD. Hence, the prevention of these diabetes-related cardiovascular 
complications, occurring at the micro- and macrocirculation, will be effective means 
in the management of DM (Bate and Jerums, 2003). 
Low vitamin D levels have been suggested as one of the risk factors in the 
development of DM and also adverse cardiovascular events.  Low vitamin D levels 
decrease pancreatic insulin release, underscore insulin resistance, impair insulin 
sensitivity, deteriorate glucose tolerance, and accelerate coronary calcification, 
leading to DM and CVD (Zittermann et al., 2007; Holick, 2007; Nemerovski et al., 
2009). Lower vitamin D levels were associated with a 40% higher risk of developing 
DM in women, whereas individuals that developed DM had lower levels of vitamin D 
compared to non-diabetics (Scragg et al., 2004; Di Cesar et al., 2006). Similarly, the 
incidences of CVD were doubled in individuals with vitamin D deficiency, indicating 




vitamin D levels (Wang et al., 2008). Reduced vitamin D levels were also observed in 
subjects with CVD such as myocardial infarction, stroke, peripheral arterial disease 
and cerebrovascular deaths (Lee et al., 2008; Kendrick et al., 2009). 
Since low vitamin D levels bring adverse impacts to human health, the 
widespread problem of vitamin D deficiency is now raising global attention (Holick, 
2007; Lips, 2010). Approximately 40-50% of individuals in Western societies with 
seasonal changes have vitamin D insufficiency (Lips, 2010; Parva et al., 2018). It is 
astonishing to discover that this public health issue is also common in tropical 
countries such as Singapore and Malaysia, where plentiful sunshine is available all 
year long. Literature reported that 30.0% to 48.0% of men in Singapore (Hawkins, 
2013) and 15.5% to 32.7% of men in Malaysia (Chin et al., 2014) were having vitamin 
D deficiency. The prevalence appears to be more pronounced in the diabetic 
population (Scragg et al., 2004; Di Cesar et al., 2006), which were reported to be 
91.1% in India (Daga et al., 2012), 73.6% in Saudi Arabia (Al-Othman et al., 2012) 
and 43.0% in Malaysia (Munisamy et al., 2016). 
Vitamin D deficiency is closely associated with endothelial dysfunction. Some 
in vivo studies have discovered that normal and diabetic patients with vitamin D 
deficiency had lower flow-mediated dilation (FMD), which is the standard indicator 
of endothelial dysfunction (Yiu et al., 2013; Malik et al., 2016). Endothelial 
dysfunction predisposes to a higher risk of diabetes-associated cardiovascular 
complications that leads to the development of CVD. Hence, endothelial dysfunction 
is an independent precursor of early atherosclerotic development and a prognosis of 




is not only limited to the macrocirculation, but also occurs in the microcirculation of a 
variety of vascular beds before the onset of atherosclerosis (Abularrage et al., 2005). 
Apart from that, low vitamin D levels have also been reported to induce 
oxidative stress in both normal and diabetic models (Tarcin et al., 2009; Efterkhari et 
al., 2014; Foroozanfard et al., 2015). Chronic hyperglycaemia coupled with low 
vitamin D levels in diabetics predisposes to augmented vascular oxidative stress 
levels (Halliwell and Gutteridge, 2007). Enhanced oxidative stress levels are due to 
the disruption in the homeostasis between the generation of reactive oxygen species 
(ROS) and the effectiveness of antioxidant defence system to scavenge them. 
Consequently, augmented oxidative stress further propagates ROS generation that 
subsequently diminishes the antioxidant activities, leading to cardiovascular 
complications and CVD (Moussa, 2008). 
Vitamin D deficiency is involved in the development of diabetes-related 
secondary complications; improving the suboptimal vitamin D levels by 
supplementation may have favourable effects on vascular and oxidative stress 
parameters. In randomised control trials, vitamin D supplementation showed 
improvement in brachial artery FMD in normal and diabetic patients with vitamin D 
deficiency (Sugden et al., 2008; Harris et al., 2011). Oxidative stress parameters in 
normal and diabetic subjects with vitamin D deficiency also improved by vitamin D 
supplementation (Tarcin et al., 2009; Shab-Bidar et al., 2015). 
1.2 Rationale of the Study 
The health issue of vitamin D insufficiency and deficiency is highly prevalent 




of cardiovascular complications, particularly in the diabetic population, there is an 
urgency to study the possible underlying pathology of low vitamin D levels in the 
development of diabetes-related cardiovascular complications. 
Endothelial dysfunction is an important prognostic marker for cardiovascular 
complications; hence the assessment of endothelial function is a useful measure 
commonly used in vascular function study. To our best knowledge, the evidence on 
the effects of vitamin D deficiency is limited to the study performed on the diabetes 
macrocirculation, yet the effects in the microcirculation of diabetics remain poorly 
understood. Since microcirculation is the initial site where the early manifestation of 
vascular dysfunction can be noticed before macrovascular dysfunction, conducting a 
study on endothelial function in the microcirculation of vitamin D-deficient diabetics 
allows early assessment of vascular functional abnormalities.  
Based on this rationale, the present study was designed to investigate the effects 
of vitamin D deficiency on microvascular function, which consisted of endothelial and 
smooth muscle responses, in normal and streptozotocin (STZ)-induced diabetic rats. 
This study also assessed whether the vascular functional abnormalities attributed to 
vitamin D deficiency involved alterations in the protein expression and localization of 
endothelial nitric oxide synthase (eNOS) in the microvascular tissue of rats with 
vitamin D deficiency. eNOS is the enzyme involved in the synthesis of nitric oxide 
(NO), the major endothelium-derived relaxing factor. 
To date, there is no related information available on the effects of vitamin D 
deficiency on oxidative stress status in the microcirculation of diabetics as a possible 
mechanism accounting for microvascular dysfunction. Hence, this consideration leads 




dismutase (SOD, an antioxidant enzyme) and malondialdehyde (MDA, the product of 
lipid peroxidation) in the microvascular tissue of normal and diabetic rats with 
different vitamin D status. This study also investigated the potential of calcitriol 
supplementation to reverse or alleviate the adverse effects attributed to low vitamin D 
levels on microvascular function and microvascular tissue oxidative stress levels. 
Calcitriol is the active metabolite of vitamin D, which does not need to undergo 
hydroxylation processes in the liver and kidney for the conversion, plays its 
physiological roles as a hormone by binding to the receptors.  
Unfortunately, insufficient human tissue samples and the difficulties faced in 
obtaining viable tissue samples do not allow the present study to look into the effects 
of vitamin D deficiency on vascular function in the microcirculation of diabetic 
patients. However, this study was able to investigate the effects of vitamin D 
deficiency on the levels of oxidative stress parameters in microvascular tissue of 
diabetic patients to assess if there are similarities in the findings of microvascular 
tissue oxidative stress parameters between animal and human diabetic models. 
The findings could provide a better understanding of the effects of vitamin D 
deficiency on microvascular function and oxidative stress status in normal and diabetic 
models. This study could also suggest the possible contributing factors leading to 
microvascular dysfunction in vitamin D-deficient diabetic models. The potential of 
vitamin D supplementation in improving any impairment in microvascular function 
and oxidative stress status in vitamin D-deficient diabetic rats was also studied. These 
may help in combating microvascular complications that predispose to a significant 
cardiovascular risk in diabetics and facilitate the development of effective therapeutic 




1.3 Objectives of the Study 
General Objectives: 
Animal Study: To investigate the effects of vitamin D deficiency on vascular function 
and tissue oxidative stress levels in the microcirculation of normal and diabetic rats. 
Human Study: To examine the effects of vitamin D deficiency on tissue oxidative 
stress levels in the microcirculation of diabetic patients. 
Specific Objectives: 
1. To investigate the effects of vitamin D deficiency on microvascular 
endothelium-dependent and independent relaxing and contracting abilities in 
mesenteric arteries of normal and STZ-induced diabetic rats. 
2. To examine the effects of vitamin D deficiency on oxidative stress parameters 
(MDA and SOD) in mesenteric arterial tissue of normal and STZ-induced 
diabetic rats. 
3. To study the alterations in the protein expression and localization of eNOS in 
mesenteric arteries of vitamin D-deficient normal and diabetic rats. 
4. To evaluate any reversibility in microvascular function and oxidative stress 
levels with vitamin D supplementation among vitamin D-deficient rats. 
5. To determine the effects of vitamin D deficiency on oxidative stress parameters 




CHAPTER 2  
LITERATURE REVIEW 
2.1 Diabetes Mellitus 
2.1.1 Definition and Classification 
Diabetes mellitus (DM) is a metabolic disorder manifested by elevated blood 
glucose levels. This metabolic disorder is due to the failure of the body to produce or 
respond to insulin (American Diabetes Association, 2008), resulting in abnormal 
metabolism of carbohydrate, protein and fat (Shi and Vanhoutte, 2009). There are three 
major types of DM according to different underlying aetiologies. 
Type 1 diabetes mellitus (T1DM), which is also known as insulin-dependent 
DM, is a diabetic condition associated with absolute insulin deficiency. It is due to the 
autoimmune destruction of pancreatic β-cells that disrupts the ability of the pancreas 
for insulin synthesis, thus leading to insufficient insulin production for glucose 
metabolism. T1DM only accounts for about 5 to 10% of all DM cases, commonly 
diagnosed during childhood and adolescence (American Diabetes Association, 2008). 
Although the actual causes of T1DM remain unknown, the researcher suggested that 
genetic and environmental factors might be the possible causes (Aathira and Jain, 
2014). 
Type 2 diabetes mellitus (T2DM), which is also known as non-insulin 
dependent DM, is initially associated with insulin resistance, progressively leading to 
insulin deficiency. At the insulin resistance stage, the targeted cell is unable to produce 




the receptor. Hence, more insulin to be produced to compensate for insulin resistance. 
Progressively, the amounts of insulin are deficient in meeting further cellular 
requirements, which is known as relative insulin deficiency, predisposing to the onset 
of hyperglycaemia. At last, the condition of hyperglycaemia further damages the 
pancreatic β-cells, resulting in absolute insulin deficiency (Pratley, 2013). T2DM 
constitutes nearly 90% of the diabetic population (American Diabetes Association, 
2008). 
Gestational diabetes mellitus (GDM) is a glucose intolerance disorder with first 
recognition during pregnancy. Insulin-blocking hormones produced by the placenta in 
pregnant women lead to high blood glucose levels in their body in variable severity. 
Women affected with gestational diabetes have a seven-fold increased risk of 
developing T2DM in the few years following initial diagnosis. Their children are also 
prone to develop T2DM early in life (Bellamy et al., 2009; Rayanagoudar et al., 2016). 
2.1.2 Diagnosis, Symptoms and Medications 
Glycated haemoglobin (HbA1c) and fasting blood glucose (FBG) tests are 
among the most common tests used to diagnose DM. HbA1c indicates the average 
blood glucose levels for the past three months while FBG indicates the blood glucose 
levels after overnight fasting. HbA1c levels of 6.5% or higher and FBG levels of 7.0 
mmol/L and above is diagnosed as DM (IDF, 2017). 
Besides conducting a specific test for DM diagnosis, recognising noticeable 
diabetic symptoms is also essential to catch DM at an early stage. Frequent urination, 
excessive thirst, increased appetite, unusual fatigue, sudden weight loss, nausea, 




with diagnosed DM. Undiagnosed and untreated DM could lead to the development 
of severe vascular complications and even premature death (IDF, 2017). 
Oral medication and/or insulin therapy sometimes are required, especially 
when a strict diet and exercise plan is unable to keep the condition of hyperglycaemia 
in diabetics under control. Biguanides (metformin) is prescribed for T2DM as first-
line treatment to lower glucose generation and improve the body’s sensitivity to 
insulin. Sulfonylureas (gliclazide, glimepiride) and meglitinides (repaglinide, 
nateglinide) stimulate the body to secrete more insulin. Insulin therapy is normally the 
last resort if glycaemic goals in T2DM patients are not met (Ministry of Health 
Malaysia, 2011). 
2.1.3 Diabetes-related Vascular Complications 
The condition of chronic hyperglycaemia in DM gradually leads to the 
complications of diabetic vasculopathy that damage many organs in a vascular system. 
The complications of diabetic vasculopathy are commonly grouped into 
macrovascular and microvascular complications. Macrovascular complications 
include coronary vascular disease, cerebrovascular disease and peripheral vascular 
disease while microvascular complications comprise of diabetic nephropathy (kidney 
damage), diabetic neuropathy (nerve damage) and diabetic retinopathy (eye damage) 
(Forbes and Cooper, 2013). 
The management of these complications is cost and time consuming, not only 
to the patients and families but also to the health authorities and the nation. Without 




cardiovascular events. CVD contribute to morbidity and mortality in diabetics, leaving 
them with diminished life quality and reduced life expectancy (Szerafin et al., 2006). 
2.2 Vascular System 
The vascular system plays a prominent role in delivering vital nutrients, 
hormones and oxygen to body cells as well as removing metabolic wastes from all 
parts of the body to maintain cellular homeostasis. There are three major types of blood 
vessels in the vascular system; namely arteries, veins and capillaries. Arteries carry 
oxygenated blood away from the heart to other parts of the body, while veins return 
deoxygenated blood collected from other parts of the body to the heart. Capillaries are 
the interchange medium that facilitates the exchange of materials between blood and 
tissues (Pugsley and Tabrizchi, 2000). 
Artery and vein are slightly different in specific characteristics to serve their 
particular functions as peripheral resistance and capacitance blood vessels 
respectively. An artery has a thicker wall to withstand a higher blood pressure whereas 
a vein has a bigger lumen to accommodate a higher blood volume. However, both 
vessels exhibit a similar general structure. Their vessel walls consist of three distinct 
layers; tunica adventitia, tunica media and tunica intima. The outermost layer, tunica 
adventitia consists of collagen fibres and connective tissues, interlaced with the vasa 
vasorum and nervi vasorum. Tunica media as the middle layer composes of vascular 
smooth muscle cells (VSMC) and circularly arranged elastic fibres. It is separated from 
tunica adventitia and tunica intima respectively by the external and internal elastic 




single layer of endothelial cells (EC) surrounded by a thin layer of subendothelial 
connective tissue that lines the lumen (Figure 2.1). 
Figure 2.1 Structure of the blood vessel. 
 
2.2.1  Microcirculation 
The microcirculation refers to the blood circulation in the microvasculature 
present within the organ tissues. Microvasculature composes of a branching network 
of microvessels classified as arterioles (10-100 µm), capillaries (5-8 µm) and venules 
(10-200 µm). Arterioles carry oxygenated blood to the capillaries, and the blood flows 
out of the capillaries into the venules. The vital function of microcirculation is to 
supply adequate tissue perfusion with nutrients and oxygen in response to demand 





Small arteries in microcirculation are responsible for providing tissue 
perfusion to the peripheral organs according to their metabolic demand (Christensen 
and Mulvany, 2001; Gutterman et al., 2016). Thus, small arteries adapt their diameter 
via vasoconstriction or vasodilation to regulate blood flow to the peripheral organ. 
This specific functional property makes small arteries important in the regulation of 
overall peripheral resistance to blood flow, which accounts for 70-90% of the systemic 
arterial pressure (DeLano et al., 1991; Christensen and Mulvany, 2001; Levy et al., 
2001). 
Since the microcirculation is an important site to investigate vascular health 
(Mulvany and Aalkjaer, 1990), assessing structural and functional changes in the 
microcirculation, particularly in small arteries, has become an area of interest for 
studies involving a variety of pathological states, such as DM, obesity and 
hypertension (Levy et al., 2001; Dokken, 2008; Al-Tahami et al., 2011). In the present 
study, small mesenteric arteries in normal and diabetic rats were used as the resistance 
artery to study microvascular function. This artery has been suggested as a potential 
representative artery to study microvascular function that may herald the development 
of CVD at an early stage (Rizzoni et al., 2001; Ang et al., 2002; Abularrage et al., 
2005; Georgescu et al., 2011; Yiu et al., 2013). 
2.3 Vascular Function 
The vascular system plays an important function in regulating vascular tone to 
provide organ and tissue with the optimum perfusion of nutrient and oxygen for 
maintaining vascular health. EC and VSMC are the main components in playing this 




factors for vasoconstriction and vasorelaxation. These factors diffuse to the underlying 
VSMC for an appropriate response (Furchgott and Zawadzki, 1980). 
2.3.1 Endothelial Function 
The endothelium is a single layer of EC lining the interior surface of blood 
vessels and cardiac valves in the entire vascular system. Besides acting as a physical 
barrier that separates the circulating blood in the lumen from the underlying VSMC in 
the vessel walls, EC also regulate the passage of materials into and away from the 
bloodstream (Verma and Anderson, 2002; Galley and Webster, 2004; Rajendran et al., 
2013). In addition, EC also involved in regulating cell growth and proliferation, 
modulating inflammatory responses and platelet activation, controlling leukocyte 
adhesion and thrombosis, modulating local vascular homeostasis, as well as exhibiting 
anti-thrombotic activities (Kuvin and Karas, 2003). 
Healthy and intact EC produce and release endothelium-derived relaxing 
factors (EDRF) and endothelium-derived contracting factors (EDCF) to regulate 
vasodilation and vasoconstriction respectively. In general, EDRF comprise of nitric 
oxide, prostacyclin and endothelium-derived hyperpolarizing factor while EDCF 
consist of endothelin I, angiotensin II and thromboxane A2 (Furchgott and Vanhoutte, 
1989; Kuvin and Karas, 2003). 
 2.3.1(a) Endothelium-derived Relaxing Factors 
 2.3.1(a)(i) Nitric Oxide 
Nitric oxide (NO) is gaining interest owing to its tremendous biological and 




responsible for the vascular tone (Furchgott and Zawadzki, 1980; Moncada and Higgs, 
1993). NO is also an anti-atherogenic and anti-inflammatory molecule that suppresses 
key processes leading to atherosclerosis. NO inhibits platelet and leukocyte adhesion, 
VSMC proliferation and low-density lipoprotein (LDL) oxidation, as well as 
suppresses pro-inflammatory cytokines production and expression (Lloyd-Jones and 
Bloch, 1996; Rubbo and O’ Donnell, 2005). 
NO synthesis involves the enzymatic action of the nitric oxide synthase (NOS) 
isozymes (Tousoulis et al., 2012). These isozymes vary in their structures and 
functions. They are identified as neuronal NOS (nNOS), inducible NOS (iNOS) and 
endothelial NOS (eNOS). nNOS is expressed primarily in neurons, iNOS is expressed 
in macrophages, neutrophils, platelets, and VSMC, as well as in non-vascular cells; 
and eNOS is expressed in endothelial cells (Boettger et al., 2007). Since there is a large 
difference in the amount generated by these isozymes, nNOS and eNOS are more 
critical for normal physiology, whereas iNOS is associated with injury (Kaszkin et al., 
2004). 
Chemical stimuli such as acetylcholine, bradykinin and thrombin or physical 
stimulus trigger the eNOS activity in an intact vascular endothelium. The stimulation 
invokes the increase in intracellular calcium ion (Ca2+) concentrations, causes 
structural changes of calmodulin in the cell cytoplasm, which allows the binding of 
eNOS for activation (Sandoo et al., 2010). eNOS catalyses the formation of NO (main 
product) and L-citrulline (by-product) from amino acid L-arginine, in the presence of 
co-substrates and cofactors. Co-substrates comprise of nicotinamide adenine 
dinucleotide phosphate (NADPH) and molecular oxygen (O2) while cofactors consist 




dinucleotide (FAD) (Sandoo et al., 2010). Synthesised NO diffuses across EC to the 
underlying VSMC.  NO binds to soluble guanylyl cyclase to activate the conversion 
of guanosine triphosphate (GTP) to the second messenger, cyclic guanosine 
monophosphate (cGMP). Increased intracellular cGMP levels activate protein kinase 
G (PKG) that involved in several mechanisms for vasodilation. 
Activated PKG stimulates myosin light chain kinase (MLCK) that 
dephosphorylates myosin, preventing its binding to actin for vasodilation. The 
activation of PKG also triggers the opening of large conductance calcium-activated 
potassium channels in VSMC (Nelson and Quayle, 1995), causing membrane 
hyperpolarization and the closure of voltage-dependent calcium channels, thus 
decreasing Ca2+ influx to VSMC (Fukao et al., 1999). Besides that, activated PKG 
promotes vasorelaxation via the phosphorylation of inositol-1,4,5-trisphosphate 
receptor (IP3R)-associated cGMP kinase substrate (IRAG) that inhibits the release of 
Ca2+ from the endoplasmic reticulum into the cytosol of VSMC (Schlossmann et al., 
2000). These mechanisms, commonly known as NO-mediated cGMP pathway, 
account for endothelium-dependent relaxation. 
Besides the involvement in cGMP-dependent protein kinase activation, NO 
also directly stimulates the sarcoplasmic/endoplasmic reticulum calcium ATPase 
(SERCA) in VSMC to facilitate the restoration of cytosolic Ca2+ into sarcoplasmic 
reticulum and reduce Ca2+ release from the sarcoplasmic reticulum (Lincoln and 
Cornwell, 1991). Hence, this cGMP-independent signalling pathway reduces the 




 2.3.1(a)(ii) Prostacyclin 
Prostacyclin (PGI2) is a major prostanoid produced by EC that contributes to 
vasorelaxation. In healthy individuals, prostacyclin acts similarly as NO in the 
prevention of platelet aggregation and regulation of vasodilation (de Nucci et al., 1988; 
Mitchell et al., 2008). However, PGI2 may contribute to vasoconstriction instead of 
vasodilation under certain pathological conditions (Vanhoutte et al., 2009). 
Hormonal stimuli increase the intracellular Ca2+ concentrations that trigger the 
enzymatic action of phospholipase A2 to release an intermediate arachidonic acid from 
the endothelial phospholipids (Mitchell and Warner, 1999). Then, the enzymes 
cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) catalyse arachidonic acid 
to form prostaglandin H2 (PGH2). PGH2 acts as a precursor which leads to the 
production of other prostaglandins by their respective enzymes. PGI2 produced by 
prostacyclin synthase (PGIS) in EC, diffuses to the underlying VSMC to bind with 
prostacyclin receptor (IP) on the cell membrane for subsequent vasodilation (Mitchell 
and Warner, 2006). Activated IP stimulates the synthesis of cyclic adenosine 
monophosphate (cAMP) from adenosine triphosphate (ATP) in the presence of 
enzyme adenylyl cyclase. Increased cytosolic cAMP levels activate protein kinase A 
(PKA) that decreases the intracellular Ca2+ concentrations via several mechanisms, 
leading to vasorelaxation. Activated PKA similarly stimulates MLCK which prevents 
the binding of myosin to actin, thus promoting vasorelaxation (Somlyo and Somlyo, 
2003). 
Besides PGI2, another prostanoid known as thromboxane (TXA2) is also 




antagonists to maintain the homeostasis of vascular function. In contrast to PGI2, 
TXA2 promotes vasoconstriction and platelet aggregation. Under normal conditions, 
PGI2 counteracts the biological effects of TXA2 whereas their actions are reversed 
when blood vessels are severely damaged (Mitchell and Warner, 2006). 
 2.3.1(a)(iii) Endothelium-derived Hyperpolarizing Factor 
Endothelium-dependent hyperpolarization (EDH)-type responses cause 
vasorelaxation through classical and non-classical pathways by NO- and PGI2-
independent mechanisms (Feletou and Vanhoutte, 2009; Edwards et al., 2010). The 
classical EDH pathway requires the activation of endothelial small and intermediate 
conductance calcium-activated potassium channels and the hyperpolarization of the 
EC, subsequently leads to vasodilation. The non-classical EDH pathway requires the 
release of EDRF to activate potassium channels by increasing potassium ion (K+) 
conductance, evoking the hyperpolarization of the underlying VSMC that leads to 
vasodilation (Edwards et al., 2010). These factors, which are neither a COX derivative 
nor NO, have been generally termed as endothelium-derived hyperpolarizing factor 
(EDHF). 
This study aimed to determine the effects of vitamin D deficiency and 
supplementation on vascular responses involved EC and VSMC in small mesenteric 
arteries of normal and diabetic rats. Hence, the present study assessed endothelium-
dependent relaxation in general and endothelium-independent relaxation in both 
cGMP and cAMP pathways. Besides, this study also assessed endothelium-dependent 




Since NO is the primary vasodilator that contributes significantly to 
vasodilation over PGI2 and EDHF (Palmer et al., 1987; Furchgott and Vanhoutte, 
1989), any alteration in NO production and its activity indicates that endothelial 
dysfunction might occur. Hence, quantification of protein expression and localization 
of eNOS was also conducted in this study via Western blot and immunohistochemistry 
respectively, to demonstrate the possible underlying mechanisms related to endothelial 
dysfunction attributed to the impairment in NO production and action. 
2.4 Oxidative Stress 
Oxidative stress reflects an imbalance between the production of highly 
reactive species and the effectiveness of antioxidant defence system in our body 
(Betteridge, 2000). Highly reactive species comprises of reactive oxygen species 
(ROS) and reactive nitrogen species (RNS), which is subdivided into free radical or 
non-radical species. Free radicals are the chemical entities that contain unpaired 
electrons in an atomic orbital. In order to achieve stable electronic configuration, free 
radicals either act as an oxidant that tends to accept an electron from other molecules 
or a reductant that tends to donate an electron to other molecules (Cheeseman and 
Slater, 1993). Hence, they are relatively unstable and highly reactive with a short half-
life (Ullah et al., 2015). 
Superoxide anion (•O2-), peroxyl (•RO2), hydroxyl radical (•OH) and 
hydroperoxyl (•HRO2-) are free radical ROS whereas non-radical ROS includes 
hydrochlorous acid (HOCl) and hydrogen peroxide (H2O2). Free radical RNS 
comprises of nitric oxide (•NO) and nitrogen dioxide (•NO2-) while nitrous oxide 




RNS (Turko et al., 2001; Evans et al., 2002). The classification of highly reactive 
species is illustrated in Figure 2.2. 
 
Figure 2.2 Classification of highly reactive species. 
 (Adapted from Lee et al., 2018) 





2.4.1 Reactive Oxygen Species 
Reactive oxygen species (ROS) is generated by neutrophils and macrophages 
during the respiratory process to eliminate antigens. They are also generally produced 
as the by-product of aerobic metabolism (Miwa and Brand, 2003). A certain amount 
of ROS is necessary to exert a protective role in maintaining normal metabolic 
processes in our body. They serve as the mediator in signalling other physiological 
functions including vascular tone regulation, fibroblast proliferation, host defence, 
signal transduction and gene expression (Gomes et al., 2012). 
However, the uncontrolled generation of ROS stimulated by metabolic 
abnormalities is likely to bring deleterious effects to the human body. Thus, ROS 
needs to be sufficiently removed by the antioxidants to maintain cellular homeostasis 
(Valko et al., 2007). The inability of the antioxidant defence system to effectively 
scavenge the excess ROS and RNS contributes to oxidative stress (Halliwell and 
Gutteridge, 2007; Pandey et al., 2010). 
Oxidative stress has been proposed as one of the underlying factors in the 
pathogenesis of DM (Ceriello and Motz, 2004). Pancreatic islets of Langerhans are 
the main structure to regulate glucose metabolism, at which ß-cells account for 
insulin synthesis and secretion. However, pancreatic ß-cells have the lowest intrinsic 
antioxidant defence levels. Hence, they are more susceptible to oxidative stress. 
Excess ROS initially induces insulin resistance, progressively causes glucose 
intolerance and subsequently the loss of pancreatic ß-cell function, leading to the 




Besides the involvement in the pathogenesis of DM, ROS is also implicated 
in diabetes-related secondary complications (Lei and Marko, 2011). Chronic 
hyperglycaemia in DM induces mitochondrial overproduction of ROS, particularly 
in the endothelium of both large and small blood vessels (Wolff, 1993). Free radical 
ROS alters the antioxidant defence system by reducing the levels of enzymatic 
antioxidants and diminishing the activities of antioxidant enzymes, subsequently 
exacerbating the imbalance condition of oxidative stress (Maritim et al., 2003). This 
impairment makes the vascular cell and tissue more prone to oxidative damage, 
ultimately contributes to the risks of secondary vascular complications and hence 
adverse cardiovascular events (Giacco and Brownlee, 2010). 
“ROS” and “free radicals” are the terms frequently used interchangeably in 
the context of oxidative stress. Among these highly reactive species, •O2-, •OH and 
•NO have been widely addressed and actively involved in diabetes-induced 
cardiovascular complications (Johansen et al., 2005). •O2- which is produced by an 
electron reduction of molecular oxygen (O2) during oxygen metabolism (in both 
enzymatic and non-enzymatic pathways), initiates the free radical chain reactions. It 
pathologically modifies •NO (produced from L-arginine by NOS) into cytotoxic 
ONOO- (Guzik et al., 2002), causing the reduction in NO bioavailability. 
Subsequently, the role of NO in mediating vasorelaxation and its property of anti-
proliferation is altered, leading to endothelial dysfunction (Turko et al., 2001). 
Besides, •O2- also stimulates LDL oxidation. Oxidised LDL is subsequently taken up 
by the scavenger receptors of macrophages, leading to the formation of foam cell and 




During SOD-catalysed dismutation, •O2- is converted into H2O2 and O2. 
However, H2O2 is converted into •OH in the presence of transition elements such as 
copper and iron, further propagating the free radical chain reactions (Evans et al., 
2003). •OH is the most potent oxidant that attacks important macromolecules in the 
body, leading to homeostatic disruption and cellular oxidative damage (Lobo et al., 
2010). Oxidative damage comprises of cellular protein nitration, membrane lipid 
peroxidation and the damage to nucleic acids (McCord, 2000). The production and 
propagation of free radicals and its adverse impacts are illustrated in Figure 2.3. 
2.4.2 Antioxidant Defence System 
Antioxidant defence system involves endogenous and exogenous 
antioxidants, is important in scavenging the elevated amount of ROS and neutralising 
the toxicity arising from excess free radicals (Pham-Huy et al., 2008). Enzymatic 
endogenous antioxidants include superoxide dismutase, catalase and glutathione 
(peroxidase and reductase) while exogenous antioxidants can be acquired from diet 
and supplements. 
2.4.2(a) Enzymatic Endogenous Antioxidants 
•O2- and H2O2 are the potent ROS that initiate and propagate the free radical 
chain reactions, building up vascular oxidative stress that brings detrimental effects to 
our body system. Thus, ROS needs to be removed or converted into harmless 
molecules by antioxidants. 
2.4.2(a)(i) Catalase 




metabolises reactive H2O2 into molecular oxygen and water in lysosome (Johansen 
et al., 2005). Chronic hyperglycaemia in DM induces the excess generation of H2O2 
and downregulates the gene expression of CAT. In turn, reduced CAT gene 
expression decreases enzyme production. The inability of reduced CAT levels to 
effectively combat with excess H2O2 production leads to the accumulation of H2O2 
for subsequent free radical chain reactions that cause cellular injury. Reduced CAT 
levels have been reported in diabetic models in both human and animal studies 
(Hwang et al., 2012; Patel et al., 2013; Wang and Zhang, 2017). 
2.4.2(a)(ii) Glutathione (Peroxidase and Reductase) 
Glutathione exists in reduced (GSH) and oxidised (GSSG) states. In healthy 
cells and tissue, GSH constitutes more than 90% of the total glutathione. An increased 
ratio of GSSG to GSH is an indicative measure of cellular oxidative stress (Lu, 2013). 
 Glutathione peroxidase (GSH-Px) is another antioxidant enzyme that 
involved in H2O2 metabolism in mitochondria (Johansen et al., 2005). GSH-Px 
metabolises reactive H2O2 into molecular oxygen and water, and in turn converts 
GSH to GSSG. The oxidised state is converted back to the reduced state in the 
presence of glutathione reductase. Glutathione reductase is critical in maintaining the 
reducing environment of the cells in view that reduced glutathione is important in the 
regulation of the intracellular redox state of vascular cells (Deponte, 2013). Both 
enzymes act as the major defence in resisting vascular oxidative stress. Reduced 
GSH-Px expression and activity have been reported in diabetic human and animal 





2.4.2(a)(iii) Superoxide Dismutase 
Superoxide dismutase (SOD) is an important antioxidant enzyme that regulates 
oxidative stress in the pathogenesis of vascular complications (Wang et al., 2008). It 
acts as the first-line defender against free radicals to encounter oxidative stress and 
subsequently reduces cellular injury (Tiwari et al., 2013). The different forms of SOD, 
mitochondrial manganese superoxide dismutase (Mn-SOD) and cytosolic copper 
superoxide dismutase (Cu-SOD) catalyse the dismutation of •O2- into O2 and H2O2 
(Evans et al., 2003). The antioxidant defence mechanism is illustrated in Figure 2.3. 
Kim (2013) reported that diabetic skin tissue expressed relatively low levels 
of extracellular SOD, which might be due to the alterations in its metabolic state that 
elevate ROS production (Kim, 2013). In the same year, Lucchesi and colleagues also 
reported that diabetes-induced oxidative stress diminished the activity of SOD and 
other enzymatic antioxidants in the liver tissue of diabetic rats (Lucchesi et al., 2013). 
A similar outcome of diminished activity and reduced levels of SOD attributed to the 
altered metabolic state of DM also observed in diabetic organs and blood samples 
(Shukla et al., 2012; Kayama et al., 2015). 
In view that enzyme SOD can be the significant parameter that demonstrates 
the effectiveness of enzymatic antioxidants in combating diabetes-induced ROS and 
free radicals, SOD levels have been chosen as one of the parameters to assess 
oxidative stress status. SOD concentrations in the mesenteric arterial tissue of rats 
and subcutaneous arterial tissue of diabetic patients were measured using a 





Figure 2.3 Free radicals’ production and antioxidant defence mechanism. 
[SOD: superoxide dismutase; CAT: catalase; GSH: reduced glutathione; GSSG: oxidised glutathione; GSH-Px: glutathione peroxidase, NOS: 
nitric oxide synthase; O2: oxygen; •O2-: superoxide anion; •OH: hydroxyl radical; HOCL: hydrochlorous acid; H2O2: hydrogen peroxide; •NO: 





2.4.2(b) Exogenous Antioxidants 
Among non-enzymatic exogenous antioxidants, vitamin C and vitamin E are 
the classic antioxidant vitamins against oxidative stress to prevent diabetes-related 
vascular complications. These antioxidant vitamins either neutralise free radicals 
directly or interact in recycling processes to regenerate reduced forms of vitamins for 
further antioxidant actions in combating oxidative stress (Ayeleso et al., 2016). 
Vitamin E protects the vascular structural and functional components from 
oxidative damage by discontinuing a potentially destructive series of oxidative chain 
reactions (Ashor et al., 2015). Vitamin E prevents glucose-induced LDL oxidation by 
downregulating the protein expression of scavenger receptors. Hence, the uptake of 
oxidised LDL by macrophages is reduced, subsequently reducing foam cell and 
atherosclerotic plaque formed (Ricciarelli et al., 2000). The supplementation of 
vitamin E (alone or in combination with vitamin C) showed a significant improvement 
in plasma total antioxidant capacity and enzymatic antioxidant concentrations (Balbi 
et al., 2018). 
Vitamin C has the molecular structure to act as a reducing agent in free radical-
mediated oxidative processes. Vitamin C donates electrons to stabilise free radicals, 
efficiently preventing them from initiating a series of oxidative events (Zerin et al., 
2010). Apart from that, vitamin C neutralises the radical forms of other antioxidants 
to regain their antioxidant ability. Duarte and Lunec (2005) reported that the 
intervention using vitamin C did not show an impactful outcome as those using vitamin 
E (Duarte and Lunec, 2005). However, intervention using both vitamin C and E 




2.4.3 Oxidative Stress Biomarkers 
It is a major problem to perform direct measurement on oxidative stress levels 
as the reactions between free radicals and antioxidants occur almost instantaneously 
(Betteridge, 2000). Thus, the indirect way to evaluate oxidative stress levels can be 
performed through the measurement of observable biomarkers (Matough et al., 2012). 
Excess production of ROS can be determined by measuring the levels of products 
produced due to free radical-mediated oxidative damage. The effectiveness of the 
antioxidant defence system in combating elevated ROS can be determined by 
measuring the levels of enzymatic antioxidants. 
Among the oxidative damages, augmented lipid peroxidation is closely 
associated with high glycaemic and oxidative stress levels in DM (Bandeira et al., 
2012). The natural presence of multiple bonds in polyunsaturated fatty acids in the cell 
membrane makes them more susceptible to lipid peroxidation by free radicals. During 
lipid peroxidation, •RO2 alters the cellular lipid profile by removing hydrogen from 
lipids to produce •HRO2-, further propagating the free radical pathway (Lobo et al., 
2010). •HRO2- can either exert toxicity directly on the cells, or it can also be degraded 
to •OH, or to react with transition metals such as iron or copper to form a stable 
aldehyde, which consequently damages cell membranes (Halliwell and Chirico, 1993; 
Giacco and Brownlee, 2010). 
Malondialdehyde (MDA) is a stable aldehyde, typically studied with 
thiobarbituric acid reactive substances (TBARS) assay to measure the degree of lipid 
peroxidation in diabetic models (Lefevre et al., 1997; Shodehinde and Oboh, 2013). 




diabetics indicated that peroxidative injury has involved in the development of 
diabetes complications (Moussa, 2008; Bandeira et al., 2012). 
In view that MDA is the primary biomarker to evaluate lipid peroxidation in 
diabetics, MDA levels have been chosen as another parameter to assess oxidative 
stress status in this study. MDA concentrations in the mesenteric arterial tissue of rats 
and subcutaneous arterial tissue of diabetic patients were measured using a commercial 
assay kit. 
2.5 Vitamin D 
Vitamin D is well known for its classical role in promoting calcium and 
phosphorus absorption and suppressing parathyroid hormone (PTH) for mineral 
homeostasis and bone metabolism (Heaney, 2008). Vitamin D as well a potent 
steroidal hormone involved in multiple biological actions. Vitamin D binds to its 
widely distributed vitamin D receptors (VDR) to exert various physiological effects. 
VDR are abundantly discovered on various body cells and organs, including those that 
do not account for calcaemic action. Vitamin D has been reported to play an important 
role in maintaining vascular health such as regulation of vascular tone and 
inflammatory mediators, induction of cell differentiation, inhibition of cell growth and 
proliferation, and immunomodulation (Holick, 2003; Holick, 2007; Wacker and 
Holick, 2013), as well as express its antioxidant action (Wiseman, 1993; Lin et al., 
2005; Javanbakht et al., 2010; Nikooyeh et al., 2014; Shab-Bidar et al., 2015). 
2.5.1 Synthesis and Metabolism 
Vitamin D is well known as the sunshine vitamin. Cutaneous production under 




20% is obtained through dietary intake. The consumption of food rich in vitamin D 
especially from animal sources, such as fortified dairy products and animal fats, and 
also the ingestion of vitamin D supplements, are the alternatives to supply sufficient 
vitamin D to the human body (Holick, 2003). 
Ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3) are the two 
primary forms of vitamin D. They are chemically different from each other only in 
their side chains, at which ergocalciferol has a double bond formed between carbon 22 
and 23, and a methyl group at carbon 24. Ergocalciferol is synthesised by ultraviolet 
irradiation of plant sterols (ergosterol) and invertebrates. Cholecalciferol is produced 
endogenously when solar ultraviolet B radiation (280-320 nm) strikes human 
epidermis and stimulates the non-enzymatic photolytic conversion of pro-vitamin D 
(7-dehydrocholesterol) to pre-vitamin D, which then undergoes thermal isomerisation 
into vitamin D3 (Holick, 2003). Just like other lipid-soluble vitamins, vitamin D 
absorbed in the small intestines is conveyed into the blood circulation via the lacteal 
and the lymphatic system (Holick, 2007). 
Vitamin D is biologically inert and needs to be biologically activated via two 
hydroxylation processes in the body. In blood circulation, vitamin D binds to vitamin 
D-binding protein (DBP) and is then transported to the liver for the first hydroxylation 
process (Juzeniene et al., 2011). In the liver, hepatic cells transform vitamin D into the 
inactive precursor, 25-hydroxyvitamin D (25(OH)D or termed as calcidiol) in the 
presence of vitamin D 25-hydroxylase. 25(OH)D is then transported to the kidney via 
blood circulation for the second hydroxylation process. In the kidney, it is metabolised 
either intrarenally by 25(OH)D-1α-hydroxylase or intracellularly in a variety of cells 




1,25-dihydroxyvitamin D (1,25(OH)2D or termed as calcitriol) (Holick, 2007; 
Christakos et al., 2012). Calcitriol enters the bloodstream and circulates in the body, 
which is then bound to VDR of targeted cells, exerting genomic and/or rapid non-
genomic responses for many physiological actions (Geiss et al., 1995; Bate and 
Jerums, 2003). The chemical structures of calcidiol (25(OH)D) and calcitriol 
(1,25(OH)2D) are shown in Figure 2.4 while the process of vitamin D synthesis and 
metabolism is illustrated in Figure 2.5.  






Figure 2.5 Vitamin D synthesis and metabolism. 
 (Adapted from Lee et al., 2018)  
[UVB: ultraviolet B radiation; DBP: vitamin D-binding protein; 25(OH)D: 25-
hydroxyvitamin D; 1,25(OH)2D: 1,25-dihydroxyvitamin D; VDR: vitamin D 
receptor] 
 
2.5.2 Measurement of Vitamin D Levels 
Although 1,25(OH)2D is the biologically active metabolite of vitamin D, it 
does not serve as an ideal indicator to determine vitamin D levels. Indeed, the 
measurement of 25(OH)D levels is the most commonly used indicator to determine 
vitamin D levels in the body (Alshahrani and Aljohani, 2013). 25(OH)D has a longer 
circulating half-life of 15 days compared to 15 hours that 1,25(OH)2D has (Jones, 
2008). Hence, the concentrations of 25(OH)D are more stable and less fluctuate for 




amount of vitamin D (both by solar-activated cutaneous production and long period 
dietary intake) in human body as 25(OH)D is the primary circulating form of vitamin 
D in our body (Heaney, 2008). 
The levels of 1,25(OH)2D are regulated by parathyroid hormone depending 
on the calcium needs of the body (Zerwekh, 2008). Unless the condition of vitamin 
D deficiency is severe, 1,25(OH)2D concentrations are typically held constant 
through homeostatic regulation or may show elevation due to secondary 
hyperparathyroidism, in the condition of vitamin D deficiency (Holick, 2007). Hence, 
1,25(OH)2D concentrations do not reliably show the actual vitamin D levels in the 
body at that particular time.  Also, vitamin D supplementation more effectively raises 
the concentrations of 25(OH)D compared to 1,25(OH)2D (Trang et al., 1998). 
2.5.3 Classification of Vitamin D Status 
In general, vitamin D status in the body can be defined as vitamin D 
deficiency, insufficiency and sufficiency based on the measurement of serum 
25(OH)D levels. The Endocrine Society of USA defines vitamin D deficiency as 
serum 25(OH)D concentrations of less than 50 nmol/L while circulating serum 
25(OH)D levels between 50–74 nmol/L is defined as vitamin D insufficiency (Holick 
et al., 2011). Vitamin D sufficiency or commonly known as optimal vitamin D levels 
is accepted as serum 25(OH)D of at least 75 nmol/L as this level is needed to optimise 
intestinal calcium absorption and to cover all physiological functions of vitamin D 
(Bischoff-Ferrari, 2007). Vitamin D deficiency and insufficiency, at which serum 
25(OH)D concentrations of less than 75 nmol/L are considered as low or suboptimal 




2.5.4 Hypovitaminosis and Hypervitaminosis D 
Hypovitaminosis D, or commonly known as vitamin D deficiency, is 
characterised as nutritional inadequacy or depletion in the body, causing disturbances 
in body functions. Hypovitaminosis D may be accompanied by severe clinical 
conditions such as hyperthyroidism, hyperparathyroidism, calcium malabsorption, 
rickets, osteomalacia and myopathy (Vieth et al., 2001). 
Although sunlight exposure can supply 10,000 IU vitamin D for covering 
human’s biological needs (Holick, 2007), the cutaneous production of vitamin D is 
still insufficient. The insufficient vitamin D production might due to aging, skin 
pigmentation, culture and clothing, application of sunscreen, sedentary lifestyle and 
other environmental factors that lead to limited sunlight exposure such as geographic 
aspects and seasonal changes. Inadequate dietary intake of vitamin D, lack of vitamin 
D supplementation and medical conditions that attenuated vitamin D conversion, also 
lead to hypovitaminosis D (Holick, 2007). 
Hypervitaminosis D, or commonly known as vitamin D toxicity, occurs when 
there is excess vitamin D intake that translates to a vast increase in circulating 
25(OH)D concentrations. Excessive sunlight exposure does not lead to 
hypervitaminosis D as pre-vitamin D3 will undergo photo-degradation to inactive 
sterols in the skin (Holick, 2003). However, excessive oral supplementation of vitamin 
D without close monitoring of 25(OH)D concentrations can lead to hypervitaminosis 
D as 25(OH)D concentrations are beyond DBP binding capacity (Holick, 2003). The 
main clinical consequence of hypervitaminosis D is hypercalcaemia, at which 




(Zittermann, 2003). Hypervitaminosis D may also be accompanied by other clinical 
symptoms including hypercalciuria, ectopic calcifications, hyperphosphatemia, 
kidney stones, polyuria and polydipsia, hypertension, anorexia, nausea, vomiting and 
constipation (Alshahrani and Aljohani, 2013). 
Although it is uncommon, hypervitaminosis D has been reported in multiple 
age groups and from multiple causes, including errors in milk fortification (Blank et 
al., 1995), errors in manufacture (Kara et al., 2014), megadose ingestion of vitamin D 
supplements (Nimesh et al., 2015) and incorrect dosing from liquid preparations (Lee 
et al., 2018). Nimesh et al. (2015) reported that a one-year-old child developed acute 
hypertension and severe hypercalcaemia due to vitamin D toxicity after high doses of 
oral calcitriol supplementation (Nimesh et al., 2015). Gallagher (2016) also showed 
that the administration of annual bolus doses of vitamin D at concentrations of 300,000 
IU or 500,000 IU resulted in an increased risk of falls and fractures among elderly 
individuals (Gallagher, 2016). 
Previously, only exceptionally high serum 25(OH)D levels of more than 220 
nmol/L (Rizzoli et al., 1994) and more than 250 nmol/L (Vieth et al., 2001; Zittermann 
et al., 2005) were reported to cause vitamin D toxicity. Nevertheless, recent findings 
recommend a much lower upper limit for the levels of 25(OH)D. The upper limit of 
125 nmol/L is suggested for elderly individuals (Gallagher, 2016), infant (Lee et al., 
2013) and healthy young adult (Diab and Watts, 2018) to prevent adverse health 




2.5.5 Vitamin D Supplementation 
Since there are studies reported an increase in cancer incidence rates and 
mortality risks at both low and high levels of serum 25(OH)D (Abnet et al., 2007; 
Melamed et al., 2008), vitamin D levels should keep at the optimal range to ensure 
no disturbance to the normal physiological functions. Vitamin D supplementation 
appears as a promising approach in enhancing vitamin D levels when there is 
insufficient cutaneous production or dietary intake. However, the effectiveness of 
vitamin D supplementation in correcting vitamin D status depends on the types of 
vitamin D analogues employed for treatment. Different vitamin D analogues have a 
different binding capacity to DBP and undergo different vitamin D metabolism 
(Aronov et al., 2008). 
Vitamin D3 is 87% more effective in raising serum 25(OH)D levels and is 
converted 500% faster to calcitriol compared to vitamin D2 (Houghton and Vieth, 
2006). Vitamin D3 is also the natural form of vitamin D that produced by our body; 
hence it is more potent in raising vitamin D concentrations and maintaining it in the 
circulatory system for a longer period, providing two- to three-fold greater storage of 
vitamin D in the body. Vitamin D3 also binds with higher affinity to DBP in plasma, 
offering approximately three times more effective in its action (Holick, 2007). 
Among the vitamin D3 analogue, calcitriol is preferable compared to calcidiol 
and cholecalciferol. Calcitriol is the active metabolite of vitamin D that can act 
immediately as a hormone to exert its physiological effects more effectively. In 
contrast, inactive analogues need to undergo hydroxylation processes in the liver and 




diminished ability of kidney in patients with kidney dysfunction, which is common 
in the diabetic population (Williams et al., 2009). 
Since calcitriol has been used to treat several medical conditions in both 
human and animal diabetic models (Hamden et al., 2009; Eftekhari et al., 2014), 
vitamin D supplementation in this project was conducted by providing oral calcitriol 
to the vitamin D-deficient rats, in both normal and diabetic models. 
2.6 Vitamin D Status and Vascular Function 
Numerous human studies have reported on the effects of vitamin D 
insufficiency or deficiency on macrovascular function in normal population and also 
in a variety of disease models. Brachial artery FMD was significantly lower in vitamin 
D-deficient subjects than controls (Tarcin et al., 2009; Malik et al., 2016). Lower FMD 
has also been demonstrated in vitamin D-deficient subjects with early Parkinson 
disease (Yoon et al., 2015) and T2DM (Yiu et al., 2013). Vitamin D supplementation 
did enhance vascular function in term of improving FMD in normal population and 
T2DM patients with vitamin D deficiency (Sugden et al., 2008; Harris et al., 2011). 
Endothelial dysfunction, which is due to the imbalance in the production and 
action of EDRF and EDCF, is the precursor of early atherosclerotic development. 
Vitamin D exerts direct vasoprotective effects against endothelial dysfunction by 
enhancing endothelium-dependent vasorelaxation and inhibiting vasoconstriction 
(Vanhoutte et al., 2009; Sitia et al., 2010). Vitamin D improves the bioavailability of 
endothelial NO, the potent vasorelaxing factor and inhibitor of platelet and leukocyte 
aggregation and adhesion. This occurs via direct enhancement of transcriptional 




kinase in EC, which activates eNOS to catalyse the NO production (Wang et al., 2008; 
Menezes et al., 2014). By inducing NO production, vitamin D also promotes EC 
proliferation and migration and inhibits apoptosis (Xiang et al., 2011). Vitamin D also 
induces the production of PGI2 in VSMC through the COX pathway, which prevents 
thrombus formation, cell adhesion and VSMC proliferation (Wakasugi et al., 1991; 
Chen et al., 2010). 
2.7 Vitamin D Status and Oxidative Stress 
Hyperglycaemia coupled with vitamin D deficiency leads to the overproduction 
of ROS and free radicals in diabetics, provoking oxidative stress that exacerbates 
diabetes-related cardiovascular complications (Wang et al., 2008; Dong et al., 2012). 
For the past decades, considerable efforts have been made in studying the antioxidant 
action of vitamin D in the pathogenesis of DM and its related secondary complications. 
Wiseman (1993) demonstrated that vitamin D acts as a direct membrane 
antioxidant to inhibit iron‐induced lipid peroxidation of brain liposomes. Its 
antioxidant ability may be due to the homologous structure to cholesterol, allowing 
vitamin D to stabilise membrane from lipid peroxidation through molecular relations 
with the hydrophobic parts (Wiseman, 1993). Vitamin D helps to diminish the 
formation of ROS by suppressing the gene expression of NADPH oxidase, which is 
one of the main resources of ROS (Labudzynskyi et al., 2015). Also, vitamin D inhibits 
the augmented mitochondrial production of ROS via regulating the autophagy process 
to maintain redox homeostasis (Wong et al., 2008). 
Vitamin D supplementation has been reported to improve the activities of 




combating oxidative stress (Hamden et al., 2009; George et al., 2012; Nikooyeh et al., 
2014; Shab-Bidar et al., 2015). Vitamin D involved in GSH metabolism through 
upregulating glutamate-cysteine ligase (a key enzyme in GSH synthesis) and 
glutathione reductase genes expression (Kanikarla-Marie and Jain, 2016). Hence, the 
normal reducing environment within the cell can be maintained to efficiently remove 
ROS, thereby oxidative stress can be attenuated. Vitamin D may possess antioxidant 
properties as potent as, or even better than the classical antioxidant vitamin E 
(Wiseman, 1993, Sardar et al., 1995, Lin et al., 2005; Javanbakht et al., 2010). 
In animal studies, there were significantly higher levels of serum TBARS found 
in vitamin D-deficient diabetic rats, which were significantly reduced nearly to control 
values after vitamin D3 supplementation (George et al., 2012). A study has reported on 
the potential of vitamin D3 supplementation either as a preventive measure or 
therapeutic strategy in diabetic rats (Hamden et al., 2009). In that study, the rats 
received vitamin D3 supplementation (5000 IU/kg body weight daily) by gastric 
gavage for two months before and after alloxan-induction respectively to serve as 
preventive and therapeutic groups of diabetics. The results showed that administration 
of vitamin D3 in both groups (preventive and therapeutic groups) enhanced hepatic and 
renal activity of SOD, CAT and GSH-Px, as well as reduced lipid peroxidation as 
indicated by decreased TBARS levels compared to untreated diabetic rats. Vitamin D 
might be better in regulating oxidative stress before the development of diabetes as 
shown by a better significant improvement in the preventive group compared to the 
therapeutic group of diabetic rats (Hamden et al., 2009). 
In human studies, serum TBARS levels of asymptomatic vitamin D-deficient 




were significantly reduced nearly to basal TBARS levels as in control group (Tarcin 
et al., 2009). In subjects with T2DM, treatment with vitamin D3-fortified doogh (a 
Persian yogurt drink) (500 IU twice a week for 12 weeks) showed a reduction in MDA 
and increased GSH levels (Shab-Bidar et al., 2015). In hypertensive, hyperlipidaemia 
and obesity patients, calcitriol supplementation also improved the activities of 
antioxidant enzymes and attenuated ROS production (Dong et al., 2012). 
However, treatment with vitamin D3 capsules (50,000 IU, given twice 
throughout six-weeks study duration) did not affect the biomarker of oxidative stress 
(MDA and GSH levels) in women with GDM (Asemi et al., 2013). Similarly, 
Eftekhari and colleagues (2014) reported that MDA levels in T2DM subjects after 
receiving calcitriol supplementation (0.5 µg/day for 12 weeks) showed no significant 
difference (Eftekhari et al., 2014). Another study in vitamin D-deficient T2DM 
patients reported that vitamin D3 treatment (5,000 IU/day for 12 weeks) did not 
significantly affect SOD levels (Yiu et al., 2013). 
2.8 Vitamin D Status and Atherosclerosis 
Epidemiological studies demonstrated that low vitamin D levels are a risk 
factor for the development of atherosclerosis (Kassi et al., 2013). Vitamin D deficiency 
correlates with endothelial dysfunction, VSMC proliferation and migration, enhanced 
oxidative stress, increased intima-media thickness (IMT) and augmented systemic 
inflammation, leading to atherosclerosis (Zittermann et al., 2007; Wang et al., 2008; 
Wang et al., 2010; Liu et al., 2012). 
IMT, which is a reflection of atherosclerotic burden, was negatively related to 




carotid artery IMT in T2DM patients with low vitamin D levels compared to those 
with higher vitamin D levels. T2DM patients who developed carotid plaque has 
significantly lower 25(OH)D concentrations compared to T2DM patients without 
carotid plaque (Wang and Zhang, 2017). Vitamin D analogues suppress the 
mechanisms that lead to increased IMT and vascular calcification by inhibiting the 
over-expression of multiple adhesive molecules on EC (Zittermann et al., 2007) and 
the accumulation of plaque lipid in VSMC (Willerson and Ridker, 2004). 
Vitamin D also possesses anti-inflammatory properties. It may suppress the 
production and release of several pro-inflammatory cytokines (Zittermann et al., 2007) 
and increase the production of anti-inflammatory cytokines (Tukaj et al., 2012). 
Vitamin D downregulates the inflammatory process by limiting the major role of T-
helper 1 in pro-atherogenic response and shifting the T-cell response to T-helper 2 to 
limit the pro-atherogenic response (Hewison, 2010). Vitamin D displays anti-
atherogenic properties through endoplasmic reticulum (ER) stress-dependent 
mechanism. ER stress acts as a major regulator in modulating macrophage 
differentiation that may have a role in atherosclerotic plaque regression in diabetics 
(Oh et al., 2012). Vitamin D acts as an ER stress reliever to prevent foam cell formation 
during macrophage differentiation, reduce macrophage infiltration and migration and 
stimulate an anti-atherogenic macrophage phenotype, thus reducing vascular 
inflammation and complications in T2DM patients. Vitamin D also reverses 
atherogenic cholesterol metabolism deposition by preventing the progression of 
macrophage cholesterol uptake and promoting cholesterol efflux in macrophages from 







3.1 Animal Study 
3.1.1 Ethical Approval 
The ethical approval for animal study was obtained from the Animal Ethics 
Committee, Universiti Sains Malaysia (USM), Health Campus, Kelantan [No. 
USM/Animal Ethics Approval/2016/(98)(711)] (Appendix A). 
3.1.2 Animals 
A total of 60 male Sprague-Dawley rats aged between 8- to 9-week-old with 
body weight ranged between 200-300 g were purchased from the Animal Research 
and Service Centre, USM, Health Campus, Kelantan. Sprague-Dawley rat is 
commonly used as an animal diabetic model and has contributed significantly in 
diabetes-related research studies (Shi et al., 2007; Leo et al., 2011). Male rats were 
used in this study considering that female rats are more physiologically influenced by 
sexual hormones, that might interfere with the study outcome. 
Rats were housed in polypropylene cage in a well-ventilated animal room with 
room temperature of 25±2°C and the exposure to 12-hours light-dark cycle. The rats 
had unrestricted access to tap water ad libitum including during fasting. Food pellets 
provided to the rats were maintained at 25±5 g daily unless they were fasted for a 
specific experimental procedure. Bedding was changed regularly to minimise 




for one to two weeks before the experiment. The experiment started when the rats 
achieved 10-week-old. 
3.1.3 Preparation of Working Solutions 
i. Sodium citrate buffer (0.1 M, pH 4.5) 
To prepare 0.1 M sodium citrate buffer, 2.94 g of trisodium citrate dehydrate 
(Sigma Aldrich, USA) was fully dissolved in 100 mL of double distilled water 
(ddH2O). The solution was adjusted to pH 4.5. This solution was freshly prepared prior 
to usage. Sodium citrate buffer was used as the diluent of streptozotocin (STZ) for 
diabetes induction and also as the vehicle for normal rats. 
ii. Lysis buffer 
To prepare lysis buffer, a tablet of cOmpleteTM Protease Inhibitor Cocktail 
(Roche Diagnostic, Germany) were fully dissolved in 10 mL of 
radioimmunoprecipitation assay (RIPA) lysis buffer (Sigma Aldrich, USA), mixed 
well and stored at 4°C. 
3.1.4 Experimental Design 
 3.1.4(a) Diabetes Induction 
At 10-week-old, rats were randomly divided into two groups of 30 rats each: 
normal and diabetic groups. Following an overnight fast, diabetic group was 
intraperitoneally injected with STZ dissolved in sodium citrate buffer, at the dosage of 
50 mg/kg body weight (Nishigaki et al., 1989). Normal group was intraperitoneally 




STZ destroys the Langerhans islet ß-cells of the rats within two to four days (Weiss, 
1982). STZ be administered to fasted rats is to minimise the competition between STZ 
and glucose for the uptake into ß-cells via low-affinity glucose transporter (GLUT-2), 
thus improving the efficacy of STZ in inducing experimental hyperglycaemia 
(Chaudhry et al., 2013).  
After 72 hours, blood samples of the rats were drawn from tail tips by needle 
pricking to measure baseline fasting blood glucose (FBG) concentrations using a 
portable one-touch glucometer (Accu-check, Roche Diagnostics, USA), following an 
overnight fast. Rats with FBG concentrations of more than 16.6 mmol/L, which 
indicate the complete and irreversible degeneration in Langerhans islet ß-cells (Shi et 
al., 2007), were regarded as the successfully induced diabetic group. 
FBG concentrations and body weight measured on the day of successful 
diabetes induction (defined as week one, W1) were recorded and used as baseline 
value. FBG concentrations and body weight were monitored weekly throughout the 
study period to ensure the rats remained under normal or diabetic conditions in 
respective study groups. At the end of 10-weeks study duration, FBG concentrations 
and body weight measured on the day of sacrifice (defined as week ten, W10) were 
recorded and used as final value. 
 3.1.4(b) Diet and Supplementation 
After the confirmation of normal and diabetes status, both normal and diabetic 
groups were respectively subdivided into three study groups of 10 rats each: (i) rats 
receiving control diet for 10 weeks, (ii) rats receiving vitamin D-deficient diet for 10 




supplementation for four consecutive weeks, starting from the beginning of week 
seven (W7) to the end of week ten (W10). The group classification of normal and 
diabetic rats is illustrated in Table 3.1 and Table 3.2 respectively. 
Table 3.1 Group classification of normal rats. 
Groups Number of Rats Diet/Supplementation 
NC 10 Control diet for 10 weeks (W1 to W10) 
ND 10 Vitamin D-deficient diet for 10 weeks 
(W1 to W10) 
NDS 10 Vitamin D-deficient diet for 10 weeks 
(W1 to W10) + calcitriol supplementation 
for four weeks (W7 to W10) 
[W1: week one; W7: week seven; W10: week ten] 
 
Table 3.2 Group classification of diabetic rats. 
Groups Number of Rats Diet/Supplementation 
DC 10 Control diet for 10 weeks (W1 to W10) 
DD 10 Vitamin D-deficient diet for 10 weeks 
(W1 to W10) 
DDS 10 Vitamin D-deficient diet for 10 weeks 
(W1 to W10) + calcitriol supplementation 
for four weeks (W7 to W10) 
[W1: week one; W7: week seven; W10: week ten] 
 
Control diet is a standard rodent diet (AIN93G, Specialty Feeds, AUS) 




Vitamin D-deficient diet is a modified AIN93G rodent diet with no added vitamin D 
(SF03-009, Specialty Feeds, AUS) containing 0.70% of calcium and 0.35% of 
phosphorus. All diets were provided to the rats throughout the study duration of 10 
weeks (from W1 to W10).  
In this study, calcitriol, the physiologically active metabolite of vitamin D, is 
the vitamin D analogue used for supplementation. Calcitriol (Rocaltrol, Roche, 
Switzerland) dissolved in extra virgin organic coconut oil (Country Farm Organics, 
Philippines) was given by oral gavage feeding to the rats with the dosage of 0.15 µg/kg 
body weight (Mancuso et al., 2008; Dong et al., 2012; Lee et al., 2014). Calcitriol 
supplementation was given five days per week for four consecutive weeks (Lee et al., 
2014; Huda et al., 2014), starting from the beginning of week seven until the end of 
the 10-weeks study duration (from W7 to W10). Based on a previous study conducted 
on the aorta of hypertensive rats, vitamin D deficiency causes endothelial dysfunction 
in six-week duration (Dong et al., 2012). Hyperglycaemia in diabetes has also been 
reported in leading to microvascular endothelial dysfunction in a six weeks’ study 
(Mokhtar et al., 2016). Giving a four-weeks calcitriol supplementation shall be 
sufficient in correcting vascular functional abnormality and also preventing 
vasculopathy in diabetes microcirculation attributed to vitamin D deficiency. At the 
end of week ten after successful diabetes induction (Palmer et al., 1998), the rats were 
fasted overnight, anaesthetized with an intraperitoneal injection of sodium 






3.1.4(c) Blood Sample Collection and Serum Preparation 
During deep anaesthetization, blood samples (approximately 5 mL) were 
drawn from the left ventricle of the rats via cardiac puncture and were collected into a 
plain Vacutainer tube. The blood samples were allowed to clot at 4ºC before being 
centrifuged using Eppendorf Centrifuge (5810R, Kubota, Japan) at 4000 x g at 4ºC for 
10 minutes. The yielded serum was collected and outsourced to a local certified 
laboratory (BP Healthcare, Kota Bharu, Malaysia) for the measurement of serum 
calcium concentrations. The balance of the serum was kept at -80ºC for subsequent 
measurement of 25(OH)D concentrations using a commercially available assay kit. 
 3.1.4(d) Dissection and Isolation of Mesenteric Arteries 
The rats were dissected to isolate mesenteric vascular bed after blood sample 
collection. The isolated mesenteric vascular bed was immediately placed in a petri dish 
filled with pre-chilled, oxygenated physiological saline solution of the following 
composition (mM): NaCl 118.0, KCl 4.7, CaCl2 2.5, MgSO4 1.2, NaHCO3 25.0, 
KH2PO4 1.2, glucose 5.5 (details please refer to Table 3.3), ready for microscopy 
dissection of mesenteric artery under a dissecting microscope (Motic, China). During 
artery dissection, several distinctive physical characteristics were used to differentiate 
artery from vein. Artery has a smooth adventitial surface, a thicker wall in proportion 
to a smaller lumen, a visible distinction between media and lumen, a V-shaped branch 
tip, is relatively rigid in vessel shape, and brighter in blood colour. After artery 
identification, first branch order of superior mesenteric arteries (luminal diameter of 
150-200 µm) (Figure 3.1) was harvested as a small resistance artery for microvascular 




conducted in this study included the assessments of endothelium-dependent relaxation 
and contraction, as well as endothelium-independent relaxation and contraction. 
[Schematic diagram was adapted from Fabrice Pourageaud, 1997] 
The remaining mesenteric arteries were collected to prepare vascular tissue 
lysate for subsequent oxidative stress analysis and also to conduct Western blot. 
Oxidative stress analysis on mesenteric arterial tissue was performed by measuring the 
concentrations of oxidative stress parameters such as superoxide dismutase (SOD), an 
antioxidant enzyme and malondialdehyde (MDA), the biomarker of oxidative injury. 
Western blot was conducted to quantify the protein expression of endothelial nitric 
oxide synthase (eNOS) in the vascular tissue samples. An intact mesenteric artery was 
harvested to conduct immunohistochemistry for the detection of the presence and 
localization of protein eNOS. Artery dissecting procedures were handled with gentle 
care to prevent damage to the endothelial cells (EC) and vascular smooth muscle cells 
(VSMC) for vessel’s viability. The detailed flow chart of the experimental design is 
illustrated in Figure 3.2. 
Figure 3.1 Identification of branch order of mesenteric artery from an isolated 
mesenteric vascular bed of Sprague-Dawley rat. 
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Figure 3.2 Detailed flow chart of experimental design for animal study. 
* Four-weeks calcitriol supplementation was starting from the beginning of week 7 to the end of 10-weeks study duration (W7 to W10). 
[STZ: streptozotocin; i.p.: intraperitoneal; FBG: fasting blood glucose; 25(OH)D: 25-hydroxy vitamin D; eNOS: endothelial nitric oxide synthase; 
MDA: malondialdehyde; SOD: superoxide dismutase] 
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 3.1.4(e) Tissue Lysate Preparation 
Mesenteric artery cleaned of excess fat and connective tissues were rinsed three 
times with physiological saline solution to remove excess blood that might interfere 
with the study outcome. The artery was then finely chopped in a microcentrifuge tube 
filled with 100 µL of pre-chilled lysis buffer on ice using dissecting scissors. The tissue 
lysate was incubated at 4ºC for 10 minutes, followed by centrifugation at 12,000 x g 
at 4ºC for five minutes. The yielded supernatant was kept at -80°C and ready to be 
used for total protein quantification, oxidative stress analysis and Western blot. 
3.2 Vascular Functional Study 
3.2.1 Wire Myography 
Myography is a technique developed by Mulvany and Halpern (1976) for the 
in vitro investigation of active and passive properties of small isolated vessels (with 
an internal diameter of 100 to 1000 µm). The properties of small vessels included their 
functional responses and vascular reactivity to vasoactive substances are evaluated 
under isometric conditions in myography (Mulvany and Halpern, 1976; Mulvany and 
Aalkjaer, 1990). The standard experimental protocols of myography consist of 
preparation and mounting of vessel rings, normalization procedures and vascular 
functional responses towards specific pharmacological agents. 
This technique has been widely used to determine the functional and 
mechanical properties of isolated arteries from a variety of vascular bed in various 
pathological states (Spiers and Padmanabhan, 2005). In this study, dual chamber wire 
myograph (410A, DanishMyo Technology, Denmark) (Figure 3.3) was used to 
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evaluate the microvascular functional properties in the mesenteric arteries of normal 
and diabetic rats with different vitamin D status. 




AIIA2: Transducer Al 
Myo~apn cnamoer 
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3.2.2 Physiological Saline Solution 
Physiological saline solution (PSS) used in this study is a modified Krebs 
buffer with specific salt concentrations, aeration, pH and temperature to maintain the 
similar physiological conditions of the vessel during wire myography as the vessel 
exists in the living body. To prepare PSS, the chemicals purchased from Merck KGaA, 
Darmstadt, Germany as listed in Table 3.3 were fully dissolved in 1 L of double 
distilled water according to the desired mass and mixed well. The solution was slowly 
aerated with carbogen gas (95% oxygen + 5% carbon dioxide) for approximately 30 
minutes until the solution reached pH 7.4 (Mokhtar et al., 2016). PSS was freshly 
prepared in view that the glucose levels of the solution might deteriorate over time. 










Sodium chloride NaCl 58.44 118.99 6.95 
Potassium 
chloride 








KH2PO4 136.08 1.18 0.16 
Sodium hydrogen 
carbonate 
NaHCO3 84.01 25.00 2.10 
D(+)-glucose 
monohydrate 
C6H12O6.H2O 198.17 5.50 1.09 
Calcium chloride 
dehydrate 
CaCl2.2H2O 147.02 2.50 0.37 
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3.2.3 Pharmacological Agents for Vascular Functional Responses 
Vascular functional responses of the vessel towards particular pharmacological 
agents were assessed in this study. All stock solutions of pharmacological agents were 
freshly prepared to prevent the deterioration in their pharmacological potency over 
time. To prepare pharmacological agents for myography, the chemicals were fully 
dissolved in respective diluents and were serially diluted to the appropriate 
concentrations. The final concentrations of each chemical loaded in the myograph 
chamber were determined based on preliminary studies or previous study in the 
literature (Mokhtar et al., 2016). The pharmacological agents used in vascular 
functional study are listed in Table 3.4. 







Country of Origin 
Acetylcholine chloride (ACh) 181.66 ddH2O Sigma Aldrich, USA 
Calcium ionophore A23187 (CaI) 523.62 DMSO Sigma Aldrich, USA 
L-NG-Nitroarginine methyl ester 
hydrochloride (L-NAME) 
269.70 ddH2O Cayman Chemicals, 
USA 
Phenylephrine (PE) 203.67 ddH2O Sigma Aldrich, USA 
Salbutamol hemisulfate (SB) 576.70 ddH2O Tocris Bioscience, UK 
Sodium nitroprusside dehydrate 
(SNP) 
297.95 ddH2O Sigma Aldrich, USA 
[DMSO: dimethyl sulfoxide; ddH2O: double distilled water] 
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3.2.4 Preparation and Mounting of Vessel Rings 
The myograph chambers were pre-washed with ice-cold PSS for three times to 
remove any dust or dirt. Then, the chambers were filled up with PSS with the chamber 
cover on to prevent evaporation. A temperature probe was inserted, and the internal 
heating system set at 37ºC was turned on. Gas tubing with clamps was manually 
adjusted to start the aeration of carbogen gas (95% oxygen + 5% carbon dioxide) in 
the chambers. 
The isolated first branch order of mesenteric artery which had been cleaned 
from fat and connective tissues was then cut into vessel rings with 2-mm-length. For 
endothelium-dependent response study, blood vessel with intact endothelium was used. 
For endothelium-independent response study, the endothelium of blood vessel was 
removed by gently scrubbing the lumen of the vessel ring with a human hair during 
dissection (Kirkby et al., 2012). 
The lumen of the vessel ring was gently cannulated with first tungsten wire (40 
µm in diameter) held by forceps in a smooth motion with the aid of the dissecting 
microscope, ready for mounting in myograph chambers. Once sufficient aeration and 
an optimum temperature of 37ºC were achieved, the chamber cover was removed, and 
the chamber was moved under the microscope. The cannulated vessel ring was then 
transferred to the middle of the chamber. 
The myograph jaws were brought near to each other by adjusting the 
micrometer to hold the wire in place, followed by securing both free ends of the wire 
tightly underneath the screws of the jaw attached to a micrometer. Once the first wire 
was mounted, the jaws were moved slightly apart following by threading the second 
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tungsten wire into the lumen along the top of the first wire. Cannulation was done in a 
smooth motion to avoid endothelial injury or creating trauma to the vessel. 
Again, the jaws were moved to be in contact to secure the wire end underneath 
the screws of the jaw attached to an isometric force transducer. The jaws were then 
moved slightly apart to adjust the wires to be parallel on the same plane, thereby 
allowing the radial forces generated in the vessel segment during vascular responses 
towards pharmacological agents to be measured (Mulvany and Halpern, 1976). The 
chamber cover was then put on. The mounting protocol of vessel rings in myograph 
chamber is illustrated schematically in Figure 3.4. 
Vessel ring was suspended in the myograph chamber filled with PSS of pH 7.4, 
with a maintained temperature of 37°C and continuous carbogen gas aeration 
throughout the experimental procedures. Once the vessel ring was mounted in the 
chamber, the ring was washed three times with PSS to remove excess blood. The vessel 
ring was then left to equilibrate in PSS for 30 minutes before performing 
normalization. 
 
  56 
 
Figure 3.4 Schematic diagram of the mounting protocol of vessel rings in 
myograph chamber.       
A. Arterial ring cannulated with first wire placed in the middle of the jaws. 
B. The free ends of the wire were then secured tightly under the screws of the  
     myograph jaw attached to a micrometer (M). 
C. Second wire was inserted on top of the first wire. 
D. The free ends of second wire were then secured tightly under the screws of the  
     myograph jaw attached to a transducer (T). 
E. Labelled diagram of myograph chamber with vessel ring mounted. 
(Modified from https://www.dmt.dk/dual_wire_myograph_420a_520a.html - online 
Myograph User Guide) 
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3.2.5 Normalization 
The purpose of normalization is to obtain the optimum degree of stretch for 
optimum vascular responses. The active response and sensitivity of the vessel to 
pharmacological stimulation depends on the degree of stretch. Less stretch renders the 
vessel in a less sensitive condition whereas excessive tension causes damage to the 
delicate EC and VSMC. 
The normalization procedure was performed in accordance to the 
Normalization Module of the Chart Software (AD Instruments, UK). A series of 
stepwise passive stretches were performed on the vessel by adjusting the micrometer 
at small increments. Passive tension developed across the vessel wall was obtained by 
using a chart recorder. The stretch was continued at 8-minutes “stress-relaxation” 
intervals, until the internal circumference of the vessel was pre-determined at a given 
transmural pressure of 100 mmHg. Then, the vessel was stretched to achieve an 
internal circumference equivalent to 90% of pre-determined internal circumference. 
The passive tension-internal circumference of the vessel at its standard initial condition 
for optimal contraction was then determined (Mulvany and Halpern, 1976). The 
internal circumference was remained constant throughout the experimental protocols, 
so that vascular responses can be examined under isometric conditions. 
3.2.6 Smooth Muscle Viability Test 
The vessels were equilibrated for an hour after normalization. Following that, 
smooth muscle viability test was conducted before subsequent isometric tension 
measurement. The VSMC of vessel ring were tested for the contractile function by 
exposing the vessel ring to high concentrations of potassium ions. High exposure to 
potassium ions depolarizes the membrane of VSMC and activates the opening of 
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voltage-dependent calcium channels, resulting in an influx of extracellular calcium 
ions (Ca2+). The influx of Ca2+ raises the intracellular Ca2+ levels in VSMC, thus 
inducing arterial contraction (Vanhoutte et al., 2017). 
In this procedure, the vessel in the myograph chambers was exposed to 60 mM 
KCl solution for 10 minutes or until the contraction was stable. Allowing at least 10-
minutes interval alleviates the possibility that the vessels might spontaneously relax to 
baseline. The vessel is maximally contracted with KCl to ensure that the technique of 
artery isolation and mounting did not have any adverse effect on the viability of 
VSMC. VSMC was considered intact and experience no damage if a substantial 
contraction of at least 4 N in response to KCl achieved. Vessel segment that failed to 
substantially contract in response to KCl was discarded. 
In addition, this procedure is also necessary to provide a reference contraction 
for subsequent vascular response study. This is in view that the exposure of vessel to 
KCl produces a regular and sustained contraction, enabling greater reproducibility 
when analysing contraction and relaxation subsequently. The solution in the myograph 
chamber was then removed by using a hand vacuum and replaced with fresh PSS. 
Vessel segment was allowed to relax to the baseline for 10 minutes. The application 
of KCl solution was then repeated for a second time. 
3.2.7 Endothelial Function Test 
This test is used to examine the integrity of the endothelium of vessel ring. This 
test is necessary in view that the delicate endothelium can be easily damaged during 
dissecting or mounting procedure. This test is able to give confirmation that the 
endothelium is intact and viable for the study evaluating endothelium-dependent 
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responses and also to confirm whether the endothelium is successfully removed for the 
study evaluating endothelium-independent responses. 
The vessel ring was pre-constricted with a standard vasoconstrictor, PE (10-4 
M) for 10 minutes or until a stable contraction is achieved (Mokhtar et al., 2016). This 
procedure is to observe the contractile function of the vessel ring. PE induces 
vasoconstriction by acting on the α1-adrenergic receptor located on VSMC. The 
contraction of the vessel to PE must reach at least 80% of KCl reference contraction, 
to be included in endothelium-dependent response study. 
Once the PE contraction remained plateau, the vessel ring was then exposed to 
an endothelium-dependent vasodilator, ACh (10-4 M) to observe the relaxing ability of 
EC. ACh activates the muscarinic receptor located on EC, which stimulates the release 
of NO from the functioning endothelium; thus mediating endothelium-dependent 
relaxation. A normal functioning vessel that showed a substantial ACh-induced 
relaxation (greater than 60% of the pre-contracted tone) confirmed the endothelium as 
functionally intact and can be used for endothelium-dependent response study (Ang et 
al., 2002). For endothelium-independent response study, a partial (less than 30% of 
the pre-contracted tone) or no relaxation in respond to ACh would be observed to 
verify successful removal of the endothelium (Prieto et al., 2010). 
Once the vessels reached maximum relaxation, the vessels were washed and 
incubated with fresh PSS. The washing procedures were repeated for at least three 
times to alleviate the problem of remaining pharmacological agents in the chamber 
that may cause spontaneous contraction or relaxation to the vessel. The vessel was then 
allowed to relax to baseline before conducting subsequent experimental protocols. 
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3.2.8 Vascular Responses Study 
The protocol for vascular functional study in rats’ mesenteric arteries is 
summarised in Table 3.5. 
 3.2.8(a) Endothelium-dependent Relaxation 
Endothelium-dependent relaxation was investigated in a pre-constricted 
mesenteric artery with intact endothelium. In brief, vessel ring with intact endothelium 
was pre-constricted with the α1-adrenergic receptor agonist, PE (10-4 M) to produce a 
sustained maximal contraction of the response curve. Then, the vessel ring was 
exposed to cumulative concentrations (10-8 to 10-4 M) of the muscarinic receptor 
agonist, ACh for relaxation (Wang et al., 2000). 
 3.2.8(b) Endothelium-dependent Contraction 
Endothelium-dependent contraction was studied in a quiescent mesenteric 
artery with intact endothelium. In brief, vessel ring with intact endothelium was 
incubated with L-NAME (10-4 M) for 30 minutes, then exposed to cumulative 
concentrations of calcium ionophore (CaI) (10-8 to 10-4 M). L-NAME is the inhibitor 
of eNOS; incubation with L-NAME hinders the production of NO, eradicating NO-
induced relaxation (Georgescu et al., 2011). The increase in intracellular Ca2+ levels 
induced by CaI in turn evokes the release of cyclooxygenase products such as 
thromboxane A2 and prostaglandin E2 from EC, thus inducing vasoconstriction (Shi et 
al., 2007). 
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 3.2.8(c) Endothelium-independent Relaxation 
Endothelium-independent relaxation was determined in a pre-constricted 
mesenteric artery with removed endothelium. In brief, vessel ring without endothelium 
was pre-constricted with PE (10-4 M), thereafter exposed to cumulative concentrations 
of the following relaxing agents: 
a) Sodium nitroprusside, SNP (10-8 to 10-4 M) 
SNP is an exogenous NO donor that induces vasorelaxation through cGMP 
pathway reaction. 
b) Salbutamol hemisulfate, SB (10-8 to 10-4 M) 
SB is an agonist of the β2-adrenergic receptor located on VSMC that induces 
vasorelaxation through cAMP pathway reaction. 
 3.2.8(d) Endothelium-independent Contraction 
Endothelium-independent contraction was studied in a quiescent mesenteric 
artery with removed endothelium. In brief, vessel ring without endothelium was 
subjected to cumulative concentrations of PE (10-8 to 10-4 M), an agonist of the α1-
adrenergic receptor located on VSMC (Rizzoni et al., 2001). 
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Table 3.5 Protocol for vascular functional study in rats’ mesenteric arteries. 
















Endothelium Intact Intact Removed Removed Removed 
Standard procedures Equilibration (30 minutes); Normalization; Equilibration (60 minutes) 
Smooth muscle viability test (60 mM potassium chloride, twice) 
Endothelial function test (10-4 M PE; then 10-4 M acetylcholine) 
Specific incubation N/A L-NAME (30 minutes) N/A N/A N/A 




(10-8 to 10-4 M) 
Calcium ionophore 
(10-8 to 10-4 M) 
Sodium nitroprusside 
(10-8 to 10-4 M) 
Salbutamol 
(10-8 to 10-4 M) 
Phenylephrine 




Agonist of the 
muscarinic receptor 
located on EC (NO 
inducer) 
Transport Ca2+ across 
cell membrane of EC, 
increases intracellular 
Ca2+ levels in EC 
Exogenous NO donor 
(cGMP pathway) 
Agonist of the β2-
adrenergic receptor 
located on VSMC 
(cAMP pathway) 
Agonist of the α1-
adrenergic receptor 
located on VSMC 
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3.2.9 Experimental Parameters 
From the raw myograph tracing obtained during vascular responses study, the 
percentage of relaxation with reference to the contraction induced by PE (10-4 M) and 
the percentage of contraction with reference to the contraction induced by KCl (60 
mM) for each concentration was calculated using Microsoft Excel template. The value 
obtained was used to generate the individual dose-response curve of each agonist using 
Prism Version 7 (GraphPad Software, La Jolla, California, USA). Maximal relaxation 
(Rmax) or maximal contraction (Emax) were calculated from dose-response curves. 
3.3 Total Protein Quantification 
Total protein quantification was used to determine total protein concentrations 
in vascular tissue samples. It is reliably used to normalise the readings obtained from 
oxidative stress analysis, and also as the indicator to ensure equal loading of vascular 
tissue samples during Western blot. In this study, Protein Determination Kit (704002, 
Cayman Chemical, USA) was used for rapid total protein quantification based on the 
well-known Bradford method. 
In brief, the principle of this assay is based on the binding of the Coomassie 
dye to the proteins in the samples in an acidic medium. This protein complex showed 
visible colour changes from brown to blue immediately. Absorbance at the wavelength 
of 595 nm as per manufacturer’s suggestion was measured using VarioskanTM Flash 
Multimode Reader (Thermo Fisher Scientific, USA). 
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3.3.1 Preparation of Working Solutions 
i. Diluted assay reagent 
To prepare diluted assay reagent (dye reagent), 7.5 mL of concentrated assay 
reagent was diluted to 50 mL with ddH2O. The diluted assay reagent was stored at 4°C 
in an amber bottle prior to usage. The diluted assay reagent was brought to room 
temperature and was gently mixed before used. 
ii. Bovine serum albumin standards 
To prepare bovine serum albumin (BSA) standard stock solution (40 µg/mL), 
4 µL of BSA stock solution (10 mg/mL in a 0.9% saline solution with 0.05% sodium 
azide) was diluted to 1 L with ddH2O. This stock solution was then serially diluted 
with ddH2O to prepare BSA standards (Standard A to H) with ascending 
concentrations according to the manufacturer’s suggestion. 
3.3.2 Preparation of Tissue Samples 
The stored supernatant of mesenteric arterial tissue lysate of rats was further 
diluted with ddH2O in pre-labelled microcentrifuge tube in the dilution ratio of 1:200 
(based on preliminary study) to prepare animal tissue samples for assay. 
3.3.3 Assay Procedures 
Briefly, 100 µL of each BSA standard (Standard A to H) and diluted tissue 
sample was added in the designated well on a 96-wells plate, followed by the addition 
of 100 µL of diluted assay reagent to each well. The plate was incubated at room 
temperature for five minutes, followed by measuring the absorbance at the wavelength 
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of 595 nm using VarioskanTM Flash Multimode Reader (Thermo Fisher Scientific, 
USA). 
3.3.4 Calculations 
The corrected absorbance value was calculated by subtracting the absorbance 
value of Standard A (blank) from the absorbance value of other standards and samples. 
BSA standard curve was constructed by plotting BSA concentrations against the 
corrected absorbance values of the standards as a second-order polynomial curve fit. 
The equation obtained from the curve fit was used to determine the total protein 
concentrations (mg protein/mL) of each sample, by inserting the corrected absorbance 
value of each sample to the x-value of the equation, and then multiplied by the 
respective dilution factor. 
3.4 Oxidative Stress Analysis 
Oxidative stress levels were determined by measuring SOD and MDA 
concentrations in vascular tissue samples using commercially available assay kits 
according to the manufacturer's instructions. 
3.4.1 Superoxide Dismutase Levels 
Superoxide dismutase (SOD) acts as an important antioxidant defence enzyme 
against oxidative damage by catalysing the dismutation of superoxide anion into 
molecular oxygen and hydrogen peroxide. In this study, SOD concentrations in the 
tissue samples were quantitatively determined by using EnzyChromTM Superoxide 
Dismutase Assay Kit (ESOD-100, BioAssay Systems, USA) to assess whether the 
effectiveness of antioxidant defence system was affected in vitamin D-deficient rats. 
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This study also aimed to explore whether calcitriol supplementation could ameliorate 
SOD enzyme activity in rats with vitamin D deficiency. 
Briefly, the principle of SOD assay is based on the reaction between superoxide 
anion (generated by xanthine oxidase (XO) catalysed reaction) and tetrazolium salt 
(WST-1), to form a stable formazan dye. The increase in SOD levels scavenges 
superoxide anions that available for the chromogenic reaction, reducing the formation 
of formazan dye. Thus, lower optical density (OD) at the wavelength of 440 nm was 
obtained. 
 3.4.1(a) Preparation of Working Solutions 
i. Working reagent 
To prepare working reagent for each standard and tissue sample, Assay Buffer, 
Xanthine and WST-1 in the ratio of 160:5:5 were mixed well and kept in amber bottle 
prior to usage. 
ii. Diluted XO enzyme 
To prepare diluted XO enzyme, concentrated XO enzyme was diluted in 
Diluent (50 mM potassium phosphate, pH 7.4, supplied ready-to-use) in the dilution 
ratio of 1:20. 
iii. SOD standards 
SOD standard stock solution (3 U/mL) was prepared by mixing 8 µL of SOD 
enzyme with 392 µL of Diluent. This stock solution was serially diluted with Diluent 
to prepare SOD standards (S1 to S8) with descending SOD concentrations according 
to the manufacturer’s suggestion. 
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 3.4.1(b) Preparation of Tissue Samples 
The stored supernatant of the mesenteric arterial tissue lysate of rats was further 
diluted with ice-cold lysis buffer in the dilution ratio of 1:20 (based on preliminary 
study) to prepare animal tissue samples for assay. 
 3.4.1(c) Assay Procedures 
Briefly, 20 µL of SOD standards and tissue samples were added to the 
designated well of a clear flat-bottom 96-well plate. Then, 160 µL of working reagent 
was transferred into each well and mixed well by tapping the plate gently to avoid 
spillage. Immediately, 20 µL of diluted XO enzyme was added in and mixed well. 
Colorimetric quantification was performed by using VarioskanTM Flash Multimode 
Reader (Thermo Fisher Scientific, USA) to obtain OD at 440 nm (initial read). The 
plate was covered with aluminium foil and incubated at room temperature for an hour 
on a shaker, followed by reading OD at 440 nm (final read). 
 3.4.1(d) Calculations 
Net absorbance (∆OD) of each standard and sample was obtained by 
subtracting initial read from final read. The corrected absorbance value (∆∆OD) was 
calculated by subtracting ∆OD of other standards (S1 to S7) and samples from ∆OD 
of S8 (blank). SOD standard curve was constructed by plotting the ∆∆OD values of 
the standards against their SOD working standard concentrations. The following 
equation was used to determine SOD concentrations of each sample, at which the slope 
and y-intercept were obtained from the standard curve. 
SOD (U/mL) = #(∆∆OD)-(y-intercept)slope ' x	dilution	factor 
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One unit of SOD is defined as the amount of SOD needed to exhibit 50% 
dismutation of superoxide anion. The SOD concentrations (U/mL) for each sample 
were normalised to the total protein concentrations (mg protein/mL) of the same 
sample, expressed in U/mg protein. 
3.4.2 Malondialdehyde Levels 
Malondialdehyde (MDA) is the product of lipid peroxidation. It is one of the 
most commonly used markers to evaluate the oxidative degradation of lipids. In this 
study, MDA concentrations in vascular tissue samples were measured using 
NWLSSTM Malondialdehyde Assay (NWK-MDA01, Northwest Life Science 
Specialty, USA), to study whether vitamin D deficiency in rats enhances the degree of 
lipid peroxidation. This study also aimed to assess whether oxidative degradation of 
lipids improved by calcitriol supplementation to vitamin D-deficient rats. 
Briefly, the principle of MDA assay is based on the reaction between MDA 
(generated from the lipid peroxidation process) and two thiobarbituric acids (TBA), 
forming an MDA-TBA2 complex that has the highest absorbance at the wavelength of 
532 nm. The increase in the availability of MDA increases the formation of the 
complexes, subsequently showing higher absorbance at the wavelength of 532 nm. 
 3.4.2(a) Preparation of Working Solutions 
i. TBA reagent 
To reconstitute TBA reagent, TBA powder in the bottle was fully dissolved 
with 10.5 mL of ddH2O, mixed well and kept at room temperature prior to usage. 
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ii. Ready-to-use reagents 
Acid reagent (1M phosphoric acid), butylated hydroxytoluene (BHT) reagent, 
calibrators (0-4 µM MDA equivalent) and assay buffer (phosphate buffer, pH 7.0) 
were supplied ready-to-use. 
 3.4.2(b) Preparation of Tissue Samples 
The stored supernatant of the mesenteric arterial tissue lysate of rats was further 
diluted with assay buffer in the dilution ratio of 1:200 (based on preliminary study) to 
prepare animal tissue samples for assay. 
 3.4.2(c) Assay Procedures 
Briefly, 10 µL of BHT reagent, 250 µL of each calibrator (C0 to C4) or tissue 
sample, 250 µL of acid reagent and 250 µL of TBA reagent was added in sequence to 
a pre-labelled microcentrifuge tube. The tubes were recapped and vortexed using 
vortex mixer (IKA, Germany) at five counts to allow complete mixing. The mixtures 
were incubated in a water bath set at 60°C for an hour. Following incubation, the 
mixtures were centrifuged at 10,000 x g for three minutes. The yielded supernatant 
from each mixture was loaded into a quartz semi-micro cuvette. The absorbance at the 
wavelength of 532 nm and 572 nm (for maximum and minimum absorbance 
respectively) was measured by using UV spectrophotometer (Shimadzu Corp., Japan). 
Absorbance at 572 nm removed most of the undesired background to yield more 
accurate absorbance value according to the manufacturer’s suggestion. 
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 3.4.2(d) Calculations 
Net absorbance value of each sample was obtained by subtracting the 
absorbance value at 572 nm from the absorbance value at 532 nm. The corrected 
absorbance value was calculated by subtracting the net absorbance value of C0 (blank) 
from the net absorbance value of other calibrators and samples. MDA standard curve 
was constructed by plotting the corrected absorbance value of the standards against 
their MDA working standard concentrations. The following equation was used to 
determine MDA concentrations of each sample, at which the slope and y-intercept 
were obtained from the standard curve. 
 
MDA (µM) = #(Corrected absorbance)-(y-intercept)slope ' 	x	dilution	factor 
 
MDA concentrations (µM) were normalised to the total protein concentrations 
(mg protein/mL) of the same sample, expressed in µmol/mg protein.
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3.5 Western Blot 
Western blot is used in this study to assess the relative protein expression of 
eNOS, which is responsible for NO production. Reduced NO bioavailability may lead 
to functional abnormalities occurring in the microcirculation of diabetics. Hence, this 
study aimed to determine whether the effects of vitamin D deficiency on microvascular 
function in rats are related to the changes in protein expression of eNOS. In addition, 
this study also assessed whether calcitriol supplementation to vitamin D-deficient rats 
is able to improve the protein expression of eNOS. 
3.5.1 Chemicals 
Chemicals used in Western blot are listed in Table 3.6. 
Table 3.6 Chemicals used in Western blot. 
Chemicals Manufacturer, 
Country of Origin 
Ammonium persulfate Bio-Rad Laboratories, USA 
Tris(hydroxymethyl)-aminomethane (Tris-base) Merck, Germany 
Sodium dodecyl sulfate (SDS) Bio-Rad Laboratories, USA 
Glycine Bio-Rad Laboratories, USA 
Methanol HmbG Chemicals, Germany 
Ponceau-S Sigma Aldrich, USA 
Isopropanol Sigma Aldrich, USA 
Coomassie Brilliant Blue Sigma Aldrich, USA 
Acetic acid Sigma Aldrich, USA 
Sodium chloride Merck, Germany 
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3.5.2 Preparation of Working Solutions 
i. Ammonium persulfate solution (10%) 
To prepare 10% ammonium persulfate solution, 0.01 g of ammonium 
persulfate was fully dissolved in 100 µL of ddH2O. This solution was freshly prepared 
and kept in a microcentrifuge tube wrapped with aluminium foil. 
ii. Resolving buffer (pH 8.8) 
To prepare resolving buffer, 18.16 g of Tris-base and 0.40 g of SDS were fully 
dissolved in 70 mL of ddH2O. The solution was adjusted to pH 8.8. The buffer was 
then topped up with ddH2O to make it 100 mL and stored at 4°C. 
iii. Stacking buffer (pH 6.8) 
To prepare stacking buffer, 6.05 g of Tris-base and 0.40 g of SDS were fully 
dissolved in 70 mL of ddH2O. The solution was adjusted to pH 6.8. The buffer was 
then topped up with ddH2O to make it 100 mL and stored at 4°C. 
 
 
Tween-20 Sigma Aldrich, USA 
Skimmed milk (Anlene) Fonterra, NZ 
Bovine serum albumin (BSA) Agros Organic, USA 
30% Acrylamide/bis-acrylamide solution (19:1) Bio-Rad Laboratories, USA 
TEMED Sigma Aldrich, USA 
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iv. Reducing loading buffer (1X) 
Blue Loading Buffer Pack (#7722) was purchased from Cell Signaling Tech, 
USA. To reconstitute reducing loading buffer (1X), 0.1 mL of DTT reducing agent 
(30X) was added into 1.0 mL of blue loading buffer (3X), then topped up with ddH2O 
to 2.0 mL. The buffer was freshly prepared prior to usage. Reducing loading buffer is 
used to lyse cells and reduce protein disulphide bonds for Western blotting analysis.   
v. Running buffer (pH 8.3) 
To prepare running buffer, 3.03 g of Tris-base, 14.40 g of glycine and 1.00 g 
of SDS were fully dissolved in 800 mL of ddH2O. The solution was adjusted to pH 
8.3. The buffer was then topped up with ddH2O to make it 1 L and stored at 4°C. 
vi. Transfer buffer (pH 8.3) 
To prepare transfer buffer, 3.03 g of Tris-base and 14.40 g of glycine were fully 
dissolved in 800 mL of ddH2O. The buffer was then topped up to 1 L with methanol. 
The solution was adjusted to pH 8.3 and stored at 4°C. 
vii. Ponceau-S solution 
To prepare Ponceau-S solution, 0.5 g of Ponceau-S powder was fully dissolved 
in 1 mL of isopropanol, then topped up to 100 mL with ddH2O. 
viii. Coomassie blue solution (stainer) 
To prepare Coomassie blue solution, 1.0 g of Coomassie Brilliant Blue powder 
was fully dissolved in 125 mL of isopropanol, topped up to 450 mL with ddH2O. 
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ix. Acid solution (de-stainer) 
To prepare acid solution, 100 mL of acetic acid was added to 100 mL of 
isopropanol, then topped up to 1 L with ddH2O. 
x. Tris-buffered saline (TBS) (pH 7.4) 
To prepare 1 L of TBS, 2.4 g of Tris-base and 8.8 g of sodium chloride were 
fully dissolved in 800 mL of ddH2O. The solution was adjusted to pH 7.4. The buffer 
was then topped up to 1 L with ddH2O. 
xi. Tris-buffered saline + Tween-20 (0.1%) (TBS-T) 
To prepare TBS-T, 1 mL of Tween-20 was added into 1 L of TBS, mixed well 
and stored at room temperature. TBS-T was used as wash buffer. 
xii. Blocking buffer 
To prepare blocking buffer (2% skimmed milk in TBS-T), 2.0 g of skimmed 
milk powder was fully dissolved in 100 mL of TBS-T. This solution was freshly 
prepared prior to usage. Blocking buffer was also used as the diluent of secondary 
antibody. 
xiii. Bovine serum albumin (BSA) (3%) 
To prepare 3% BSA, 0.3 g of BSA powder was fully dissolved in 10 mL of 
TBS-T. This solution was freshly prepared. BSA was used as the diluent of primary 
antibody. 
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3.5.3 Apparatus Set-up 
The cassette was assembled by placing a small sterile glass plate in front of a 
large sterile glass plate, inserting them into a casting clamp and clamped together. The 
bottom of these two plates was well aligned before assembling the cassette onto the 
casting stand. Sterile water was applied between two glass plates and allowed to stand 
for 30 minutes to check whether the set-up was tightly sealed with no leakage. At last, 
water was removed and dried completely. 
3.5.4 Preparation of SDS-polyacrylamide Gel 
Preparation of SDS-polyacrylamide gel was performed according to the 
method developed by Laemmli (1970). Resolving and stacking gels were prepared 
according to the composition of chemicals as listed in Table 3.7. 
Chemicals Resolving Gel (10%) Stacking Gel (4%) 
Volume (µL) Volume (µL) 
30% acrylamide/bis-acrylamide 2500 650 
Resolving buffer 1875 - 
Stacking buffer - 1250 
Double distilled water 3125 3150 
Ammonium persulfate (10%) 50 25 
TEMED 12 8 
(Gel with 1.0 mm thickness) 
 
Table 3.7 Preparation of stacking and resolving gels. 
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To prepare resolving gel, all desired chemicals were mixed well, with 
ammonium persulfate and TEMED added at last. The mixture was then immediately 
loaded into the space between the glass plates to prevent undesired polymerisation. 
The mixture was loaded until the marked level, followed by relaying the top layer with 
sterile water. Water was relayed slowly as rushing may cause irregular shapes formed 
on the top surface of the resolving gel, that might incur unnecessary resistance. The 
resolving gel was left for 45 minutes to polymerise. The topping water was removed 
completely once the gel was set. 
Following that, the mixture to prepare stacking gel was loaded on the top 
surface of the resolving gel. A preparatory comb was immediately inserted, and the 
stacking gel was left for 45 minutes to polymerise. Once the gel was set, the comb was 
gently removed, and the wells were cleaned with water to ensure the complete removal 
of acrylamide residue. Water and bubbles in the wells were drained completely. 
3.5.5 Preparation of Tissue Samples 
Total protein mass of tissue samples to be loaded was fixed at 30 µg (based on 
preliminary study) to ensure equal loading of each sample into the well. Total protein 
concentrations of tissue samples were quantified as described in Section 3.3. The 
loading volume of the stored supernatant of mesenteric arterial tissue lysate of rats was 
determined from the following formula: 
Loading volume (µL) = 5 total protein mass (30 µg)total protein concentrations (mg/mL)6 
An equal amount of reducing loading buffer was mixed well with the tissue 
samples in the ratio of 1:1. The mixture was vortex mixed for two minutes, followed 
by heating to 95ºC for five minutes and was centrifuged at 12,000 x g for five minutes. 
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3.5.6 SDS-polyacrylamide Gel Electrophoresis 
The glass plates containing set gel were removed from the casting clamp and 
placed into an electrode assembly with small plate facing inward and balance it with a 
plastic buffer dam on the other side (with the grove surface facing outward). The plates 
were clamped together and put in Mini-PROTEAN® Tetra Cell (Bio-Rad 
Laboratories, USA) according to the correct polarities. Running buffer was slowly 
poured into the small chamber to test for leakage, then into the big chamber to cover 
the plates up to the line marked 2-gels. Excess bubbles formation should be avoided 
as it might create more resistance during electrophoresis. 
First well of the gel was loaded with 5 µL of 3-colour broad range (3.5 kDa to 
245 kDa) protein marker (PM 2700, SMOBIO, USA) as protein ladder. The tissue 
samples (excluding pellet) were loaded to the remaining wells. The tank was covered 
taking note of the polarity, and the gel electrophoresis was performed at 100 volts for 
approximately 1.5 hours or until the dye front reached the bottom of the glass plates. 
3.5.7 Protein Transfer 
When electrophoresis was completed, the cassettes were removed and 
dissembled. A plastic blade was used to separate the glass plates. The stacking gel was 
gently removed and discarded, while the resolving gel was ready for blot ‘sandwich’ 
preparation. 
Immobilon-P Polyvinylidene Difluoride (PVDF) membrane (Merck, 
Germany) was cut according to the size of blotting filter paper. PVDF membrane was 
pre-treated with methanol to activate the membrane for better protein adsorption. 
PVDF membrane and blotting filter papers were then soaked in separate container 
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filled with pre-chilled transfer buffer and placed on a shaker for five minutes 
(Scotsman Ice Systems, USA). 
The flat surface of Trans-blot® SD Semi-Dry Transfer Cell (Bio-Rad 
Laboratories, USA) was wet evenly with transfer buffer. Blot ‘sandwich’ was stacked 
up at the centre in the sequence of blotting filter paper at the bottom, followed by 
PVDF membrane, resolving gel and another blotting filter paper covered on the top. 
Plastic roller was used to roll on the blot ‘sandwich’ to remove bubbles trapped 
between the layers. Tissue paper was used to wipe off excess buffer surrounding the 
blot ‘sandwich’. The apparatus was covered and connected to the terminals of 
PowerPacTM Basic Power Supply (Bio-Rad Laboratories, USA) to transfer the proteins 
from gel to PVDF membrane at 15 volts for approximately 1.5 hours. 
3.5.8 Staining of Membrane and Gel 
Once the process of protein transfer was completed, PVDF membrane was 
removed and stained with Ponceau-S solution for approximately a minute, and then 
de-stained with sterile water slowly until the bands are visible. This step is important 
as it helps to identify the location of the desired protein according to the protein 
marker. A line was drawn horizontally just below the red colour protein band, and the 
membrane was cut into two parts horizontally along the line. The membrane was then 
de-stained thoroughly to remove Ponceau-S residue. The top part consisted of red 
colour protein band (protein size of 75 kDa) and the bottom part consisted of green 
colour protein band (protein size of 25 kDa) were ready for subsequent antibody 
incubation to identify the desired protein with different protein size. 
The gel was stained with Coomassie blue solution for an hour on a shaker. 
Coomassie blue solution was then removed, followed by incubation with acid solution 
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for an hour to de-stain the gel. The acid solution was removed and replaced for few 
times until the background turned clear. This step is to ensure the protein transfer 
process is completed without protein leftover. 
3.5.9 Blocking and Antibodies Incubation 
The cut PVDF membrane was incubated in blocking buffer at room 
temperature for an hour on a shaker. Blocking process helps to block the remaining 
membrane surface from non-specific binding of any detection antibodies during 
incubation. The membrane was washed with TBS-T for five minutes three times. 
Primary antibody was diluted in BSA with the dilution of 1:1000 for mouse 
monoclonal to eNOS (AB 76198, Abcam, UK) and 1:5000 for mouse monoclonal to 
ß-actin (AB 8226, Abcam, UK) (Mokhtar et al., 2016). The top part of the membrane 
was incubated with anti-eNOS antibody to identify eNOS with protein size of 133 kDa, 
while bottom part was incubated with anti-beta actin antibody to identify ß-actin with 
protein size of 42 kDa. Beta actin was used as the loading control to normalise for the 
amount of protein. The membrane was incubated at 4ºC for 16 hours on a shaker, 
followed by washing with TBS-T for five minutes three times. 
Secondary antibody was diluted in blocking buffer with the dilution of 1:1000 
for eNOS and 1:2000 for ß-actin (Mokhtar et. al., 2016). The membrane was incubated 
with horseradish peroxidase (HRP)-conjugated goat polyclonal secondary antibody at 
room temperature for an hour on a shaker. The membrane was washed with TBS-T 
five minutes three times and ready for subsequent visualization. 
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3.5.10 Visualization of Protein Expression 
Chemiluminescent HRP substrate (Nacalai Tesque, Japan) was used for protein 
band visualization. Substrate A and B were mixed in the ratio of 1:1 before transferring 
the mixture onto the membrane placed on a transparent sheet. The sheet was slightly 
agitated to ensure the whole surface of the membrane was soaked with the mixture. 
Excess solution was drained, followed by covering the sheet and with all visible 
bubbles removed. 
Chemiluminescent exposure to the membrane for 10 seconds was performed 
using Fusion Molecular Imager (FX-7.826.WL, Vilber Lourmat, France) to obtain the 
protein bands with visible intensity. A single band of eNOS with protein size of 
approximately 133 kDa and another single band of ß-actin with protein size of 
approximately 42 kDa were visible. The intensity of the protein bands was measured 
with Image J software version 1.8.0_112. The intensity of eNOS protein band 
represents the amounts of eNOS in the sample while the intensity of ß-actin protein 
band indicates the amount of total proteins in the same sample (Sigumura et al., 2010). 
Relative protein expression of eNOS normalised to the amount of total proteins was 
calculated according to the following equation.  
Relative protein expression of eNOS = 5 Amount		of	eNOS		Amount of total proteins6
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3.6 Immunohistochemistry 
Immunohistochemistry is conducted in this study to demonstrate the presence 
and localization of a specific protein in vascular tissue sections. This method is 
accomplished with a highly specific antibody that binds only with targeted 
antigens/proteins. The antibody-antigen relationship is then visualized using 
chromogenic detection. The outcomes from immunohistochemistry coupled with 
Western blot provide a better picture to explain the underlying mechanisms related to 
the effects of vitamin D deficiency on microvascular functional properties in rats, 
particularly regarded to the presence and localization of eNOS. Besides that, whether 
calcitriol supplementation improves the presence and localization of eNOS after a 
period of vitamin D deficiency was also examined. 
3.6.1 Chemicals 
 Chemicals used in immunohistochemistry are listed in Table 3.8. 
Table 3.8 Chemicals used in immunohistochemistry. 
Chemicals Manufacturer, Country of Origin 
Formaldehyde solution Mallinckrodt Chemicals, USA 
Xylene Merck, Germany 
Absolute ethanol HmbG Chemicals, Germany 
Trisodium citrate dehydrate Sigma Aldrich, USA 
Phosphate buffered saline (PBS) tablets Sigma Aldrich, USA 
3,3’-Diaminobenzidine (DAB) Invitrogen, USA 
Harris hematoxylin solution Labchem, Malaysia 
Dibutyl phthalate (DPX) mountant VWR International, UK 
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3.6.2 Preparation of Working Solutions 
i. Formalin solution (10%, pH 7.4) 
To prepare 100 mL of 10% formalin solution, 10 mL of formaldehyde solution 
was diluted to 100 mL with ddH2O and mixed well. The solution was adjusted to pH 
7.4. 
ii. Ethanol solution (95%) 
To prepare 100 mL of 95% ethanol solution, 95 mL of absolute ethanol (100%) 
was mixed well with 5 mL of ddH2O. 
iii. Ethanol solution (80%) 
To prepare 100 mL of 80% ethanol solution, 80 mL of absolute ethanol (100%) 
was mixed well with 20 mL of ddH2O. 
iv. Ethanol solution (70%) 
To prepare 100 mL of 70% ethanol solution, 70 mL of absolute ethanol (100%) 
was mixed well with 30 mL of ddH2O. 
v. Ethanol solution (50%) 
To prepare 100 mL of 50% ethanol solution, 50 mL of absolute ethanol (100%) 
was mixed well with 50 mL of ddH2O. 
vi. Phosphate buffered saline (pH 7.4) 
To prepare 1 L of phosphate buffered saline (PBS), 5 tablets of PBS was fully 
dissolved in 1 L of ddH2O. The solution was adjusted to pH 7.4. 
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vii. Sodium citrate buffer (0.01 M, pH 6.0) + Tween-20 (0.05%) 
To prepare 0.01 M sodium citrate buffer, 2.94 g of trisodium citrate dehydrate 
was fully dissolved in 1 L of ddH2O. The solution was adjusted to pH 6.0. 500 µL of 
Tween-20 was added into the solution, mixed well and stored at room temperature. 
viii. Tris-buffered saline + Tween-20 (0.1%) (TBS-T) 
To prepare 1 L of TBS-T, 2.4 g of Tris-base and 8.8 g of sodium chloride were 
fully dissolved in 1 L of ddH2O. The solution was adjusted to pH 7.6. 1 mL of Tween-
20 was added into the solution and mixed well. TBS-T was used as wash buffer and 
also in the preparation of blocking buffer. 
ix. Blocking buffer 
To prepare 5% blocking buffer (5% skimmed milk in TBS-T), 5.0 g of 
skimmed milk powder was fully dissolved in 100 mL of TBS-T. This solution was 
freshly prepared prior to usage. Blocking buffer was used as the diluent for antibodies. 
3.6.3 Experimental Protocols 
 3.6.3(a) Tissue Fixation, Embedding and Sectioning 
The harvested mesenteric arteries of the rats which had been cleaned of 
excessive fat and connective tissues were rinsed with ice-cold PSS to remove blood 
residue prior to tissue fixation. This precaution step is to prevent the detection of 
haematological antigens that might interfere with the detection of the targeted antigens. 
The arteries were fixed in 10% formalin solution at room temperature for 16 hours. 
The fixed arterial tissues were then cut into a 5-mm-thick section, wrapped with gauze 
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and enclosed in a pre-labelled tissue processing cassette, ready to be processed in an 
automatic tissue processor (TP 1020, Leica, Germany). 
The processed tissues were subsequently embedded in paraffin wax on the 
tissue embedding centre (Thermo Fisher Scientific, USA), left to solidify on a cold 
plate (Thermo Fisher Scientific, USA) to yield the paraffin-embedded tissue blocks. 
The blocks were pre-chilled, followed by sectioning into a 4-µm-thick tissue section 
using a rotary microtome (DM 2235, Leica, Germany). The sectioned tissues were 
flattened on a tissue floatation bath (HI 1210, Leica, Germany) set at 40ºC and 
subsequently mounted onto the surface of a clean pre-labelled poly-L-lysine slide. The 
slides were placed on a slide warmer (Thermo Fisher Scientific, USA) set at 50°C for 
an hour, followed by an overnight air-drying at room temperature and kept for 
subsequent immunohistochemical staining. 
 3.6.3(b) Heat Antigen Retrieval 
The tissue slides were heated on a slide warmer set at 60°C for an hour to 
increase tissue adherence to the slides. The slides were arranged in a glass rack, and 
the paraffin-embedded tissue sections underwent deparaffinization in xylene and serial 
rehydration in descending grades of alcohol, ready for heat antigen retrieval. Heat 
antigen retrieval is used to reverse the loss of antigenicity of the tissues during formalin 
fixation and paraffin block embedding. 
In brief, a glass beaker with sodium citrate buffer was heated in a water bath 
(Memmert, Germany) set at 95°C.  The slides were arranged surrounding the inner 
side of the beaker and incubated for 30 minutes. The beaker was left to cool in a basin 
filled with running tap water for 30 minutes. The slides were placed back in the glass 
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rack, immersed in ddH2O for five minutes and in TBS-T for 10 minutes three times, 
ready for primary antibody incubation. 
 3.6.3(c) Antibodies Incubation 
Primary antibody against eNOS was diluted in blocking buffer in the dilution 
ratio of 1:100. Tissue slides arranged on a staining tray were incubated with primary 
antibody at room temperature for two hours on a slow agitating shaker. The slides were 
then placed back in the glass rack, immersed in ddH2O for five minutes and in TBS-T 
for 10 minutes three times, ready for secondary antibody incubation. 
HRP-conjugated secondary antibody was diluted in blocking buffer in the 
dilution ratio of 1:200. Tissue slides arranged back on a staining tray were incubated 
with secondary antibody at room temperature for an hour on a slow agitating shaker. 
The slides were then placed back in the glass rack, immersed in ddH2O for five minutes 
and in TBS-T for 10 minutes three times, ready for tissue staining. 
 3.6.3(d) Tissue Staining 
Tissue slides arranged back on a staining tray were incubated with DAB 
substrate for five minutes. The presence of a reddish brown-coloured product on the 
stained tissues is the result of the reaction between HRP and DAB substrate, for the 
detection and visualization of protein. The slides were then placed back in the glass 
rack, immersed in ddH2O, TBS-T and ddH2O for three minutes each, proceeding to 
serial dehydration in a series of ascending grades of alcohol solutions and finally 
cleared in xylene. 
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 3.6.3(e) Slides Mounting and Visualization 
The stained tissue sections were then mounted under a coverslip using DPX 
mountant and ready for microscopy visualization. The stained tissue sections were 
examined under a light microscope equipped with an image analyser and digital 
camera (Olympus Corp, Japan) to capture photomicrographs. The visual intensity of 
reddish-brown colour was used to qualitatively demonstrate the presence and 
localization of the targeted protein on the tissue samples. A brief summary of general 
steps for immunohistochemical staining is illustrated in Figure 3.5. 
 
Figure 3.5 General steps for immunohistochemical staining. 
*Descending series of alcohol: 100% (2 minutes, 2 times), 95% (2 minutes), 80% (2 
minutes), 70% (2 minutes), 50% (2 minutes) 
#Ascending series of alcohol: 50% (2 minutes), 70% (2 minutes), 80% (2 minutes), 
95% (2 minutes), 100% (2 minutes, 2 times) 
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3.7 Measurement of Serum 25(OH) D Levels 
Serum concentrations of 25(OH)D is considered as the most reliable measure 
of overall vitamin D status. Serum 25(OH)D concentrations of rats and patients were 
measured using 25-Hydroxy Vitamin Ds Enzyme Immunoassay Assay Kit (AC-57SF1, 
IDS, UK) as per manufacturer’s protocol. 
The principle of this kit is based on the selective binding of HRP-labelled 
avidin to 25(OH)D in acidic medium, followed by detection with a chromogenic 
substrate. The absorbance at the wavelength of 450 nm (with reference to 650 nm) was 
obtained to develop a four-parameter logistic (4PL) curve fit using online MyAssay 
software (https://www.myassays.com). 
3.7.1 Preparation of Working Solutions 
i. 25(OH)D-biotin solution 
All reagents were brought to room temperature prior to usage. Buffer (3 mL) 
was added to the lyophilised 25(OH)D labelled with biotin. The solution was mixed 
well to dissociate 25(OH)D from binding proteins. The reconstituted biotin 
concentrate was added back to the remaining buffer to make 25(OH)D-biotin solution. 
The solution was mixed well and stored at 4ºC in an amber bottle. 
ii. Ready-to-use reagents 
Calibrators and Controls (serum containing 25(OH)D and 0.09% sodium 
azide), Assay Buffer (proprietary reagent for dissociating 25(OH)D from binding 
proteins), Enzyme Conjugate (avidin linked to HRP), Acid Solution (0.5 M 
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hydrochloric acid) and TMB Substrate (aqueous tetramethylbenzidine and hydrogen 
peroxide) were supplied ready-to-use. 
iii. Wash buffer 
To prepare 1L of wash buffer (1X), 50 mL of wash concentrate (phosphate 
buffered saline containing Tween, 20X) was diluted with ddH2O, mixed well and 
stored at room temperature. 
3.7.2 Preparation of Serum Samples 
Blood serum obtained from rats was further diluted with Assay Buffer in the 
dilution ratio of 1:5 (based on preliminary study) to prepare serum sample for assay. 
3.7.3 Assay Procedures 
Briefly, 25 µL of each calibrator, control and serum sample was added to a pre-
labelled microcentrifuge tube, followed by the addition of 1 mL of 25(OH)D-biotin 
solution, and vortexed thoroughly for 10 seconds. Then, 200 µL of calibrators (C1 to 
C6), controls (Ctrl 1 and Ctrl 2) and serum samples were loaded into the designated 
well of the microplate coated with 25(OH)D sheep polyclonal antibody. The plate was 
covered with an adhesive plate sealer and incubated at room temperature for two hours 
on a shaker. After incubation, the wash step was performed for three times; inverting 
the plate sharply to decant the contents, followed by dispensing 250 µL of wash buffer 
to all wells. The inverted plate was tapped firmly on an absorbent tissue to remove 
excess wash buffer. 
A multichannel pipette was used to add 200 µL of Enzyme Conjugate to all 
wells. Then, the plate was covered with adhesive plate sealer and incubated at room 
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temperature for 30 minutes on a shaker. Wash step as mentioned previously was done 
for three cycles. Following that, 200 µL of TMB Substrate was added to all wells using 
a multichannel pipette to avoid lapses in reaction time. Then, the plate was covered 
with adhesive plate sealer and incubated for another 30 minutes on a shaker. When the 
colour of the contents in the wells was visible, the reaction was stopped immediately 
by adding 100 µL of Acid Reagent to all wells. As soon, the absorbance of the mixtures 
was measured using VarioskanTM Flash Multimode Reader (Thermo Fisher Scientific, 
USA) set at the wavelength of 450 nm (with the reference absorbance at 650 nm). 
3.7.4 Calculations 
The net absorbance value of each sample was obtained by subtracting the 
absorbance value at 650 nm from the absorbance value at 450 nm. The corrected 
absorbance value was calculated by subtracting the net absorbance value of C0 (blank) 
from the net absorbance value of other calibrators, controls and samples. A 4PL curve 
fit was developed by constructing the corrected absorbance value of the standards 
against their respective 25(OH)D concentrations. The curve-fit equation generated was 
used to calculate the serum concentration of each sample based on their respective 
corrected absorbance values, expressed in SI units of nmol/L. 
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3.8 Sample Size Calculations 
The sample size for vascular response study and oxidative stress analysis of 
animal study was shown in Table 3.9. Calculation of sample size for animal study was 
performed using two means statistical formula based on the method developed by 
Florey (1993). 
n = 2 (Zα + Zβ)2 s2/d2 
Zα = 1.96 for the constant of α at 5% level of significance (two-tailed) 
Zβ =1.28 for the constant of β at 90% of study power. 
[n: sample size for each group; s: standard deviation of the measured variable; d: 
difference of interest] 
Table 3.9 Sample size calculations for vascular responses study and oxidative 





References Sample Size 
Vascular 
responses 
14.24% 9.27% Mokhtar et al., 2016 8.89  ͌  9 
Details:   Difference of interest was the Rmax mean difference in ACh-induced 
endothelium-dependent relaxation between diabetic and control rats. Standard 







Coskun et al., 2005 6.35  ͌  7 
Details: Tissue MDA levels. Difference of interest was the mean difference in tissue 
MDA concentrations between diabetic and control rats. Standard deviation for tissue 







Aydin and Celik, 2012 9.34  ͌  10 
Details: Tissue SOD levels. Difference of interest was the mean difference in tissue 
SOD concentrations between diabetic and control rats. Standard deviation for tissue 
SOD concentrations was taken from control rats. (p value < 0.005) 
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3.9 Statistical Analysis and Data Presentation 
Statistical analysis was performed using the IBM Statistical Package for the 
Social Sciences (SPSS) software version 24.0 (Armonk, NY, USA). The normality of 
data distribution was determined using both statistical test and descriptive methods 
involving visual inspection of the normality of data. Shapiro-Wilk test was preferred 
in this study compared to Kolmogorov-Smirnov test as Shapiro-Wilk test yielded 
higher study power and is an appropriate significance test for the normality of data 
involving a smaller sample size (Thode, 2002). The frequency distribution 
(histogram), stem-and-leaf plot, boxplot, P-P plot (probability-probability plot) and Q-
Q plot (quantile-quantile plot) were the descriptive methods used to perform visual 
inspection of the normality of data (Field, 2009). Normally distributed data were 
presented as mean±standard deviation (SD) in the table and text. The data were 
presented as mean±standard error of mean (SEM) in the figure. Non-normally 
distributed data were expressed as median±interquartile range (IQR). In all cases, the 
p value of less than 0.05 was considered as statistically significant. 
Levene’s test was used to determine the homogeneity of variance to ensure the 
variance is equal across groups before performing parametric or non-parametric test. 
If the assumption of the homogeneity of variance is fulfilled, the differences of the 
mean between the groups in normal and diabetic rats respectively were analysed using 
one-way analysis of variance (ANOVA). If the test is significant, Bonferroni’s post-
hoc test was performed to determine the mean differences between each pair. If the 
assumption is violated, non-parametric test is more appropriate to be conducted. The 
differences of the median between the groups were analysed using Kruskal-Wallis test. 
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If the test is significant, Dunn’s post hoc test was performed to compare the median 
differences between each pair. 
In animal study, the outcomes of all parameters were presented and analysed 
into two parts; (i) in the microcirculation of normal rats and (ii) in the microcirculation 
of diabetic rats. In the microcirculation of normal rats, the effects of vitamin D 
deficiency were studied by comparing between groups NC and ND. Groups ND and 
NDS were compared to determine if there was any improvement in the same parameter 
by calcitriol supplementation. Groups NC and NDS were also compared to study 
whether vitamin D supplementation is able to normalise the values of the parameters 
studied. 
Similarly, groups DC and DD were compared to determine the effects of 
vitamin D deficiency in diabetic rats, while DD and DDS groups were compared to 
study if there was any reversibility in the same parameter in the microcirculation of 
vitamin D-deficient diabetic rats by calcitriol supplementation. Groups DC and DDS 
were also compared to determine whether vitamin D supplementation normalised the 
values. There was no direct comparison made between normal and diabetic rats with 
different vitamin D status. However, any valuable finding on the pattern of studied 
parameters showed by normal and diabetic rats was discussed briefly. 
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3.10 Human Study 
3.10.1 Ethical Approval 
The ethical approval for human study was obtained from the Human Research 
Ethics Committee, USM, Health Campus, Kelantan (No. USM/JEPeM/15100337) 
(Appendix B). This cross-sectional study was conducted according to the provisions 
of the Declaration of Helsinki. 
3.10.2 Patients 
The study subjects were recruited from diabetic patients who needed to 
undergo lower limb surgical procedures by Orthopaedic Department, Hospital 
Universiti Sains Malaysia (HUSM), Kelantan. 
 3.10.2(a) General Information and Physical Evaluation 
After recruitment, general information of the subjects such as age, gender, 
disease duration, previous medical conditions and medication history, current medical 
illness and on-going medication list were obtained and recorded in a case report form 
(Appendix D). Physical evaluation included measurements of weight and height for 
body mass index (BMI) determination, measurements of systolic (SBP) and diastolic 
(DBP) blood pressures were also conducted and recorded for all subjects. 
 3.10.2(b) Inclusion and Exclusion Criteria 
All subjects needed to fulfil inclusion and exclusion criteria as listed in Table 
3.10 to be accepted into this study. The accepted participants were required to give 
written informed consent after the research details have been explained to them prior 
to surgical procedures. 
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Table 3.10 Inclusion and exclusion criteria for diabetic patients’ recruitment. 
Inclusion Criteria Exclusion Criteria 
Aged between 18 to 65 years old. 
 
Had uncontrolled hypertension 
(brachial blood pressure > 160/90 
mmHg). 
Diagnosed with diabetes (HbA1c > 6.5%) 
for at least 10 years. 
Had medical history of myocardial 
infarction and coronary heart disease. 
Needed to undergo lower limb 
orthopaedic surgical procedures. 
Had renal or hepatic failure. 
Agreed to sign the informed consent form. Underwent surgery for tumour tissue 
removal. 
 Had taken or taking vitamin D and/or 
calcium as supplements within a year 
 
At the beginning, a total of 50 diabetic patients were recruited to participate. 
Of these, only 23 patients who fulfilled the inclusion and exclusion criteria and agreed 
to sign the informed consent form (Appendix C) were included in this study. 
3.10.3 Experimental Design 
 3.10.3(a) Blood Sample Collection 
A day before the surgery, venous blood samples were collected from the 
subjects into a plain Vacutainer tube for the assay of serum 25(OH)D levels. The blood 
samples were allowed to clot at 4ºC before being centrifuged at 4000 x g at 4ºC for 10 
minutes. The serum yielded was collected and stored at -80ºC before subsequent 
measurement of 25(OH)D concentrations using an assay kit. 
For the assessment of other parameters such as FBG, glycated haemoglobin 
(HbA1c) levels, calcium and total cholesterol levels, latest results (not longer than three 
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months) were extracted from their medical records prior to surgery. If the latest result 
is not available for the patient, the blood samples collected from the subjects were 
aliquoted and sent to HUSM laboratory for the measurements of these parameters. 
 3.10.3(b) Specimen Collection and Subcutaneous Artery Isolation 
During lower limb surgical procedures such as below knee amputation, above 
knee amputation, ray amputation, wound debridement and skin grafting, subcutaneous 
fat tissue sample was collected from the removed parts of the subjects by the 
orthopaedic surgical team from Orthopaedic Department, HUSM, Kelantan. The 
amount of tissue sample collected varies depending on the types of surgical procedures 
conducted. A piece of normal and healthy tissue sample, away from the infected area 
and with intact blood vessels, with the dimension of approximately 2 cm (length) x 2 
cm (width) x 2 cm (thickness), was preferred in this study. However, there were cases 
of less tissue could be taken as the area of surgery was limited, particularly during 
wound debridement and ray amputation. In that case, relatively smaller pieces of tissue 
samples were also acceptable. The non-infected tissue sample harvested was 
confirmed by the visualization of normal and healthy appearance (absence of signs of 
gross infection such as pus or slough), while the presence of blood vessels was 
identified by good bleeding from the tissue.  
The specimen was immediately placed in a plastic container filled with ice-
cold, oxygenated PSS and transferred to Pharmacology Vascular Laboratory for 
microscopy dissection. Subcutaneous arteries with luminal diameter of less than 200 
µm were isolated with gentle care to ensure the viability of the vessels for subsequent 
measurement of oxidative stress parameters (SOD and MDA levels). The isolated 
subcutaneous artery was further dissected to remove excess fat and connective tissues. 
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 3.10.3(c) Tissue Lysate and Supernatant Preparation 
Isolated subcutaneous artery which had been cleaned of excess fat and 
connective tissues was rinsed with PSS for three times to remove excess blood that 
might interfere with the study outcome. The artery was then finely chopped in a 
microcentrifuge tube filled with 100 µL of pre-chilled lysis buffer on ice using 
dissecting scissors to prepare subcutaneous arterial tissue lysate. The tissue lysate was 
incubated at 4ºC for 10 minutes, followed by centrifugation at 12,000 x g at 4 ºC for 
five minutes. The yield supernatant was kept at -80°C for subsequent experimental 
protocols of total protein quantification and oxidative stress analysis. 
 3.10.3(d) Group Division 
After sufficient collection of samples from study subjects, the measurement of 
serum 25(OH)D levels was performed. Based on the levels of serum 25(OH)D, the 
study subjects were categorised into two groups: vitamin D non-deficient diabetic 
patients (DNP) and vitamin D-deficient diabetic patients (DDP). As defined by the 
Endocrine Society of USA, subjects with serum 25(OH) D levels of < 50 nmol/L were 
considered as vitamin D-deficient (Holick et al., 2011). Subjects with serum 25(OH)D 
concentrations of ≥ 50 nmol/L were regarded as vitamin D non-deficient. In this study, 
10 subjects who had serum 25(OH)D levels of ≥ 50 nmol/L were categorised into 
group DNP; while 13 subjects who had serum 25(OH)D levels of < 50 nmol/L were 
categorised into group DDP. After group division, the measurements of oxidative 
stress parameters (MDA and SOD levels) were then conducted. The detailed flow chart 
of the human study is illustrated in Figure 3.6. 
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Figure 3.6 Flow chart for the human study. 
Microvascular Tissue Oxidative Stress  
* superoxide dismutase (SOD) levels 
* malondialdehyde (MDA) levels 
Vitamin D-deficient Diabetics 
(Serum 25(OH)D < 50 nmol/L) 
[Group DDP]  
(n = 13) 
Vitamin D Non-deficient Diabetics 
(Serum 25(OH)D ≥ 50 nmol/L) 
[Group DNP]  
(n = 10) 
Recruitment of Diabetic Patients 
Lower Limb Surgical Procedures 
General Information & Physical Evaluation 
Subcutaneous Fat Tissue Sample Collection  
& Subcutaneous Artery Isolation 
Blood Sample Collection for  
Serum 25(OH)D Levels Measurement 
 
Fulfilled Inclusion & 
 Exclusion Criteria 
Given Written 
 Informed Consent 
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3.10.4 Measurement of Serum 25(OH)D Levels 
The stored blood serum was further diluted with Assay Buffer in the dilution 
ratio of 1:2 (based on preliminary study) to prepare human blood serum samples for 
assay. The assay was then performed as described in Section 3.7 to measure serum 
25(OH)D concentrations. 
3.10.5 Total Protein Quantification 
The stored supernatant of subcutaneous arterial tissue lysate was further diluted 
with ddH2O in the dilution ratio of 1:100 (based on preliminary study) to prepare 
human tissue samples for assay. The assay was performed as described in Section 3.3 
to quantify total protein concentrations. 
3.10.6 Oxidative Stress Analysis 
3.10.6(a) Superoxide Dismutase Levels 
The stored supernatant of the subcutaneous arterial tissue lysate was further 
diluted with ice-cold lysis buffer in the dilution ratio of 1:10 (based on preliminary 
study) to prepare human tissue samples for assay. The assay was performed as 
described in Section 3.4.1 to measure SOD concentrations. 
3.10.6(b) Malondialdehyde Levels 
The stored supernatant of the subcutaneous arterial tissue lysate was further 
diluted with assay buffer in the dilution ratio of 1:100 (based on preliminary study) to 
prepare human tissue samples for assay. The assay was performed as described in 
Section 3.4.2 to measure MDA concentrations. 
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3.10.7 Sample Size Calculations 
Sample size calculation for oxidative stress analysis of human samples was 
performed using the following two means statistical formula (Florey, 1993). The 
sample size for oxidative stress analysis of human study was shown in Table 3.11. 
n = 2 (Zα + Zβ)2 s2 / d2 
Zα = 1.96, the constant of α at 5% level of significance (two-tailed) 
Zβ =1.28, the constant of β at 90% of study power. 
[n: sample size for each group; s: standard deviation of the measured variable; d: 
difference of interest] 





References Sample Size 
Oxidative Stress 
(SOD Levels) 




Hisalkar et al., 2012 7.40  ͌  8 
Details: Serum SOD levels. Difference of interest was the mean difference in serum 
SOD concentrations between diabetic patients and controls. Standard deviation for 







Kumawat et al., 2013 8.56  ͌  9 
Details: Plasma MDA levels. Difference of interest was the mean difference in plasma 
MDA concentrations between diabetic patients and controls. Standard deviation for 
plasma MDA concentrations was taken from diabetic patients. (p value < 0.05) 
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3.10.8 Statistical Analysis and Data Presentation 
Statistical analysis was performed using the IBM Statistical Package for the 
Social Sciences (SPSS) software version 24.0 (Armonk, NY, USA). The methods to 
determine the normality of data were as described in Section 3.9. Normally distributed 
data were presented as mean±standard deviation (SD) in the table and text. The data 
were presented as mean±standard error of mean (SEM) in the figure. Non-normally 
distributed data were expressed as median±interquartile range (IQR). In all cases, the 
p value of less than 0.05 was considered as statistically significant. 
The differences for numerical variables between vitamin D-deficient and 
vitamin D non-deficient diabetic patients were determined by using independent t-test 
(for normally distributed data) or Mann-Whitney test (for non-normally distributed 
data) as appropriate. Pearson Chi-Square test was used to determine the differences for 
categorical variables between two study groups. When a significant difference for a 
particular parameter between vitamin D-deficient and vitamin D non-deficient diabetic 
patients was found, or the particular parameter has been suggested in previous study 
as the potential covariate, the parameter was subsequently tested in the analysis of 
covariance (ANCOVA).  
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CHAPTER 4 
RESULTS 
4.1 Animal Study 
Normally distributed data were presented as mean±standard deviation (SD) 
while non-normally distributed data were expressed as median±interquartile range 
(IQR) in Tables. The data were presented as mean±standard error of mean (SEM) in 
Figures. In all cases, the p value of less than 0.05 was considered as statistically 
significant.  
If the assumption of the homogeneity of variance is fulfilled, one-way analysis 
of variance (ANOVA) followed by a Bonferroni’s post-hoc test was performed. If the 
assumption is violated, Kruskal-Wallis test followed by a Dunn’s post hoc test was 
performed.  The changes of a parameter over time within the same group were tested 
using paired t-test. 
4.1.1 Body Weight 
Baseline body weight (BW) was measured on the day of successful diabetes 
induction (defined as week one, W1). At the end of 10-weeks study duration, final body 
weight was measured on the day of sacrifice (defined as week ten, W10). Body weight 
changes throughout the 10-weeks study period were calculated based on the following 
formula: 
BW	Changes	(%) = 	Final	BW − Baseline	BWBaseline	BW 	x	100 
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Normal Rats 
Baseline and final body weight of normal rats with corresponding body weight 
changes were listed in Table 4.1. Baseline body weight of all study groups in normal 
rats was similar at the beginning of the study (W1). Throughout the 10-weeks study 
duration, all groups in normal rats gained significant weight over time (p < 0.001). At 
the end of 10-weeks study period (W10), all groups in normal rats had comparable final 
body weight. 
In normal rats, there was no significant difference in body weight changes 
between rats receiving control diet (group NC) and rats receiving vitamin D-deficient 
diet (group ND) at the end of study duration (W10) (p = 0.480). However, calcitriol 
supplementation to vitamin D-deficient rats (group NDS) showed the trend of reduced 
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Table 4.1  Body weight (BW) of normal rats at baseline and after ten-weeks 
study duration with corresponding body weight changes.   
Groups Baseline BW at W1 (g) Final BW at W10 (g) BW Changes (%) 
NC 250.70±28.39 442.60±74.15 * 77.80±30.15 
ND 245.60±32.15 476.40±71.40 * 96.50±35.65 
NDS 261.00±25.02 431.00±14.67 * 66.60±18.28 
One-way 
ANOVA 
p = 0.483 p = 0.232 p = 0.084 
(n = 10 rats per group) 
* p < 0.001 when compared to baseline body weight. 
There was no significant difference in baseline body weight, final body weight and 
body weight changes between study groups in normal rats. 
[NC: normal rats with control diet; ND: normal rats with vitamin D-deficient diet; 
NDS: normal rats with vitamin D-deficient diet + calcitriol supplementation.] 
 
 Figure 4.1     Body weight changes of normal rats after ten-weeks study duration. 
(n = 10 rats per group) 
There was no significant difference in body weight changes between study groups in 
normal rats (p = 0.084). 
[NC: normal rats with control diet; ND: normal rats with vitamin D-deficient diet; 
NDS: normal rats with vitamin D-deficient diet + calcitriol supplementation] 
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Diabetic Rats 
Baseline and final body weight of diabetic rats with corresponding body weight 
changes were listed in Table 4.2. Baseline body weight of all study groups in diabetic 
rats was similar at the beginning of the study (W1). Throughout the 10-weeks study 
duration, diabetic rats receiving control diet (group DC) showed no significant 
difference in their body weight (p = 0.173). Diabetic rats receiving vitamin D-deficient 
diet (groups DD) and calcitriol-supplemented vitamin D-deficient diabetic rats (group 
DDS) gained significant weight over time (p = 0.021 and p = 0.007 respectively). 
However, all groups in diabetic rats had comparable final body weight at the end of 
10-weeks study duration. There was no significant difference in body weight changes 
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Table 4.2       Body weight (BW) of diabetic rats at baseline and after ten-weeks    
                       study duration with corresponding body weight changes.  
Groups Baseline BW at W1 (g) Final BW at W10 (g) BW Changes (%) 
DC 257.80±26.00 278.60±45.28 8.54±17.14 
DD 261.00±27.82 316.90±53.63 * 22.86±24.75 
DDS 233.70±32.62 276.50±31.58 # 19.97±20.11 
One-way 
ANOVA 
p = 0.088 p = 0.091 p = 0.286 
(n = 10 rats per group) 
* p < 0.05 and # p < 0.01 when compared to baseline body weight. 
There was no significant difference in baseline body weight, final body weight and 
body weight changes between study groups in diabetic rats. 
[DC: diabetic rats with control diet; DD: diabetic rats with vitamin D-deficient diet; 
DDS: diabetic rats with vitamin D-deficient diet + calcitriol supplementation] 
 
Figure 4.2     Body weight changes of diabetic rats after ten-weeks study duration.   
(n = 10 rats per group) 
There was no significant difference in body weight changes between study groups in 
diabetic rats (p = 0.286). 
[DC: diabetic rats with control diet; DD: diabetic rats with vitamin D-deficient diet; 
DDS: diabetic rats with vitamin D-deficient diet + calcitriol supplementation]
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4.1.2 Fasting Blood Glucose Levels 
Normal Rats 
Baseline and final fasting blood glucose (FBG) levels of normal rats were listed 
in Table 4.3. In normal rats, there was no significant difference in baseline and final 
FBG levels at the beginning of the study (W1) and also at the end of 10-weeks study 
duration (W10) between rats receiving control diet (group NC), rats receiving vitamin 
D-deficient diet (group ND) and vitamin D-deficient rats supplemented with calcitriol 
(group NDS). Throughout the 10-weeks study duration, the FBG levels of all groups 
in normal rats did not show significant changes over time. 
Table 4.3 Baseline and final fasting blood glucose (FBG) levels of normal rats.  
Groups Baseline FBG levels 
at W1 (mmol/L) 
Final FBG levels 
at W10 (mmol/L) 
NC 5.98±0.42 5.79±0.58 
ND 6.12±0.28 6.18±1.19 
NDS 6.05±0.30 5.75±0.61 
One-way ANOVA p = 0.658 p = 0.463 
(n = 10 rats per group) 
There were no significant changes in fasting blood glucose (FBG) levels of normal 
rats over ten-weeks study duration. 
There was no significant difference in baseline and final fasting blood glucose (FBG) 
levels between study groups in normal rats. 
[NC: normal rats with control diet; ND: normal rats with vitamin D-deficient diet; 
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Diabetic Rats 
Baseline and final FBG levels of diabetic rats were listed in Table 4.4. 
Similarly, baseline FBG levels were comparable between study groups in diabetic rats 
at the beginning of the study. Throughout the 10-weeks study duration, there was a 
significant increase in FBG levels over time observed in groups DC (p = 0.0019) and 
DDS (p = 0.0066), but not in group DD (p = 0.284). However, all groups showed no 
significant difference in final FBG levels at the end of 10-weeks study duration. 
Table 4.4 Baseline and final fasting blood glucose (FBG) levels of diabetic rats.   
Groups Baseline FBG levels 
at W1 (mmol/L) 
Final FBG levels 
at W10 (mmol/L) 
DC 25.85±4.83 31.39±2.54 * 
DD 26.39±4.45 28.73±5.32 
DDS 28.63±4.36 32.16±1.84 * 
One-way ANOVA p = 0.364 p = 0.097 
(n = 10 rats per group). 
* p < 0.01 when compared to baseline FBG levels. 
There was no significant difference in baseline and final fasting blood glucose (FBG) 
levels between study groups in diabetic rats. 
[DC: diabetic rats with control diet; DD: diabetic rats with vitamin D-deficient diet; 
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4.1.3 Vitamin D Levels 
Vitamin D levels were determined by the measurement of 25(OH)D 
concentrations in serum samples. 
Normal Rats 
In normal rats, serum vitamin D levels in rats receiving vitamin D-deficient 
diet (groups ND and NDS) were significantly lower compared to rats receiving control 
diet (group NC) (p < 0.001). No significant difference in vitamin D levels was 
observed in group NDS that received calcitriol supplementation for four weeks 
compared to group ND (p = 0.2797). (Figure 4.3). [25(OH)D - NC: 35.24±7.52 
nmol/L; ND: 3.73±2.57 nmol/L; NDS: 7.61±3.41 nmol/L] 
 
 Figure 4.3  Vitamin D levels (serum 25(OH)D concentrations) of normal rats.  
(n = 10 rats per group). 
p < 0.001 (One-way ANOVA); a p < 0.001 when compared to group NC. 
[NC: normal rats with control diet; ND: normal rats with vitamin D-deficient diet; 
NDS: normal rats with vitamin D-deficient diet + calcitriol supplementation] 
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Diabetic Rats 
A similar pattern on serum vitamin D levels was observed in diabetic rats. 
Diabetic rats receiving vitamin D-deficient diet (groups DD & DDS) showed 
significantly lower serum vitamin D levels compared to diabetic rats receiving control 
diet (group DC) (p < 0.001). However, supplementation with calcitriol for four weeks 
(group DDS) did not improve vitamin D levels when compared to group DD (p = 
0.995). (Figure 4.4). [25(OH)D - DC: 40.57±8.14 nmol/L; DD: 3.55±2.25 nmol/L; 
DDS: 5.77±2.07 nmol/L] 
 
 
Figure 4.4  Vitamin D levels (serum 25(OH)D concentrations) of diabetic rats.  
 (n = 10 rats per group). 
p < 0.001 (One-way ANOVA); a p < 0.001 when compared to group DC. 
[DC: diabetic rats with control diet; DD: diabetic rats with vitamin D-deficient diet; 
DDS: diabetic rats with vitamin D-deficient diet + calcitriol supplementation] 
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4.1.4 Calcium Levels 
Normal Rats 
In normal rats, no significant difference in serum calcium levels was observed 
in rats receiving control diet (group NC) and rats receiving vitamin D-deficient diet 
(group ND). However, serum calcium levels were significantly increased in vitamin 
D-deficient rats supplemented with calcitriol (group NDS) compared to groups NC (p 
= 0.009) and ND (p = 0.005) (Figure 4.5). [Ca - NC: 2.76±0.29 mmol/L; ND: 
2.73±0.28 mmol/L; NDS: 3.19±0.32 mmol/L] 
 
 
Figure 4.5 Serum calcium levels of normal rats. 
(n = 10 rats per group) 
p = 0.002 (One-way ANOVA) 
a p < 0.01 when compared to group NC; b p < 0.01 when compared to group ND. 
[NC: normal rats with control diet; ND: normal rats with vitamin D-deficient diet; 
NDS: normal rats with vitamin D-deficient diet + calcitriol supplementation] 
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Diabetic Rats 
In diabetic rats, there was no significant difference in serum calcium levels 
observed in rats receiving vitamin D-deficient diet (groups DD and DDS) compared 
to rats receiving control diet (group DC). Four-weeks calcitriol supplementation to 
group DDS did not show significant changes in serum calcium levels when compared 




Figure 4.6 Serum calcium levels of diabetic rats. 
 (n = 10 rats per group) 
There was no significant difference in serum calcium levels between study groups in 
diabetic rats (p = 0.060). 
[DC: diabetic rats with control diet; DD: diabetic rats with vitamin D-deficient diet; 
DDS: diabetic rats with vitamin D-deficient diet + calcitriol supplementation] 
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4.1.5 Endothelium-dependent Microvascular Responses 
 4.1.5(a) Acetylcholine-induced Endothelium-dependent Relaxation 
Normal Rats 
Figure 4.7 showed the concentration-response curves and maximal relaxation 
(Rmax) of acetylcholine (ACh)-induced endothelium-dependent relaxation in 
mesenteric arteries of normal rats. In normal rats, maximal relaxation to ACh-mediated 
response was significantly lower in rats receiving vitamin D-deficient diet (groups ND 
and NDS) compared to rats receiving control diet (group NC) (p = 0.003 and p < 0.001 
respectively). Calcitriol supplementation to vitamin D-deficient rats (group NDS) 
showed no significant difference in maximal relaxation to ACh compared to group 









Figure 4.7 Concentration-response curves and maximal relaxation of 
acetylcholine-induced endothelium-dependent relaxation in mesenteric 
arteries of normal rats. 
(n = 10 rats per group) 
p < 0.001 (One-way ANOVA) 
a** p < 0.01 and a*** p < 0.001 when compared to group NC. 
[NC: normal rats with control diet; ND: normal rats with vitamin D-deficient diet; 
NDS: normal rats with vitamin D-deficient diet + calcitriol supplementation] 
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Diabetic Rats 
Figure 4.8 showed the concentration-response curves and maximal relaxation 
(Rmax) of ACh-induced endothelium-dependent relaxation in mesenteric arteries of 
diabetic rats. In diabetic rats, rats receiving vitamin D-deficient diet (group DD) had 
significantly lower maximal relaxation to ACh compared to diabetic controls (group 
DC) (p = 0.001). Calcitriol supplementation for four weeks in group DDS showed a 
significant improvement in ACh-mediated maximal relaxation compared to group DD 
(p = 0.011) and the maximal relaxation was comparable to group DC. [Rmax - DC: 










Figure 4.8 Concentration-response curves and maximal relaxation of 
acetylcholine-induced endothelium-dependent relaxation in mesenteric 
arteries of diabetic rats. 
(n = 10 rats per group) 
p = 0.001 (One-way ANOVA) 
a** p < 0.01 when compared to group DC; b* p < 0.05 when compared to group DD. 
[DC: diabetic rats with control diet; DD: diabetic rats with vitamin D-deficient diet; 
DDS: diabetic rats with vitamin D-deficient diet + calcitriol supplementation]
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 4.1.5(b) Calcium Ionophore-induced Endothelium-dependent Contraction 
Normal Rats 
Figure 4.9 showed the concentration-response curves and maximal contraction 
(Emax) of calcium ionophore (CaI)-induced endothelium-dependent contraction in 
mesenteric arteries of normal rats. In normal rats, there was no significant difference 
in maximal contraction to CaI-mediated response between rats receiving control diet 
(group NC) and rats receiving vitamin D-deficient diet (group ND). However, vitamin 
D-deficient rats with calcitriol supplementation showed significantly higher in 
maximal contraction to CaI compared to groups ND (p = 0.016) and NC (p = 0.006). 











Figure 4.9 Concentration-response curves and maximal contraction of calcium 
ionophore-induced endothelium-dependent contraction in mesenteric 
arteries of normal rats. 
(n = 10 rats per group) 
p = 0.004 (One-way ANOVA) 
a** p < 0.01 when compared to group NC; b* p < 0.05 when compared to group ND. 
[NC: normal rats with control diet; ND: normal rats with vitamin D-deficient diet; 
NDS: normal rats with vitamin D-deficient diet + calcitriol supplementation] 
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Diabetic Rats 
Figure 4.10 showed the concentration-response curves and maximal 
contraction (Emax) of CaI-induced endothelium-dependent contraction in mesenteric 
arteries of diabetic rats. In diabetic rats, rats receiving vitamin D-deficient diet (group 
DD) showed significantly higher maximal contraction to CaI compared to rats 
receiving control diet (group DC) (p = 0.006). However, calcitriol supplementation in 
group DDS showed no significant difference in CaI-mediated maximal contraction 
compared to group DD and the maximal contraction remained significantly higher 











Figure 4.10 Concentration-response curves and maximal contraction of calcium 
ionophore-induced endothelium-dependent contraction in mesenteric 
arteries of diabetic rats. 
(n = 10 rats per group) 
p = 0.005 (One-way ANOVA) 
a** p < 0.01 when compared to group DC; a* p < 0.05 when compared to group DC. 
[DC: diabetic rats with control diet; DD: diabetic rats with vitamin D-deficient diet; 
DDS: diabetic rats with vitamin D-deficient diet + calcitriol supplementation]
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4.1.6 Endothelium-independent Microvascular Responses 
 4.1.6(a) Sodium Nitroprusside-induced Endothelium-independent Relaxation 
Normal Rats 
Figure 4.11 showed the concentration-response curves and maximal relaxation 
(Rmax) of sodium nitroprusside (SNP)-induced endothelium-independent relaxation in 
mesenteric arteries of normal rats. In normal rats, there was no significant difference 
in maximal relaxation to SNP-mediated response between rats receiving control diet 
(group NC) and rats receiving vitamin D-deficient diet (group ND). However, 
calcitriol supplementation to vitamin D-deficient rats (group NDS) showed a reduced 
trend in maximal relaxation to SNP compared to group ND (p = 0.101). Also, group 
NDS had significantly lower maximal relaxation to SNP compared to group NC (p = 








Figure 4.11 Concentration-response curves and maximal relaxation of sodium 
nitroprusside-induced endothelium-independent relaxation in 
mesenteric arteries of normal rats. 
(n = 10 rats per group) 
p = 0.025 (One-way ANOVA) 
a* p < 0.05 when compared to group NC. 
[NC: normal rats with control diet; ND: normal rats with vitamin D-deficient diet; 
NDS: normal rats with vitamin D-deficient diet + calcitriol supplementation] 
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Diabetic Rats 
Figure 4.12 showed the concentration-response curves and maximal relaxation 
(Rmax) of SNP-induced endothelium-independent relaxation in mesenteric arteries of 
diabetic rats. In diabetic rats, rats receiving vitamin D-deficient diet (group DD) had 
significantly lower maximal relaxation to SNP compared to group DC (p < 0.001). 
There was no significant difference in SNP-mediated maximal relaxation between 
group DDS that received calcitriol supplementation and group DD. [Rmax - DC: 











Figure 4.12 Concentration-response curves and maximal relaxation of sodium 
nitroprusside-induced endothelium-independent relaxation in 
mesenteric arteries of diabetic rats. 
(n = 10 rats per group) 
p < 0.001 (One-way ANOVA) 
a*** p < 0.001 when compared to group DC. 
[DC: diabetic rats with control diet; DD: diabetic rats with vitamin D-deficient diet; 
DDS: diabetic rats with vitamin D-deficient diet + calcitriol supplementation] 
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 4.1.6(b) Salbutamol-induced Endothelium-independent Relaxation 
Normal Rats 
Figure 4.13 showed the concentration-response curves and maximal relaxation 
(Rmax) of salbutamol (SB)-induced endothelium-independent relaxation in mesenteric 
arteries of normal rats. All groups in normal rats regardless of diet and supplementation 
(groups NC, ND and NDS) showed comparable maximal relaxation to SB-mediated 
response. [Rmax - NC: 91.12±9.10%; ND: 96.06±4.52%; NDS: 95.74±3.47%] 




Figure 4.13 Concentration-response curves and maximal relaxation of salbutamol-
induced endothelium-independent relaxation in mesenteric arteries of 
normal rats. 
(n = 10 rats per group) 
There was no significant difference between study groups in normal rats (p = 0.156). 
[NC: normal rats with control diet; ND: normal rats with vitamin D-deficient diet; 
NDS: normal rats with vitamin D-deficient diet + calcitriol supplementation] 
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Diabetic Rats 
Figure 4.14 showed the concentration-response curves and maximal relaxation 
(Rmax) of SB-induced endothelium-independent relaxation in mesenteric arteries of 
diabetic rats. Similarly, all groups in diabetic rats (groups DC, DD and DDS) showed 
no significant difference in SB-mediated maximal relaxation (p = 0.628). [Rmax - DC: 













Figure 4.14 Concentration-response curves and maximal relaxation of salbutamol-
induced endothelium-independent relaxation in mesenteric arteries of 
diabetic rats. 
(n = 10 rats per group) 
There was no significant difference between study groups in diabetic rats (p = 0.628). 
[DC: diabetic rats with control diet; DD: diabetic rats with vitamin D-deficient diet; 
DDS: diabetic rats with vitamin D-deficient diet + calcitriol supplementation] 
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 4.1.6(c) Phenylephrine-induced Endothelium-independent Contraction 
Normal Rats 
Figure 4.15 showed the concentration-response curves and maximal 
contraction (Emax) of phenylephrine (PE)-induced endothelium-independent 
contraction in mesenteric arteries of normal rats. All groups in normal rats (groups NC, 
ND and NDS) had comparable PE-mediated maximal contraction (p = 0.358). [Emax - 
NC: 118.50±40.31%; ND: 117.10±42.94%; NDS: 142.60±47.99%] 
 




Figure 4.15 Concentration-response curves and maximal contraction of 
phenylephrine-induced endothelium-independent contraction in 
mesenteric arteries of normal rats. 
(n = 10 rats per group) 
There was no significant difference between study groups in normal rats (p = 0.358). 
[NC: normal rats with control diet; ND: normal rats with vitamin D-deficient diet; 
NDS: normal rats with vitamin D-deficient diet + calcitriol supplementation] 
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Diabetic Rats 
Figure 4.16 showed the concentration-response curves and maximal 
contraction of PE-induced endothelium-independent contraction in mesenteric arteries 
of diabetic rats respectively. Similarly, all groups in diabetic rats (groups DC, DD and 
DDS) showed comparable maximal contraction to PE-mediated response (p = 0.577). 
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Figure 4.16 Concentration-response curves and maximal contraction of 
phenylephrine-induced endothelium-independent contraction in 
mesenteric arteries of diabetic rats. 
(n = 10 rats per group) 
There was no significant difference between study groups in diabetic rats (p = 0.577). 
[DC: diabetic rats with control diet; DD: diabetic rats with vitamin D-deficient diet; 
DDS: diabetic rats with vitamin D-deficient diet + calcitriol supplementation] 
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4.1.7 Oxidative Stress Parameters 
 4.1.7(a) Superoxide Dismutase Levels 
Normal Rats 
In normal rats, SOD levels of rats receiving vitamin D-deficient diet (group 
ND) were significantly lower than rats receiving control diet (group NC) (p = 0.002). 
Calcitriol supplementation to vitamin D-deficient rats (group NDS) did not improve 
SOD levels when compared to group ND and the SOD levels remained significantly 
lower than group NC (p = 0.003) (Figure 4.17). [SOD - NC: 27.75±10.63 U/mg 
protein; ND: 13.72±6.02 U/mg protein; NDS: 14.07±7.57 U/mg protein] 
 
Figure 4.17  Superoxide dismutase levels of normal rats. 
 (n = 10 rats per group) 
a p < 0.001 (One-way ANOVA) 
a p < 0.01 when compared to group NC. 
[NC: normal rats with control diet; ND: normal rats with vitamin D-deficient diet; 
NDS: normal rats with vitamin D-deficient diet + calcitriol supplementation] 
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Diabetic Rats 
In diabetic rats, rats receiving vitamin D-deficient diet (group DD) had 
significantly lower SOD levels than diabetic controls (group DC) (p = 0.030). 
However, calcitriol supplementation significantly increased SOD levels in group DDS 
compared to group DD (p = 0.007) and the SOD levels were comparable to group DC 
(Figure 4.18). [SOD - DC: 25.58±5.83 U/mg protein; DD: 12.38±4.28 U/mg protein; 
DDS: 28.40±16.95 U/mg protein] 
 
Figure 4.18  Superoxide dismutase levels of diabetic rats. 
(n = 10 rats per group) 
p < 0.001 (One-way ANOVA) 
a p < 0.05 when compared to group DC; b p < 0.01 when compared to group DD. 
[DC: diabetic rats with control diet; DD: diabetic rats with vitamin D-deficient diet; 
DDS: diabetic rats with vitamin D-deficient diet + calcitriol supplementation] 
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 4.1.7(b) Malondialdehyde Levels 
Normal Rats 
In normal rats, there was no statistical difference in MDA levels between all 
study groups (groups NC, ND and NDS) (p = 0.165) (Figure 4.19). [MDA - NC: 
2.14±0.91 nmol/mg protein; ND: 3.12±2.02 nmol/mg protein; NDS: 1.85±1.39 
nmol/mg protein] 
 
Figure 4.19  Malondialdehyde levels of normal rats. 
(n = 10 rats per group) 
There was no significant difference between study groups in normal rats (p = 0.165). 
[NC: normal rats with control diet; ND: normal rats with vitamin D-deficient diet; 
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Diabetic Rats 
Diabetic rats receiving vitamin D-deficient diet (group DD) had significantly 
higher MDA levels than diabetic controls (group DC) (p = 0.006). Calcitriol 
supplementation to vitamin D-deficient rats (group DDS) significantly reduced MDA 
levels when compared to group DD (p = 0.010) and the MDA levels were comparable 
to group DC (Figure 4.20). [MDA - DC: 1.85±1.57 nmol/mg protein; DD: 4.87±2.53 
nmol/mg protein; DDS: 2.06±1.60 nmol/mg protein] 
 
Figure 4.20  Malondialdehyde levels of diabetic rats. 
(n = 10 rats per group) 
p = 0.003 (One-way ANOVA) 
a p < 0.01 when compared to group DC; b p < 0.05 when compared to group DD. 
[DC: diabetic rats with control diet; DD: diabetic rats with vitamin D-deficient diet; 
DDS: diabetic rats with vitamin D-deficient diet + calcitriol supplementation] 
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4.1.8 Protein Expression and Localization of eNOS 
Normal Rats 
By performing Western blotting, a single protein band with protein size of 
approximately 133 kDa was detected as eNOS while another single protein band with 
protein size of approximately 42 kDa was identified as ß-actin.  
In normal rats, the expression levels of eNOS were significantly lower in the 
mesenteric arteries of rats receiving vitamin D-deficient diet (group ND) compared to 
rats receiving control diet (group NC) (p < 0.001). However, the expression levels of 
eNOS in the mesenteric arteries of calcitriol-supplemented vitamin D-deficient rats 
(group NDS) were comparable to group ND and the protein expression levels remained 
significantly lower than group NC (p < 0.001) (Figure 4.21). [eNOS- NC: 0.61±0.16 
arbitrary unit; ND: 0.29±0.03 arbitrary unit; NDS: 0.39±0.04 arbitrary unit] 
In normal rats, immunohistochemical staining demonstrated that the intensity 
of immunoreactive eNOS protein was lower in the mesenteric arteries of rats receiving 
vitamin D-deficient diet (group ND) compared to rats receiving control diet (group 
NC). The intensity of eNOS in the mesenteric arteries of calcitriol-supplemented 










Figure 4.21 (A) Representative Western blot results demonstrated eNOS protein 
expression in mesenteric arteries of normal rats. (B) Graphical 
representation of the data normalised to ß-actin. 
(n = 10 rats per group). 
p = 0.001 (One-way ANOVA); a p < 0.001 when compared to group NC. 
 
Figure 4.22 Representative immunohistochemical staining results demonstrated the  
                         localization of eNOS in mesenteric arteries of normal rats.  
Reddish-brown staining with arrow pointing indicates the presence of eNOS. 
Magnification 100X. 
[NC: normal rats with control diet; ND: normal rats with vitamin D-deficient diet; 
NDS: normal rats with vitamin D-deficient diet + calcitriol supplementation] 
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Diabetic Rats 
Similarly, a single protein band with protein size of approximately 133 kDa 
detected as eNOS while another single protein band with protein size of approximately 
42 kDa identified as ß-actin were visible by performing Western blotting. 
In diabetic rats, the expression levels of eNOS were significantly lower in the 
mesenteric arteries of rats receiving vitamin D-deficient diet (group DD) compared to 
rats receiving control diet (group DC) (p < 0.001). Calcitriol supplementation 
improved the expression levels of eNOS in the mesenteric arteries of calcitriol-
supplemented vitamin D-deficient rats (group DDS) compared to group DD (p < 
0.001) (Figure 4.23). [eNOS - DC: 0.21±0.01 arbitrary unit; DD: 0.09±0.02 arbitrary 
unit; DDS: 0.15±0.02 arbitrary unit] 
In diabetic rats, immunohistochemical staining demonstrated that the intensity 
of immunoreactive eNOS protein was lower in the mesenteric arteries of rats receiving 
vitamin D-deficient diet (group DD) compared to rats receiving control diet (group 
DC). Calcitriol-supplemented vitamin D-deficient rats (group DDS) showed higher 
eNOS intensity in their mesenteric arteries compared to group DD and the eNOS 










Figure 4.23 (A) Representative Western blot results demonstrated eNOS protein 
expression in mesenteric arteries of diabetic rats. (B) Graphical 
representation of the data normalised to ß-actin. 
(n = 10 rats per group)  
p < 0.001 (One-way ANOVA) 
a p < 0.001 when compared to group DC; b p < 0.001 when compared to group DD. 
 
Figure 4.24 Representative immunohistochemical staining results demonstrated the    
                        localization of eNOS in mesenteric arteries of diabetic rats.  
Reddish-brown staining with arrow pointing indicates the presence of eNOS. 
Magnification 100X. 
[DC: diabetic rats with control diet; DD: diabetic rats with vitamin D-deficient diet; 
DDS: diabetic rats with vitamin D-deficient diet + calcitriol supplementation] 
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4.2 Human Study 
Normally distributed numerical data determined by independent t-test were 
presented as mean±standard deviation (SD) while non-normally distributed data by 
Mann-Whitney test were expressed as median±interquartile range (IQR) in the tables. 
Pearson Chi-Square test was used to determine the differences for categorical variables 
between two study groups, expressed as number (%). Data were presented as 
mean±standard error of mean (SEM) in the figures. In all cases, the p value of less than 
0.05 was considered as statistically significant. 
4.2.1 Background Characteristics 
Table 4.5 showed the background characteristics of vitamin D non-deficient 
diabetic patients (group DNP) and vitamin D-deficient diabetic patients (group DDP) 
in this study. The present study showed that vitamin D levels of group DDP were 
significantly lower than group DNP (p < 0.001). The mean age of group DDP was 
significantly lower than group DNP (p = 0.001); diabetic patients with vitamin D 
deficiency were significantly younger. There was no significant difference in their 
gender, body mass index, blood pressures (both systolic and diastolic), total cholesterol 
levels and serum calcium levels between these two study groups. Vitamin D deficiency 
in diabetic patients (group DDP) did not show significant difference in glycaemic 
parameters such as FBG and HbA1c levels compared to group DNP. Based on the 
medical history of both study groups, eight patients in group DNP had hypertension 
while seven were treated for hypercholesterolemia. In group DDP, there were 11 
patients treated for hypertension, and seven patients had hypercholesterolemia. 
However, there was no significant difference in the underlying diseases between these 
study groups. 
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Table 4.5 Background characteristics of diabetic patients. 
 
Numerical data were expressed in mean (SD); Categorical data were expressed in number (%). 
* indicates a statistically significant difference between two study groups. 
[DNP: vitamin D non-deficient diabetic patients; DDP: vitamin D-deficient diabetic patients]
Parameters Group DNP (n = 10) Group DDP (n = 13) p value 
Male; n (%) / Female; n (%) 5 (50.00) / 5 (50.00) 6 (46.15) / 7 (53.85) 0.855 
Age (years old) 63.20 (6.16) 49.46 (9.87) 0.001* 
Body Mass Index, BMI (kg/m2) 23.34 (2.70) 26.15 (6.64) 0.184 
Systolic Blood Pressure, SBP (mm/Hg) 140.40 (19.77) 139.31 (13.71) 0.877 
Diastolic Blood Pressure, DBP (mm/Hg) 76.20 (9.59) 76.92 (12.22) 0.879 
Total Cholesterol Levels (mmol/L) 4.27 (1.45) 4.23 (0.90) 0.938 
Serum 25(OH)D Levels (nmol/L) 66.98 (12.73) 37.73 (6.82) <0.001* 
Fasting Blood Glucose, FBG Levels (mmol/L) 6.95 (2.10) 8.56 (2.63) 0.128 
Glycated Haemoglobin, HbA1c Levels (%) 9.25 (2.98) 9.70 (1.79) 0.679 
Calcium Levels (mmol/L) 2.09 (0.27) 1.94 (0.17) 0.156 
Underlying Diseases; n (%)    
Hypertension 8 (80.00) 11 (84.62) 0.772 
Hypercholesterolemia 7 (70.00) 7 (53.85) 0.431 
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4.2.2 Oxidative Stress Parameters 
Previous studies reported that age might be one of the potential covariates that 
affects oxidative stress levels. In this study, there was significant difference in age 
between two study groups. Hence, the analysis of covariance (ANCOVA) was 
performed to adjust the influence of this variable in oxidative stress analysis.  
 4.2.2(a) Superoxide Dismutase Levels 
As illustrated in Table 4.6, the subcutaneous artery of diabetic patients with 
vitamin D deficiency (group DDP) showed significantly lower SOD levels compared 
to vitamin D non-deficient diabetic patients (group DNP) (p = 0.001). However, after 
adjusting for age as the covariate, the difference is no longer statistically significant at 
p < 0.05. A lower trend for SOD levels was still be seen in the vitamin D-deficient 
group compared to non-deficient group (p = 0.072). 
Values were expressed in mean±standard deviation.  
Adjustment for age was made using ANCOVA. 
* indicates a statistically significant difference between two study groups. 
[SOD: superoxide dismutase; CI; confidence interval; DNP: vitamin D non-deficient 
diabetic patients; DDP: vitamin D-deficient diabetic patients] 
 DNP                 
(n = 10) 
DDP             




SOD levels  
(U/mg protein) 
2.74±1.49 0.94±0.80 1.80 (0.80, 2.80) 0.001* 
Adjusted SOD levels  
(U/mg protein) 
2.37±1.30 1.22±1.26 1.15 (-0.11, 2.40) 0.072 
Table 4.6 Superoxide dismutase levels of diabetic patients. 
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 4.2.2(b) Malondialdehyde Levels 
 As showed in Table 4.7, the subcutaneous artery of diabetic patients with vitamin 
D deficiency (group DDP) showed significantly higher MDA levels compared to 
vitamin D non-deficient diabetic patients (group DNP) (p = 0.017). After the 
adjustment of age as the covariate, the significant difference in MDA levels between 
two study groups persisted (p = 0.005). 
 
Values were expressed in mean±standard deviation.  
Adjustment for age was made using ANCOVA. 
* indicates a statistically significant difference between two study groups. 
[MDA: malondialdehyde; CI: confidence interval; DNP: vitamin D non-deficient 
diabetic patients; DDP: vitamin D-deficient diabetic patients] 
  
 DNP           
(n = 10) 
DDP             
(n = 13) 





10.60±3.79 16.71±6.63 -6.11 (-11.01, -1.22) 0.017* 
Adjusted      
MDA levels 
(nmol/mg protein) 
8.76±6.33 18.12±6.12 -9.36 (-15.50, -3.23) 0.005* 
Table 4.7 Malondialdehyde levels of diabetic patients. 
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CHAPTER 5 
DISCUSSION 
5.1 Animal Study 
5.1.1 Body Weight 
The measurement of body weight is a common way to monitor and determine 
the general health status of an animal. Baseline body weight, measured on the day of 
successful diabetes induction, was comparable at the beginning of the study for all 
study groups in normal and diabetic rats.  
Normal Rats 
In normal rats, significant body weight gain over 10-weeks study duration was 
observed for all study groups. All the groups in normal rats had comparable final body 
weight after 10-weeks study period. The similar rate of weight gain indicates that the 
rats, regardless of their vitamin D status, undergo normal growing process over time.  
Normal rats with vitamin D deficiency showed no significant difference in 
body weight changes compared to controls. This is in contrast with an increasing body 
of evidence that implied 25(OH)D levels are inversely associated with body fat mass, 
involved in weight regulation (Konradsen et al., 2008; Kremer et al., 2009). 
Asymptomatic subjects with lower 25(OH)D levels showed higher weight gain and 
body fat compared to controls with optimal vitamin D status (Erin et al., 2012). The 
possible mechanism proposed as low 25(OH)D levels trigger vitamin D receptors 
(VDR) located on adipocytes via 25(OH)D signalling, to promote greater adiposity 
through the regulation of parathyroid hormone (PTH) and the modulation of 
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adipogenesis. Low vitamin D levels increase the secretion of PTH that promotes 
calcium influx into adipocytes, thus induces lipogenesis and inhibits lipolysis, leading 
to fat accumulation and weight gain. Low 1,25(OH)D2 levels might also modulate 
adipogenesis, leads to excess differentiation of preadipocytes to adipocytes (McCarty 
and Thomas, 2003; Zemel, 2003). This as well explained the findings of the prevalence 
of vitamin D deficiency is more pronounced in overweight and obese populations 
(Konradsen et al., 2008).  
The present study found that calcitriol-supplemented vitamin D-deficient rats 
showed the reduced trend of body weight changes (p = 0.0864) compared to vitamin 
D-deficient rats. This is in line with a recent study that reported vitamin D 
supplementation induces weight loss in obese children with vitamin D deficiency, in a 
12-months intervention program (Szlagatys-Sidorkiewicz et al., 2017). 
Hydroxyvitamin D supplementation has also been shown to reduce fat mass and 
increase lean mass in rats (Siddiqui et al., 2008). Adequate vitamin D levels will lower 
PTH levels to diminish the calcium influx into adipocytes, thus increases lipolysis and 
induces apoptosis in adipocytes, leading to decreased fat mass and weight loss 
(Sergeev, 2009). Another possible reason for the weight loss might be due to vitamin 
D-induced hypercalcaemia as reported in mice (Yoshioka et al., 2017). Elevated 
calcium levels induced by cholecalciferol supplementation in mice lead to transient 
weight loss, presumably due to hypercalcaemia that disrupts calcium homeostasis and 
enhances hepatotoxicity. This explanation is in line with the present finding that 
showed the reduced trend of body weight changes in calcitriol-supplemented vitamin 
D-deficient normal rats, presumably due to vitamin D-induced hypercalcaemia.  
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Diabetic Rats 
The diabetic controls showed no significant increase in body weight 
throughout 10-weeks study period. This might due to the course of diabetes that 
interrupts weight gain in rats. At the onset of the disease, insufficient insulin alters the 
glucose metabolism for energy demand; preventing the body from getting glucose 
from the blood into the body cells as energy supply. Thus, the body starts breaking 
down fat and muscle tissue, predisposing to the reduction in body weight. Despite the 
impact of this disease, diabetic rats with vitamin D deficiency, both with and without 
calcitriol supplementation, incurred a significant increase in body weight changes after 
10-weeks study duration. Vitamin D deficiency coupled with diabetes interrupts 
glucose and lipid homeostasis by reducing the production and secretion of adipokines 
such as adiponectin, thus promoting greater adiposity (as discussed in normal rats) and 
contributing to the onset of obesity or weight gain over time (Berridge, 2017). 
Nevertheless, calcitriol-supplemented vitamin D-deficient diabetic rats showed similar 
final body weight after 10-weeks study period and comparable body weight changes 
compared to vitamin D-deficient diabetic rats.  
Comparing between normal and diabetic rats, diabetic rats in their respective 
groups gained much lower weight over 10-weeks study duration compared to normal 
rats, regardless of vitamin D status. Their final body weight and body weight changes 
were also significantly lower than respective study groups in normal rats. Reduced rate 
of body weight gain in the rats usually serves as an indicator of deteriorating health in 
the animal models (OECD, 2002a). 
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5.1.2 Fasting Blood Glucose Levels 
Normal Rats 
FBG levels of all study groups in normal rats did not show significant changes 
over time. FBG levels of normal rats, regardless of vitamin D status, remained similar 
until the end of the study. All normal rats had FBG levels within the normal range 
throughout the study duration. 
Diabetic Rats 
Diabetic rats had higher baseline FBG levels than normal rats for all categories 
of vitamin D status. This showed the effectiveness of single dose streptozotocin 
injected intraperitoneally to the rats in developing diabetic models for this study. 
Baseline FBG levels for all groups in diabetic rats were comparable. Even though 
diabetic controls and calcitriol-supplemented vitamin D-deficient diabetic rats showed 
a significant increase in their final FBG levels compared to their baseline levels, the 
final FBG levels between all study groups showed no significant difference. FBG 
levels of diabetic rats persist within the diabetes range (more than 16.6 mmol/L) until 
the end of the study indicates that the condition of hyperglycaemia developed in 
diabetic rats was preserved throughout the study duration. 
5.1.3 Vitamin D Levels 
Normal Rats 
Vitamin D-deficient normal rats demonstrated a markedly reduced serum 
25(OH)D levels compared to controls. This indicates that the 10-weeks duration of 
giving a vitamin D-deficient diet has successfully developed and maintained the rats 
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with vitamin D deficiency. According to Stavenuiter et al. (2015), the condition of 
vitamin D deficiency can be safely induced in laboratory rats with negligible effect of 
PTH within three weeks of giving vitamin D-deficient diet. Inadequate nutritional 
intake of vitamin D from daily diet with controlled exposure to ultraviolet B radiation 
attenuates the subsequent hydroxylation processes of vitamin D in the body, leading 
to the reduced serum 25(OH)D levels in vitamin D-deficient rats. 
The present finding discovered that calcitriol supplementation failed to 
increase the reduced serum 25(OH)D levels in vitamin D-deficient rats. This is 
reasonably explained by the type of vitamin D analogue given to the supplemented 
group. Vitamin D-deficient rats were supplemented with calcitriol (1,25(OH)2D) 
instead of calcidiol (25(OH)D) in the present study. Calcitriol is the physiologically 
active metabolite converted from 25(OH)D in the presence of 25(OH)D-1α-
hydroxylase during second hydroxylation process in the kidney (Christakos et al., 
2012). This explained why serum 25(OH)D levels remained low although calcitriol 
was given to the supplemented group. 
Diabetic Rats 
Similarly, significantly lower serum 25(OH)D levels were observed in vitamin 
D-deficient diabetic rats compared to diabetic controls. Calcitriol supplementation to 
vitamin D-deficient diabetic rats failed to improve serum 25(OH)D levels in the 
supplemented rats. Although serum 25(OH)D levels were not improved by calcitriol 
supplementation, the serum concentrations of circulating 1,25(OH)2D, the active form 
of vitamin D which accounts for its physiological effects, will likely be higher. 
However, the measurement of serum 1,25(OH)2D levels is not conducted in this 
study. This is because measuring the exact serum calcitriol levels is not practically 
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feasible due to its lipophilic nature and low circulating concentrations at picomolar 
levels (Wootton, 2005). Furthermore, calcitriol has a shorter half-life (Jones, 2008) 
and its levels are mainly manipulated by PTH (Zerwekh, 2008), thus the outcome 
might not conclusively represent the exact value of calcitriol concentrations in the 
blood. Thus, the measurement of 25(OH)D levels remained to be the gold standard 
used to represent the vitamin D status in the body; it circulates at 1000-fold higher 
concentrations compared to calcitriol (Alshahrani and Aljohani, 2013). 
Despite the limitation in the measurement of serum calcitriol levels, this study 
still proposed to supplement the rats with calcitriol instead of inactive vitamin D3 
analogues or vitamin D2 supplementation. This is considering the fact that other 
vitamin D analogues might have a different binding capacity to vitamin D binding 
protein; and the diabetic or disease models may have difficulties to convert vitamin D 
to its active metabolites (Aronov et al., 2008). Impaired kidney function due to diabetic 
kidney disease develops in approximately 30% of T1DM patients; this may affect the 
conversion of 25(OH)D to calcitriol which normally occurs at the kidney (Alicic et al., 
2017). Hence, calcitriol is preferred as it is the active metabolite of vitamin D that can 
directly exert its physiological role without biological conversion. 
The present study also discovered that vitamin D levels between normal and 
diabetic rats in their respective categories of vitamin D status were similar. This 
showed that diabetes does not significantly exacerbate the condition of vitamin D 
deficiency in rat models in the present study. 
5.1.4 Calcium Levels 
1,25(OH)2D and PTH are the main hormonal regulators of ionised calcium. 
Theoretically, vitamin D facilitates the absorption of calcium from food through the 
  150 
intestinal wall and transports it into the circulatory system, through the interaction with 
VDR. High vitamin D levels improve intestinal calcium absorption, thus increasing 
calcium levels in the blood, which is essential for calcium homeostasis and bone 
metabolism (Heaney et al., 1997). Low vitamin D levels lead to the defect in intestinal 
calcium absorption and subsequently lower intracellular calcium levels. 
Hypocalcaemia was reported in vitamin D-deficient models and also VDR knockout 
mice (Erben et al., 2002). Low calcium levels induced by low vitamin D levels 
promotes secondary hyperparathyroidism. The increased production and secretion of 
PTH, which in turn stimulates the release of more calcium ions from large calcium 
stores in the bones into the bloodstream, in an attempt to increase calcium levels 
(Fraser, 2009).  
Normal Rats 
Vitamin D-deficient normal rats showed comparable calcium levels compared 
to controls. This might due to calcium homeostasis that maintains the calcium levels 
in the blood even when the body does not get enough vitamin D from diet or through 
sunlight exposure. Bone reserves might serve as the protective measure to sustain the 
calcium levels in the blood regulated by PTH (Lieben and Carmeliet, 2013). This 
explains why 10-weeks duration of having a vitamin D-deficient diet successfully 
reduced vitamin D levels in rats, but calcium levels remained constant in this study. 
Serum calcium levels in calcitriol-supplemented vitamin D-deficient rats were 
significantly higher compared to vitamin D-deficient rats, as well as compared to 
controls. Calcitriol enhances intestinal calcium absorption in normal rats, which in 
excess might interfere with calcium homeostasis, leading to the unfavourable effects 
of hypercalcaemia. Nevertheless, calcitriol-supplemented vitamin D-deficient non-
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diabetic rats in this study did not show any observable sign of vitamin D toxicity and/or 
hypercalcaemia such as retarded growth, dehydration, polyuria, polydipsia and foamy 
urine throughout the study period. The dosage of calcitriol supplementation in the 
present study was chosen based on previous studies which gave the same dose of 
calcitriol (0.15 µg/kg/day) to control rats, for four and 13 weeks by subcutaneous 
injection (Mancuso et al., 2008; Lee et al., 2014) and for 18 weeks by oral gavage 
(Dong et al., 2012). Similar studies and even longer duration of calcitriol 
supplementation did not report signs of hypercalcaemia in their control groups.  
Diabetic Rats 
Similarly, vitamin D deficiency in diabetic rats showed no significant 
difference in calcium levels compared to diabetic controls, mainly due to calcium 
homeostasis being regulated by PTH. However, the same dosage of calcitriol 
supplemented to vitamin D-deficient diabetic rats showed different finding as in 
normal rats. Calcitriol supplemented to vitamin D-deficient diabetic rats did not 
significantly potentiate serum calcium levels. The same amount of calcitriol given to 
diabetic rats might not be fully utilised for its physiological role in facilitating 
intestinal calcium absorption as those given to normal rats. The course of diabetes may 
deteriorate intestinal calcium absorption, leading to a reduction in calcium uptake into 
the body for calcium metabolism (Wong et al., 2017).  
Comparing between calcitriol-supplemented vitamin D-deficient normal and 
diabetic rats, their serum calcium levels were similar. The different findings in their 
vascular and oxidative stress parameters in the present study might possibly be due to 
the actual amounts of free calcium ions in the circulatory system. The calcium levels 
measured in the blood are the total amounts of calcium ions, which consist of 
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free/ionised calcium ions, calcium ions bound to proteins like albumin and calcium 
ions bound to various organic anions.  
Free calcium ions are the most active functional group responsible for its 
physiological role. High calcium levels in normal rats possibly indicate higher free 
calcium ions, which in excess might be responsible for hypercalcaemia. Unlike 
diabetic rats that received vitamin D supplementation, which might experience the 
alteration in vitamin D metabolism; the same dosage of calcitriol might not be fully 
utilised for improving intestinal calcium absorption, or the calcium ions might in a 
higher ratio of bounded form than in free form (McNair et al., 1983). This might well 
explain why calcitriol supplementation to vitamin D-deficient diabetic rats showed 
favourable outcome in vascular parameters, although their serum calcium levels were 
similar to those calcitriol-supplemented vitamin D-deficient rats with hypercalcaemia.  
5.1.5 Microvascular Tissue Oxidative Stress Status 
Oxidative stress reflects an imbalance between the production of free radicals 
and the effectiveness of antioxidant defence system to counteract them (Betteridge, 
2000). Oxidative stress plays a dominant role in the development of vascular 
complications, particularly in diabetic subjects (Pham-Huy et al., 2008). The 
improvement in oxidative stress parameters, indicating reduced oxidative stress levels, 
is likely to confer vascular protection.   
5.1.5(a) Superoxide Dismutase Levels 
Superoxide dismutase (SOD) is the antioxidant enzyme that acts as a major 
defender in antioxidant defence system to encounter oxidative stress and subsequently 
reduce the risk of cellular injury (Tiwari et al., 2013). SOD catalyses the dismutation 
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of superoxide anion to hydrogen peroxide and molecular oxygen (Evans et al., 2003). 
Accumulating evidence reported that the levels and activity of SOD may be low and 
diminished due to its depletion, in order to counteract with excess free radicals over 
time (Giacco and Brownlee, 2010; Shukla et al, 2012; Kayama et al., 2015). The 
depletion of antioxidant enzymes may render the animal models more susceptible to 
ROS attack and more vulnerable to oxidative damage.  
Normal Rats 
Vitamin D-deficient normal rats exhibited significantly lower SOD levels 
compared to controls.  Lower SOD levels found in vitamin D-deficient rats may be a 
compensatory response to combat with excess ROS induced by vitamin D deficiency. 
Vitamin D deficiency impairs mitochondrial respiratory functions (excessive 
respiration leads to elevated ROS production), upregulates the gene expression of 
NADPH oxidase (the key producer of ROS) and downregulates cellular antioxidants 
expression, leading to the elevated formation of free radicals and ROS (Dong et al., 
2012; Wimalawansa, 2019). There was a significant positive correlation between 
serum 25(OH)D levels and erythrocyte SOD activity in vitamin D-deficient subjects 
receiving vitamin D3 supplementation (Javanbakht et al., 2010); reduced SOD levels 
have been reported in vitamin D-deficient subjects (Tarcin et al., 2009).  
Calcitriol supplementation to vitamin D-deficient rats showed comparable 
SOD levels as in non-supplemented vitamin D-deficient rats. SOD levels are most 
likely to be increased by calcitriol supplementation in the present study. However, 
hypercalcaemia induced by calcitriol supplementation might induce the generation of 
ROS in calcitriol-supplemented vitamin D-deficient rats. Augmented oxidative stress 
depletes SOD levels, this possibly explained why SOD levels remained low even after 
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four-weeks calcitriol treatment in vitamin D-deficient rats with hypercalcaemia. High 
calcium levels induced by vitamin D supplementation presumably potentiate oxidative 
stress by decreasing total antioxidant activities (Yoshioka et al., 2017).  
Diabetic Rats 
Likewise, vitamin D-deficient diabetic rats showed markedly reduced SOD 
levels compared to diabetic controls. SOD levels were depleted presumably as a result 
of its antioxidant defence activities. Reduced SOD levels and activity have been 
reported in diabetic animal models (Hamden et al., 2009; George et al., 2012; Alatawi 
et al., 2018). Hyperglycaemia in diabetes could serve as an additional source of 
mitochondrial ROS overproduction by both enzymatic and non-enzymatic pathways, 
rendering diabetics to augmented oxidative stress (Tiganis, 2011). Reduced SOD 
levels may exacerbate oxidative stress status, which is one of the risk factors preceding 
the development of atherosclerosis and secondary complications in diabetics. 
However, there were other studies that reported preserved or increased SOD levels in 
diabetic models (Bandeira et al., 2012; Jang et al., 2000). The difference in findings is 
due mainly to the disease duration of diabetes. There was a triphasic change in SOD 
levels in diabetes pathogenesis. SOD levels might first increase to encounter with 
increased ROS levels, preserved when the antioxidant defence mechanism is ongoing 
and might lastly decrease or deplete due to long-term defence process. 
Vitamin D-deficient diabetic rats given calcitriol supplementation showed a 
significant increase in SOD levels to values similar as diabetic controls. The outcome 
is similar with the animal studies conducted in diabetic Wistar rats supplemented with 
four-weeks calcitriol (Hamden et al., 2009), two-weeks cholecalciferol (George et al., 
2012) and four-weeks vitamin D3 with calcium (Alatawi et al., 2018) respectively. 
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However, there were contradictory findings that reported T2DM patients with 
suboptimal vitamin D levels receiving vitamin D3 tablets once daily for 12 weeks, did 
not significantly improve SOD levels (Yiu et al., 2013). The types of vitamin D 
analogues provided to the study models are the main determinant for a favourable 
outcome. Calcitriol is more efficient in its physiological role as it is the active 
metabolite compared to other vitamin D3 analogues such as cholecalciferol and 
calcidiol. Likewise, vitamin D3 is more efficacious compared to vitamin D2 as vitamin 
D3 is the type of vitamin D naturally exists in the body.  
5.1.5(b) Malondialdehyde Levels 
The measurement of the levels of ROS (such as superoxide anion) is not 
practical, in view that the free radical chain reactions occurred almost instantaneously. 
An exceptional increase in free radicals that is unable to be sufficiently scavenged by 
antioxidant enzymes initiates the free radical chain reactions, predisposing to 
peroxidative injury. MDA is one of the by-products of polyunsaturated fatty acid 
peroxidation in the cells. It is the most frequently used biomarker of oxidative stress 
in CVD (Khoubnasabjafari et al., 2015). The measurement of MDA levels is reliably 
documented as the gold standard to indicate the levels of cellular peroxidative injury 
attributable to augmented ROS levels (Lefevre et al., 1998); higher MDA levels 
represent higher ROS levels that ultimately lead to higher degree of lipid peroxidation. 
Normal Rats 
Vitamin D deficiency in normal rats did not show significant changes in MDA 
levels compared to controls. Vitamin D deficiency in normal rats induces the 
generation of excess ROS, which is likely to be efficiently removed by the antioxidant 
SOD. Hence, vitamin D deficiency did not induce lipid peroxidation in normal rats, 
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due to the protective role played by the antioxidant enzymes. This is well explained by 
the reduced SOD levels in conjunction with preserved MDA levels as detected in 
mesenteric arteries of vitamin D-deficient rats in the present study.  
Calcitriol supplementation to vitamin D-deficient rats showed comparable 
MDA levels as in vitamin D-deficient rats. This may be explained that the antioxidant 
activities by SOD are most likely sufficient to convey vascular protection from 
peroxidation injury in calcitriol-supplemented vitamin D-deficient rats.  
Diabetic Rats 
Vitamin D-deficient diabetic rats showed significantly increased MDA levels 
compared to diabetic controls. Chronic hyperglycaemia coupled with vitamin D 
deficiency in diabetes induces excess ROS production and diminishes the antioxidant 
activity by SOD, leading to augmented oxidative stress and subsequently peroxidative 
injury. Increased MDA levels have been well reported in diabetic animal models 
(Hamden et al., 2009; George et al., 2012; Alatawi et al., 2018).  
Calcitriol supplementation to vitamin D-deficient diabetic rats successfully 
reversed the enhanced MDA levels back to values similar as diabetic controls. This is 
in line with animal studies that exhibited administration of vitamin D3 to diabetic rats 
reduced lipid peroxidation as indicated by decreased TBARS levels in hepatic and 
renal tissues (Hamden et al., 2009) and in the liver (George et al., 2012), as well as 
reduced serum MDA levels (Alatawi et al., 2018) of diabetic Wistar rats. In human 
studies, serum MDA levels of vitamin D-deficient T2DM subjects receiving vitamin 
D3 supplementation for 12 weeks was significantly reduced compared to T2DM 
subjects receiving placebo (Shab-Bidar et al., 2015). However, T2DM patients with 
hyperlipidaemia with unknown baseline vitamin D levels receiving calcitriol for 12 
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weeks did not show the improvement in MDA levels (Eftekhari et al., 2014). Baseline 
vitamin D levels of the diabetic subjects might possibly be one of the crucial factors 
to obtain a favourable outcome of vitamin D supplementation. Vitamin D 
supplementation may not be adequate to sufficiently increase the severe deficient 
baseline vitamin D levels of the disease models to the optimal levels for favourable 
therapeutic effects.  
Oxidative stress analysis in the present study showed different findings in MDA 
and SOD levels of normal and diabetic rats; MDA levels were preserved in non-
diabetic rats with vitamin D deficiency but were increased in vitamin D-deficient 
diabetic rats. SOD levels were reduced in both diabetic and non-diabetic rats with 
vitamin D deficiency. Reduced SOD levels representing a compensatory response in 
combating excess ROS, in order to prevent the propagation of free radical chain 
reactions that ultimately lead to vascular peroxidative injury. Reduced SOD levels with 
preserved MDA levels as observed in normal rats, indicates that the antioxidant system 
was effective in protecting the blood vessels from lipid peroxidative injury. However, 
the antioxidant defence system may not be as effective in diabetic models. SOD might 
be depleted as the consequence of counteracting more ROS, subsequently exacerbates 
vascular oxidative stress status, leading to vascular peroxidative injury (higher MDA 
levels) as seen in diabetic rats.   
5.1.6 eNOS Protein Expression 
eNOS plays an important role in endothelium-dependent relaxation as reported 
in animal models (Chataigneau et al., 1999). The activity of eNOS is regulated by the 
changes in intracellular Ca2+ concentrations which will affect its binding with 
calmodulin. eNOS binds to calmodulin to activate the transfer of electron from 
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NADPH to heme iron, which then catalyses the production of NO from L-arginine and 
molecular oxygen in endothelial cells (Abu-Soud et al., 1994). NO plays a dominant 
role in regulating vascular tone and acts as the major vasodilator responsible for 
endothelium-dependent relaxation in most vessels (Palmer et al., 1987; Furchgott and 
Vanhoutte, 1989; Moncada and Higgs, 1993). Studies have reported that eNOS control 
(+/+) mice showed the presence of endothelium-dependent relaxation, whereas eNOS 
knockout (-/-) mice demonstrated the absence of relaxation in aorta, carotid and 
coronary arteries. 
Normal Rats 
Vitamin D-deficient normal rats showed reduced protein expression of eNOS 
in their mesenteric arterial tissue compared to controls. Vitamin D is involved in 
enhancing the transcription of eNOS and non-genomic activation of eNOS, to promote 
NO production in endothelial cells. Reduced expression of eNOS was discovered in 
VDR mutant mice (Andrukhova et al., 2014) and vitamin D-deficient rats (Daniele et 
al., 2014).  
There was no significant difference in protein expression of eNOS between 
calcitriol-supplemented vitamin D-deficient rats and vitamin D-deficient rats. This 
explained best by high calcium levels found in the supplemented rats that interfere 
with the activity of eNOS. The unfavourable effects of hypercalcaemia downregulate 
the eNOS protein expression. This is supported by previous study that implied negative 
correlation between NO production and calcitriol levels was found in peripheral-blood 
mononuclear cells from hypercalcaemia patients (Chang et al., 2004).  
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Diabetic Rats 
Vitamin D-deficient diabetic rats showed reduced protein expression of eNOS 
compared to diabetic controls. Chronic hyperglycaemia and presumably augmented 
oxidative stress have been suggested to relate with reduced eNOS protein expression 
in diabetics (Srinivasan et al., 2004). Decreased eNOS protein expression and levels 
were reported in cultured human coronary arterial and aortic endothelial cells that were 
incubated in media with elevated glucose concentrations (Ding et al., 2000; Srinivasan 
et al., 2004), and also in subcutaneous arteries of diabetic patients (Mokhtar et al., 
2016). However, these observations are not in line with the finding that implied 
diabetes might not change the expression of total eNOS protein but may decrease the 
proportion of eNOS expressed as a dimer (Leo et al., 2011). A higher ratio of eNOS 
monomer to its dimer is likely associated with oxidative-driven events that lead to 
reduced production of NO by eNOS and thus impaired endothelium-dependent 
relaxation. However, the levels of total eNOS may become normal as diabetes 
progresses, as part of the mechanisms for endothelial protection (Leo et al., 2011). 
Calcitriol supplementation to vitamin D-deficient diabetic rats showed 
significant improvement in protein expression of eNOS. This may be explained by the 
improvement in the oxidative stress status as indicated by reduced MDA and increased 
SOD levels found in the mesenteric arterial tissue of calcitriol-supplemented diabetic 
rats.  
5.1.7 Microvascular Endothelial Function 
The delicate balance between endothelium-dependent relaxation and 
endothelium-dependent contraction maintains vascular homeostasis and ensures fine 
regulation of vascular tone. Endothelial dysfunction is characterised by the imbalance 
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between the role of endothelium-derived vasoactive substances, generally due to 
reduced production of EDRF or/and augmented secretion of EDCF. Endothelial 
dysfunction which serves as an independent prognostic cardiovascular marker, can be 
early manifested in the microcirculation involving smaller arteries. Endothelial 
dysfunction can be initiated either as a consequence of reduced production and release 
of NO and/or by increased inactivation of NO due to the overproduction of ROS 
(Bauer and Sotnikova, 2010). 
5.1.7(a) Endothelium-dependent Relaxation 
Normal Rats 
The present study showed that endothelium-dependent relaxation in mesenteric 
arteries of normal rats with vitamin D deficiency was significantly impaired compared 
to controls. This is in accordance with the previous findings that showed chronic 
vitamin D insufficiency decreased endothelium-dependent vasodilation in rats’ 
mesenteric arteries (Tare et al., 2011) and reduced brachial flow-mediated dilation in 
healthy subjects (Jablonski et al., 2011). Likewise, endothelium-specific deletion of 
vitamin D receptors blunts endothelium-dependent relaxation in the mouse. 
Epidemiological studies also implied that low vitamin D levels are associated with 
impaired vascular function. Reduced protein expression and presence of eNOS as 
detected in the mesenteric arteries of vitamin D-deficient rats, appear to account for 
the blunting of ACh-induced endothelium-dependent relaxation in vitamin D-deficient 
rats in the present study. Reduced eNOS levels attenuate the production of NO, and 
hence curtail its role as the major vasodilator, leading to impaired endothelium-
dependent relaxation.   
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In addition, a wealth of evidence also demonstrated the role of augmented 
oxidative stress that reduces NO bioavailability, in leading to vascular dysfunction 
(Ungvari et al., 2008; Gori and Munzel, 2011). Excess ROS induced by vitamin D 
deficiency (details please refer to Section 2.7) increases the monomerization of the 
enzyme eNOS, leading to the dissociation of eNOS dimer to its monomer (Yang et al., 
2009). The uncoupling of eNOS alters its function as the NO producer, accounts for 
the impairment in NO-mediated relaxation of mesenteric arteries. Furthermore, the 
uncoupled and dysfunctional eNOS turns to be the producer of superoxide anion, 
further exacerbates oxidative stress status (Leo et al., 2011).  
Endogenous antioxidant enzymes, particularly SOD, play a crucial role in 
scavenging excess superoxide anion produced in the cells to prevent peroxidative 
injury. In the present study, reduced SOD levels in conjunction with preserved MDA 
levels in vitamin D-deficient rats might represent a compensatory mechanism of SOD 
antioxidant activity in combating excess ROS to protect the blood vessels from lipid 
peroxidation. The diminished antioxidant enzymes might subsequently exacerbate the 
imbalance condition of vascular oxidative stress.  
Calcitriol supplementation to vitamin D-deficient normal rats did not improve 
the impaired endothelium-dependent relaxation. The protein expression of eNOS in 
the mesenteric arteries of calcitriol-supplemented vitamin D-deficient rats remained 
low and comparable to vitamin D-deficient rats. The MDA and SOD levels were also 
comparable between vitamin D-deficient and calcitriol-supplemented normal rats. 
These observations implied that calcitriol supplementation did not exhibit favourable 
effects on vascular and oxidative stress parameters in non-diabetic vitamin D-deficient 
rats. This might well be explained by the unfavourable condition of hypercalcaemia 
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induced by calcitriol supplementation in the supplemented rats. High calcium levels 
may inhibit basal NO release from endothelial cells, leading to impaired NO-mediated 
vasorelaxation in calcitriol-supplemented rats. Hypercalcaemia has been suggested as 
one of the possible factors in the progression of endothelial dysfunction, as reported in 
both animal and human models (Lopez-Jaramillo et al., 1990; Nilsson et al., 2001). 
Diabetic Rats 
Accumulating findings showed that endothelial dysfunction, which is defined 
as impaired endothelium-mediated relaxation, is evident in mesenteric arteries of 
diabetic animal models (Lagaud et al., 2001; Pannirselvam et al., 2002; Leo et al., 
2011). In the present study, the impairment in endothelium-dependent relaxation was 
more prominent in mesenteric arteries of vitamin D-deficient diabetic rats than in 
normal rats. This is possibly associated with the course of the disease in diabetic 
models. In addition to the pathology of hyperglycaemia, the condition of vitamin D 
deficiency might be the additional possible underlying mechanism involved in 
exacerbating oxidative stress status. The increased superoxide anion production 
induced by hyperglycaemia and vitamin D deficiency impairs the catalytic activity of 
eNOS by causing eNOS uncoupling to become a dysfunctional superoxide-generating 
enzyme, severely compromising cellular NO generation by eNOS (Alderton et al., 
2001; De Pascali et al., 2014). Under these pathophysiological conditions, excess 
superoxide anion scavenges NO produced by eNOS avidly with the resulting 
formation of peroxynitrite, reduces considerably the bioavailability of NO as the major 
vasodilator, predominantly leads to the attenuated endothelium-dependent relaxation 
in diabetic models. Reduced endothelium-dependent relaxation has also been 
consistently reported to be associated with increased oxidative stress levels.   
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Interestingly, the effectiveness of calcitriol supplementation on ACh-induced 
endothelium-dependent relaxation in vitamin D-deficient normal and diabetic rats 
showed contradictory finding. The same dosage of calcitriol given to the supplemented 
group in diabetic rats significantly reversed the impaired endothelium-dependent 
relaxation back to similar values as in diabetic controls. The unfavourable effects of 
hypercalcaemia were not observed in calcitriol-supplemented diabetic rats, although 
their calcium levels were similar to those calcitriol-supplemented non-diabetic rats. 
This is possibly due to the actual levels of free calcium ions that account for its 
physiological role between these two groups were different. Calcitriol-supplemented 
non-diabetic rats might have higher free calcium ions compared to diabetic rats; 
leading to the unfavourable effects of hypercalcaemia.  
Calcitriol supplementation in vitamin D-deficient diabetic rats significantly 
increased SOD and reduced MDA levels, indicating an improvement in oxidative 
stress status. The protein expression of eNOS in the mesenteric arterial tissue of 
vitamin D-deficient diabetic rats with calcitriol supplementation also showed a 
significant improvement. Reduced oxidative stress attenuates the propagation of 
oxidative-driven adverse events, coupled with the enhanced protein expression of 
eNOS that indicates increased NO bioavailability, thus the impairment in endothelium-
dependent relaxation was successfully ameliorated.  
5.1.7(b) Endothelium-dependent Contraction 
Endothelium-dependent contraction is evoked by endothelium-derived 
contracting factors, such as endothelial COX-derived prostanoid. These 
vasoconstrictor prostanoids diffuse into underlying VSMC and directly activate 
respective receptors located on the VSMC for subsequent contractile responses. To 
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initiate endothelium-dependent contractions, an increase in intracellular calcium 
concentrations is essential. Calcium ionophore is the carrier that facilitates the 
transport of calcium ions across the endothelial cell membrane into EC, hence 
intracellular calcium levels are increased, then the calcium-dependent calmodulin 
mechanism is activated in the endothelium for subsequent NO production. By 
incubating the vessels with L-NAME (the eNOS inhibitor), the catalytic activity of 
eNOS for NO production is inhibited, causing an immediate potentiation of EDCF-
mediated responses.  
Normal Rats 
The present finding discovered that endothelium-dependent contraction in 
vitamin D-deficient rats was similar compared to controls. This is likely due to vitamin 
D-deficient normal rats in the present study exhibited well-controlled ROS levels, as 
shown by similar MDA levels compared to controls. Otherwise, excess ROS 
stimulates the activity of COX in endothelial or smooth muscle cells to release 
prostanoid, augmenting vasoconstriction (Tang and Vanhoutte, 2009). 
Surprisingly, calcitriol supplementation to vitamin D-deficient normal rats 
significantly augmented endothelium-dependent contraction. This is in contrast with a 
study that reported calcitriol reduces the increased cytosolic free calcium 
concentrations in endothelial cells, leading to the decrease in endothelium-dependent 
contraction of aortic rings of the spontaneous hypertensive rat (Wong et al., 2008). 
The difference in finding is possibly due to the increased calcium levels induced by 
calcitriol supplementation as seen in the supplemented group in this study. 
Hypercalcaemia amplifies the enhanced intracellular calcium levels, leading to 
increased vascular resistance and triggering vasoconstriction (Moussawi et al., 2018).  
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Diabetic Rats 
In the present study, endothelium-dependent contraction was augmented in 
mesenteric arteries of vitamin D-deficient diabetic rats compared to diabetic controls. 
In certain pathological conditions such as diabetes, attenuated NO production initiates 
the contraction of VSMC (Shi et al., 2007). The insufficiency of NO bioavailability 
induces the production of endothelium-derived vasoconstrictor prostanoids and also 
endothelin-1 (Vanhoutte et al., 2017), leading to vasoconstriction which amplifies the 
degree of endothelial dysfunction. An enhanced endothelium-dependent contraction 
in diabetes might also relate to hyperglycaemia-induced augmented oxidative stress 
and upregulation of COX-2 protein expression, as reported in human aortic endothelial 
cells cultured in high glucose medium (Cosentino et al., 2003). Vitamin D deficiency 
in addition to hyperglycaemia in vitamin D-deficient diabetic rats, coupled with 
enhanced oxidative stress and possibly vascular inflammation induce the 
overproduction of superoxide anions. Superoxide anions effectively inactivate EDRF, 
favouring the production of cyclooxygenase product responsible for vasoconstriction 
(such as thromboxane A2), leading to augmented endothelium-dependent 
vasoconstriction and hence endothelial dysfunction (Tang and Vanhoutte, 2009).  
Calcitriol supplementation to vitamin D-deficient diabetic rats did not show 
significant improvement in reducing endothelium-dependent contraction. Although 
vascular oxidative stress has been improved in calcitriol-supplemented rats, 
hyperglycaemia in diabetics is still favouring the cyclooxygenase pathway that 
enhance vasoconstriction.  
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5.1.8 Microvascular Smooth Muscle Function 
Besides the impairment in endothelial cells, impairment might also occur in 
VSMC in some disease states. This is generally termed as vascular dysfunction, the 
impairment in both endothelial and smooth muscle cells (Vanhoutte et al., 2017). In 
order to evaluate whether vitamin D deficiency alters the function of VSMC in normal 
and diabetic rats respectively, mesenteric arteries without endothelium were 
stimulated with sodium nitroprusside and salbutamol to study endothelium-
independent relaxation and phenylephrine for endothelium-independent contraction. 
5.1.8(a) Sodium Nitroprusside-induced Endothelium-independent Relaxation  
Normal Rats 
With the removal of endothelium, NO is unable to be produced by eNOS. The 
shortage of endogenous NO can be bypassed with exogenous NO donor. SNP acts as 
an endothelium-independent exogenous NO donor to activate soluble guanylyl cyclase 
in VSMC to catalyse the production of cGMP, initiating subsequent mechanisms 
responsible for vasodilation (Rapoport and Murad, 1983).  
In the present study, SNP-induced endothelium-independent relaxation was 
found to be preserved in mesenteric arteries of vitamin D-deficient normal rats. 
Although vascular endothelial function was significantly impaired in vitamin D-
deficient rats, the impairment did not involve vascular smooth muscle function. 
Impaired endothelium-dependent vasodilation in vessels with intact SNP 
responsiveness indicates a reduction in NO production or bioavailability, consistent 
with increased oxidative stress (Tare et al., 2011). This is in line with the present 
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finding that showed augmented oxidative stress as indicated by reduced SOD levels 
and reduced NO bioavailability as indicated by lower protein expression of eNOS.  
However, calcitriol supplementation in vitamin D-deficient normal rats 
showed the trend of reduced SNP-induced endothelium-independent relaxation 
compared to vitamin D-deficient rats and the relaxation was significantly lower than 
the controls. This is likely due to high calcium levels found in calcitriol-supplemented 
rats; high calcium levels have been suggested as one of the possible mechanisms 
leading to the functional abnormality of VSMC (Kapustin and Shanahan, 2012).  
Diabetic Rats 
The reduction in responses to endothelium-dependent vasodilators can be due 
to the concomitant release of endothelium-derived vasoconstrictors or to the reduced 
or abnormal responsiveness of VSMC to NO or vasodilator stimuli. In this study, the 
response of VSMC to SNP was significantly attenuated in vitamin D-deficient diabetic 
rats compared to diabetic controls. This observation suggests that vitamin D deficiency 
combined with hyperglycaemia and oxidised lipids in diabetics promote the 
dysfunction of both endothelial and vascular smooth muscle cells.  
The impairment in endothelium-independent relaxation via the cGMP pathway 
in vitamin D-deficient diabetic rats may be explained by the reduced NO 
bioavailability responsible for vasorelaxation (Tare et al., 2011). Although NO is 
provided by the exogenous NO donor SNP directly into VSMC for endothelium-
independent relaxation, NO might be dissociated and degraded into toxic peroxynitrite 
in the presence of superoxide anion, attenuated the subsequent cGMP-mediated 
vasorelaxation (Yeo et al., 2004). Augmented vascular oxidative stress, which is 
mainly caused by an imbalance between the enhanced production of ROS and the 
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reduced activity of antioxidant enzymes, has been reported to be involved in increasing 
the chemical inactivation of bioactive NO (Vanhoutte, 1989).  
The impairment in NO-mediated relaxation could also in part be explained by 
the decrease in the sensitivity of VSMC to its vasodilator stimuli. Hyperglycaemia and 
vitamin D deficiency in diabetic rats induce overproduction of ROS and/or diminished 
the activity of antioxidants in VSMC, further facilitate the dissociation of NO 
molecules and impair the responsiveness of VSMC, leading to the attenuated 
endothelium-independent relaxation. This is in line with the finding by Okon et al. 
(2000) that showed the sensitivity of VSMC to NO was decreased in internal 
mammary arteries from diabetic patients, which was evident from the impaired 
relaxation to SNP. VDR deficiency on VSMC may also be one of the possible 
mechanisms that alter the vascular smooth muscle responses to NO (Wu-Wong et al., 
2007), whereby the crosstalk between vascular EC and VSMC was affected.   
Impaired endothelium-independent responses via the cGMP pathway may arise 
from several mechanisms such as abnormality in the cGMP signalling mechanism and 
PKG activity and reduction in smooth muscle guanylyl cyclase (Lamireau et al., 2002). 
However, the present observation was in contrast with the previous study that 
demonstrated preservation of smooth muscle response to SNP in subcutaneous arteries 
of pregnant women with T1DM compared to controls (Ang et al., 2002). The 
difference in finding is likely due to the non-deficient vitamin D levels in the subjects. 
However, calcitriol-supplementation failed to ameliorate the impairment in SNP-
induced endothelium-independent relaxation of vitamin D-deficient diabetic rats. 
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5.1.8(b) Salbutamol-induced Endothelium-independent Relaxation 
Normal Rats 
Salbutamol exerts its role as a vasodilator (an exogenous prostacyclin) by 
binding to β2-adrenergic receptors on VSMC to activate adenylyl cyclase.  Activated 
adenylyl cyclase catalyses the production of cAMP responsible for vasodilation. The 
cAMP signalling pathway is also the pathway used by endothelium-derived 
prostacyclin to produce relaxation in normal condition, whereby prostacyclin binds to 
IP receptors on VSMC (Lim et al., 2002). The removal of endothelium attenuates the 
production of prostacyclin, while providing the vitamin D-deficient rats with 
salbutamol, propagates the cAMP signalling pathway for vasodilation. 
In the present study, endothelium-independent relaxation of mesenteric arterial 
smooth muscle to salbutamol was comparable between vitamin D-deficient rats and 
controls. Similarly, calcitriol supplementation did not show any effect on SB-induced 
relaxation. These observations suggest that vitamin D deficiency and supplementation 
do not affect the function of VSMC through the cAMP pathway in normal rats. Ten-
weeks duration of having a vitamin D deficiency in normal rats did not produce 
adverse effect on the blood vessels through this pathway.  
Diabetic Rats 
Similarly, endothelium-independent relaxation of mesenteric arterial smooth 
muscle to salbutamol was comparable in both vitamin D-deficient and supplemented 
diabetic rats. These observations suggest that even in diabetic models, vitamin D 
deficiency and supplementation do not affect the function of smooth muscle through 
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the cAMP signalling pathway. This is likely due to the presence of β2-adrenergic 
receptors on VSMC is not altered by hyperglycaemia and vitamin D deficiency. 
5.1.8(c) Endothelium-independent Contraction 
Normal Rats 
Phenylephrine (PE) acts as a standard vasoconstrictor commonly used to 
induce endothelium-independent contraction. PE binds to α1-adrenergic receptors on 
VSMC, increasing the concentrations of intracellular calcium ions in VSMC to evoke 
subsequent vasoconstriction. In the present study, vitamin D-deficient rats showed 
similar endothelium-independent contraction in their mesenteric arterial smooth 
muscle as controls. Calcitriol supplementation to vitamin D-deficient rats did not show 
any effect on PE-induced contraction. These findings suggest that 10-weeks duration 
of having a vitamin D deficiency and four weeks of calcitriol supplementation do not 
alter the contractile function of VSMC in normal rats.  
Diabetic Rats 
Likewise, the contraction of VSMC to PE in rats’ mesenteric arteries is not 
affected in diabetic rats, regardless of their vitamin D status. Removal of endothelium 
did not affect the contractile responses of mesenteric arteries to phenylephrine. 
 5.2 Human Study 
There were difficulties in obtaining sufficient and viable human tissue samples 
to perform functional and detailed mechanistic studies compared to animal samples. 
During the recruitment, we had successfully recruited 50 patients at the beginning. 
However, after the assessment for inclusion and exclusion criteria, only 23 patients 
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had been accepted for this study. Since the samples have to be fresh to sustain the 
viability of the vessels for functional studies, the challenges arose in obtaining suitable 
and viable samples during surgery. Nevertheless, adequate human tissue samples were 
obtained to study the effects of vitamin D deficiency on the levels of oxidative stress 
parameters (SOD and MDA levels). This allows the current project to assess if there 
are similarities in the findings of microvascular tissue oxidative stress parameters 
between animal diabetic models and human diabetic models. 
5.2.1 Background Characteristics 
Lower limb subcutaneous arteries were harvested and used in conducting this 
human study. Subcutaneous arteries in diabetic patients and mesenteric arteries in rats 
are classified as small resistance arteries with the vessel size of less than 200 µm, thus 
termed microcirculation.  
In this study, we found that 13 out of 23 recruited diabetic patients had vitamin 
D deficiency. This is supported by growing evidence indicating higher prevalence of 
vitamin D deficiency in diabetic population. In Malaysia, the prevalence of vitamin D 
deficiency in normal population has been reported as 16-33% (Chin et al., 2014), 
whereas the prevalence is more pronounced in the diabetic population, which is 43% 
(Munisamy et al., 2016). Diabetic patients had lower vitamin D levels (serum 
25(OH)D < 50 nmol/L) compared to non-diabetics. Likewise, lower vitamin D levels 
incur higher risks of developing diabetes (Scragg et al., 2004; Di Cesar et al., 2006).  
All patients in this study have more than 10 years history of diabetes. A longer 
duration of diabetes of at least 10 years was preferred in this study. It is likely that with 
this duration, all patients will be having diabetic vasculopathy. All of them were on 
insulin therapy or taking oral hypoglycaemic agents for diabetes treatment. More than 
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80% of diabetic patients in both study groups (DNP: 80.00% vs DDP: 84.62%) have 
hypertension and taking anti-hypertensive drugs which include calcium channel 
blocker, angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor. 
Likewise, 70.00% of group DNP and 53.85% of group DDP also have 
hypercholesterolemia and taking lipid-lowering drugs from the statin groups which 
include simvastatin and atorvastatin. Due to concerns that certain medications might 
exert effects on oxidative stress levels, statistical analysis (Chi-square test) was 
performed to assess if there is any significant difference in concurrent medications 
between these study groups. The statistical outcome showed that there was no 
significant difference in concurrent medications between these groups (Appendix E).  
As shown in Table 4.5, there were no significant differences in the background 
characteristics such as gender, body mass index (BMI), blood pressures, total 
cholesterol, fasting blood glucose (FBG), glycated haemoglobin and calcium levels, 
between diabetic patients with vitamin D deficiency and non-deficiency. However, 
this study found that diabetic patients with vitamin D deficiency are significantly 
younger than those with vitamin D non-deficiency. It is possibly that the younger 
subjects have a more sedentary lifestyle, lack of physical and outdoor activity and low 
exposure of sunlight compared to those older subjects with a more active lifestyle. 
Younger subjects may spend more time on social media and electronic gadgets, or they 
are working more comfortably in the office without the need of much physical efforts. 
This might well explain the observation that showed higher BMI in subjects from 
group DDP compared to group NDP, although it is not statistically significant.  
Previous findings reported a negative relationship between age and SOD levels 
in normal and diabetic populations (Bolzan et al., 1997; Ozbay and Dulgar, 2002). 
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Similarly, a positive relationship between age and MDA levels was reported in the 
literature (Hassina et al., 2012). Since age is markedly different between two study 
groups and has been reported to be closely associated with oxidative stress levels, 
statistical adjustment of age as the covariate was performed for our results of oxidative 
stress parameters using ANCOVA analysis. 
5.2.2 Microvascular Tissue Oxidative Stress Status 
5.2.2(a) Superoxide Dismutase Levels 
Vitamin D deficiency in diabetics amplifies the overproduction of free radicals 
and ROS (see Section 2.7). SOD as the antioxidant enzyme plays its vascular 
protective role in scavenging the excess ROS. A decrease in SOD levels in conjunction 
with reduced ROS levels might represent the effectiveness of the antioxidant defence 
system to counteract with the increased levels of ROS.  
In the present study, there was a significant difference in SOD levels between 
vitamin D-deficient and vitamin D non-deficient diabetic patients with independent t-
test. SOD levels were significantly lower in the subcutaneous arteries of diabetic 
patients who are vitamin D-deficient. However, after adjusting for age as the covariate 
in the analysis, the difference in SOD levels between two groups was no longer 
statistically significant, although group DDP still showed a lower trend of SOD levels 
(p = 0.072) compared to group NDP. A decrease in SOD levels presumably as the 
compensatory response for its antioxidant activities to combat with excess ROS 
induced by hyperglycaemia coupled with vitamin D deficiency. Vitamin D deficiency 
was also reported to reduce the amount of antioxidant enzymes and diminish the 
antioxidant activities (Nikooyeh et al., 2014; Shab-Bidar et al., 2015).  
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The present finding is in line with the previous studies that reported diminished 
SOD levels and activities in the liver tissue of diabetic rats (Lucchesi et al., 2013), as 
well as skin tissue, organs and blood samples of diabetic subjects (Shukla et al., 2012; 
Kim, 2013; Kayama et al., 2015). Reduced SOD levels were presumably due to the 
elevated ROS production and the enhanced oxidative stress induced by 
hyperglycaemia in diabetics. However, there is also contradictory finding that reported 
SOD levels in hepatic tissue remained unchanged in diabetic subjects (Kumawat et al., 
2013). The study also reported that the levels of catalase (another important 
antioxidant enzyme) were significantly increased in diabetic subjects compared to 
controls as the compensatory mechanism. The overall antioxidant status of diabetic 
subjects therefore remained unchanged.  
SOD levels have been reported to relate with age in diabetic population; elderly 
diabetics normally have lower SOD levels (Ozbay and Dulger, 2002). Vitamin D 
deficiency has also been reported to diminish SOD levels in the diabetics. 
Nevertheless, diabetic patients with vitamin D deficiency who are relatively younger 
in this study showed reduced SOD levels. This contradictory finding might be 
explained by the duration of having diabetes, besides being vitamin D-deficient. The 
younger age of diabetic patients in our study does not necessarily represent a shorter 
disease duration. All subjects have more than 10 years of diabetes duration, regardless 
of their age. Disease duration might be more important than age in contributing to 
oxidative stress in diabetes. 
5.2.2(b) Malondialdehyde Levels 
Chronic hyperglycaemia in diabetes coupled with vitamin D deficiency 
induces excess formation of ROS production, propagating free radical chain reactions. 
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Enhanced ROS levels impair the antioxidant defence mechanism by attenuating the 
antioxidant activities of antioxidant enzymes.  Hence, the effectiveness of endogenous 
antioxidant defence system to scavenge the on-going overproduction of free radicals 
might be reduced due to the reduced levels of antioxidants, exacerbating the imbalance 
condition in oxidative stress status. The built-up of oxidative stress brings detrimental 
effects to our body system, such as lipid peroxidative injury. MDA levels indicate the 
degree of lipid peroxidation induced by excess ROS. Higher MDA levels represent 
higher levels of ROS.  
In the present study, MDA levels were significantly higher in diabetic patients 
with vitamin D deficiency compared to non-deficient group. Reduced SOD levels in 
conjunction with augmented MDA levels in vitamin D-deficient diabetic patients 
found in the present study might well indicate augmented oxidative stress. Elevated 
TBARS and MDA levels reported in plasma, serum, and skin tissues in diabetics 
indicated that peroxidative injury has involved in the development of diabetes 
complications (Moussa, 2008; Bandeira et al., 2012).  
There is limited evidence reported on the effects of vitamin D deficiency on 
MDA levels in diabetes microcirculation. However, previous studies reported MDA 
levels were lower in vitamin D-deficient asymptomatic subjects and patients with other 
CVD such as hypertension and obesity (Yesilbursa et al., 2005; Hamidreza et al., 
2014; Wang et al., 2015), presumably due to the alterations in metabolic states that  
induces excess mitochondrial production of free radicals, which is unable to be 
detoxified by antioxidants. The propagating free radical chain reactions ultimately lead 
to lipid peroxidation as lipid is more susceptible to oxidative damage. 
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CHAPTER 6 
CONCLUSION 
6.1  Summary 
6.1.1  Animal Study 
All objectives of the animal study were fulfilled. In summary, the present 
animal study demonstrates that: (i) Vitamin D deficiency impaired ACh-induced 
endothelium-dependent relaxation in isolated mesenteric arteries of both normal and 
diabetic rats; (ii) Endothelium-dependent contraction was augmented in vitamin D-
deficient diabetic rats; (iii) Vitamin D deficiency in diabetic rats attenuated NO-
mediated cGMP pathway but cAMP pathway was preserved; (iv) Lower SOD levels 
and protein expression of eNOS were observed in vitamin D-deficient normal and 
diabetic rats; (v) Vitamin D deficiency in diabetic rats enhanced MDA levels, 
indicating peroxidative injury. 
Endothelial dysfunction in vitamin D-deficient rats is associated with reduced 
protein expression of eNOS which mediates NO production and augmented oxidative 
stress levels; the imbalance between the excess production of ROS and reduced 
antioxidant activities. Both mechanisms contribute to the reduced bioavailability of 
NO, the potent vasodilator that modulates vascular tone, leading to the impairment in 
NO-mediated vasodilation via cGMP pathway. However, relaxation of VSMC to 
salbutamol and contraction to phenylephrine were not affected in both vitamin D-
deficient normal and diabetic models. 
Furthermore, the present animal study also illustrates that: (i) Calcitriol 
supplementation improved ACh-induced endothelium-dependent relaxation in 
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isolated mesenteric arteries of vitamin D-deficient diabetic but not normal rats; (ii) 
Augmented endothelium-dependent contraction was observed in vitamin D-deficient 
normal rats with calcitriol supplementation; (iii) Calcitriol supplementation to vitamin 
D-deficient diabetic rats improved SOD levels and protein expression of eNOS; (iv) 
Reduced MDA levels were found in vitamin D-deficient diabetic rats receiving 
calcitriol supplementation; (v) Calcitriol-supplemented vitamin D-deficient normal 
rats showed increased calcium levels. 
Calcitriol supplementation ameliorates microvascular endothelial dysfunction 
(improves vasorelaxation) in diabetic rats with vitamin D deficiency by upregulating 
eNOS expression and improving oxidative stress status. However, calcitriol 
supplementation failed to show any improvement in endothelium-dependent 
contraction and SNP-induced endothelium-independent relaxation. Calcitriol 
supplementation in normal rats with vitamin D deficiency even leads to vascular 
dysfunction as shown by augmented endothelium-dependent contraction and reduced 
trend in endothelium-independent relaxation via cGMP pathway. It is possibly due to 
the altered calcium homeostasis induced by calcitriol leads to hypercalcaemia that 
contributes to the unfavourable effects seen in normal rats. 
6.1.2  Human Study 
All objectives of the human study were fulfilled. In summary, the present 
human study showed that: (i) SOD levels of vitamin D-deficient diabetic patients 
showed the reduced trend after adjusting for age as the covariate; (b) Higher MDA 
levels were observed in diabetic patients with vitamin D deficiency. These findings 
were consistent with the study outcome from the present animal study, where vitamin 
D-deficient diabetic rats showed reduced SOD and increased MDA levels, indicating 
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augmented vascular oxidative stress levels. Enhanced oxidative stress levels may 
subsequently predispose to peroxidative injury in diabetics. 
6.2  Significance and Novelty of the PhD Study 
Diabetes mellitus is a growing threat to public health. This disease poses a 
significant risk of secondary complications and cardiovascular events that lead to high 
mortality in diabetics. It is critical to recognise and treat this devastating disease early 
to delay or even prevent serious diabetes-related cardiovascular complications.  
This is the first study that demonstrated vitamin D deficiency impairs vascular 
function in the microcirculation of diabetic rats, attributed to reduced eNOS protein 
expression and augmented oxidative stress. This study also discovered that calcitriol 
supplementation ameliorates endothelial dysfunction in vitamin D-deficient diabetic 
rats, by upregulating eNOS protein expression and improving oxidative stress. This 
study also showed that calcitriol supplementation aggravates endothelial dysfunction 
in vitamin D-deficient rats, possibly due to calcitriol-induced hypercalcaemia.   
Realising the adverse impacts of vitamin D deficiency on diabetes mellitus and 
its complications, emphasis should be given in preventing or reducing the prevalence 
of vitamin D deficiency in the country to effectively reduce diabetes-related adverse 
cardiovascular events associated with low vitamin D levels. The study outcome also 
reinforces the need for the authorities to encourage vitamin D-deficient and diabetic 
individuals to optimise their vitamin D levels; this can be achieved by more sunlight 
exposure and increased dietary vitamin D intake. Vitamin D supplementation might 
be a potential strategy to reduce the adverse effects of low vitamin D levels on 
microvascular function in the diabetic population with vitamin D deficiency.  
  179 
6.3  Study Limitations and Recommendations 
6.3.1  Animal Study 
The present study has a few limitations that deserve more attention and 
improvement in future research. Firstly, this animal study assessed the effects of 
vitamin D deficiency and supplementation on vascular responses in general but not 
studied in detail the contribution of particular vasodilators (NO, prostacyclin and 
EDHF). This is restricted by the dual chamber wire myograph system that allows the 
simultaneous study of only two arteries at one time. Considering the viability of an 
isolated blood vessel in the physiological solution is about 20 hours (Ang et al., 2012), 
only endothelium-dependent and independent relaxation and contraction in control 
solution were examined in the study. Besides that, assessment to explain the 
underlying mechanisms involved only protein expression of eNOS, in view that NO is 
the major vasodilator that accounts for endothelium-dependent relaxation. 
Nevertheless, this limitation might underestimate the contribution of other vasodilators 
such as prostacyclin and EDHF in leading to vascular dysfunction in the 
microcirculation of vitamin D-deficient rats. Further evaluation on the role of specific 
vasodilators and vasoconstrictors on vascular responses in diabetic microcirculation is 
an important area of future studies. 
Secondly, the dosage of calcitriol supplemented to animal models remained a 
great challenge. The present study showed a beneficial effect in diabetic models but 
an adverse outcome in normal rats even though same dosage of calcitriol was provided. 
This observation suggests the need for close monitoring of calcium levels and other 
vitamin D-associated minerals and hormones such as phosphate and parathyroid 
hormone from time to time.  
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6.3.2  Human Study 
There are a few limitations in the present human study for future improvement. 
Firstly, there are difficulties in obtaining sufficient and suitable human tissue samples 
to study the vascular responses and to perform Western blot and 
immunohistochemistry as the animal study did. Nevertheless, this PhD project was 
able to conduct a matching study on assessing microvascular tissue oxidative stress 
levels in diabetic patients with different vitamin D status. Hence, conducting a 
matching study on microvascular responses in human models is an important area of 
research that deserves further investigation. It is able to provide a better understanding 
of the similarities between experimental and clinical studies on the effects of vitamin 
D deficiency on microvascular function in diabetic and normal conditions. 
Secondly, despite our best efforts to match medications that subjects were 
taking during the study, there might remain some dissimilarities of some drugs 
between the two groups. We acknowledge the potential effects of different drugs on 
oxidative stress. Hence, to minimise the bias in the study outcome, statistical analysis 
(Chi-square test) was performed to ensure the difference in concurrent medications 
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Dr. Sahran Yahaya 
Department of Orthopaedics 
School of Medical Sciences 
Universiti Sains Malaysia 
16150 Kubang Kerian, Kelantan. 
JEPeM USM Code: USM/JEPeM/15100337 
Jawatankuasa Etika 
Penyelidikan Manusia USM (JEPeMI 
Human Research Eth1cs Comm1ttet: USM (HRECJ 
Universiti Sains Malaysia 
Kampus Kesihatan, 
16150 Kubang Kenai' Kel n. Malays1a 
T {6109-767 31XXl/Z354/2362 
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Study Protocol Title: The Effect of Vitamin D Deficiency on Microvascular Endothelial Function 
in Diabetic Patients. 
Dear Dr: 
We wish to inform you that the Jawatankuasa Etika Penyelidikan Manusia, Universiti Sains 
Malaysia (JEPeM-USM) acknowledged receipt of Continuing Review Application dated 25" 
February 2018. 
Upon review of JEPeM-USM Form 3(B) 2017: Continuing Review Application Form, the 
committee's decision for the EXTENSION OF APPROVAL IS APPROVED (start from 1" March 2018 
till 28"' February 2019). The report is noted and has been included in the protocol file. 
Thank you for your continuing compliance with the requirements of the JEPeM-USM. 
Thank you. 
"ENSURING A SUSTAINABLE TOMORROW" 
very truliyrrs, 
(ASSO~DR. AZLAN HUSIN) 
Deputy Chairperson 
Jawatankuasa Etika Penyelidikan (Manusia), JEPeM 
Universiti Sa ins Malaysia 
c.c Secretary 
Jawatankuasa Etika Penyelidikan (Manusia), JEPeM 
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Tajuk Kajian:  KESAN KEKURANGAN VITAMIN D KE ATAS FUNGSI SALUR DARAH  
KECIL DI KALANGAN PESAKIT DIABETES 
Nama Penyelidik: Dr. Sahran Yahaya       
Prof. Dr. Aida Hanum Ghulam Rasool 




Sedia dimaklumkan bahawa lebih daripada 3.2 juta rakyat Malaysia dilaporkan menghidapi 
penyakit kencing manis pada tahun 2014, dan dijangka akan mencecah sebanyak 4.5 juta 
penyakit kencing manis pada tahun 2020. Diketahui umum bahawa penyakit kencing manis 
akan merosakkan fungsi salur darah, dan seterusnya akan menyumbang kepada masalah 
kardiovaskular (sistem darah dan jantung). Komplikasi sebegini memerlukan rawatan yang 
berpanjangan dan juga melibatkan perbelanjaan yang besar.  
Paras vitamin D yang rendah turut dilaporkan berhubungkait dengan kegagalan fungsi salur 
darah kecil di kalangan pesakit diabetes. Oleh sedemikian, anda dipelawa untuk menyertai 
satu kajian penyelidikan secara sukarela. Kajian ini adalah untuk menyelidik kesan 
kekurangan vitamin D ke atas fungsi salur darah kecil di kalangan pesakit diabetes (kencing 
manis).  
Dianggarkan seramai 50 pesakit kencing manis akan menyertai kajian ini. Paras vitamin D 
para peserta akan diukur untuk mengenalpasti golongan pesakit, sama ada dalam golongan 
yang mempunyai paras vitamin D yang normal ataupun golongan yang mengalami masalah 
kekurangan vitamin D.   
Sebelum anda bersetuju untuk menyertai kajian penyelidikan ini, adalah penting untuk anda 
membaca dan memahami borang ini. Sekiranya anda menyertai kajian ini, anda akan 
menerima satu salinan borang untuk disimpan sebagai rekod anda.  
 
TUJUAN KAJIAN  
Protokol kajian ini telah diluluskan oleh Jawatankuasa Etika Penyelidikan (Manusia), Universiti 
Sains Malaysia. Kajian ini bertujuan untuk menyelidik kesan kekurangan vitamin D ke atas 
fungsi salur darah kecil di kalangan pesakit diabetes. Kajian ini dapat mengetahui kesan 
kekurangan vitamin D ke atas fungsi salur darah, maka maklumat tersebut dapat membantu 
untuk mengenalpasti rawatan penyakit kencing manis yang berpotensi untuk membawa 
  
manfaat kepada kesihatan salur darah. Oleh sedemikian, kerosakan salur darah dapat 
dicegah dengan awal dan kegagalan fungsi salur darah yang akan menyebabkan komplikasi 
akan diatasi.  
Terdapat kemungkinannya bahawa maklumat yang dikumpulkan semasa kajian ini akan 
dianalisasikan oleh pihak penyelidik pada masa depan untuk kegunaan lain yang mungkin 
atau untuk tujuan perubatan atau saintifik yang selain daripada yang kini dicadangkan. 
KELAYAKAN PENYERTAAN 
Doktor yang bertanggungjawab dalam kajian ini atau salah seorang kakitangan kajian telah 
membincangkan kepada anda tentang kelayakan yang diperlukan untuk menyertai kajian ini. 
Adalah penting untuk anda berterus-terang dengan doktor dan kakitangan tersebut tentang 
sejarah kesihatan anda. Anda tidak seharusnya menyertai kajian ini sekiranya anda tidak 
memenuhi semua syarat kelayakan yang ditetapkan. 
 
Beberapa syarat kelayakan yang telah ditetapkan untuk menyertai kajian ini, seperti: - 
• Anda mesti menghidapi penyakit diabetes.  
• Anda mesti berumur antara 18 hingga 60 tahun. 
• Anda akan menjalani pembedahan kaki.  
 
Anda tidak boleh menyertai kajian ini sekiranya  
• Anda menghidapi masalah jantung dan hati. 
• Anda mengalami tekanan darah tinggi melebihi 160/100 mmHg. 
• Anda terpaksa menjalani pembedahan kaki yang berkaitan dengan tumor. 
• Anda sedang mengambil vitamin D atau/dan calcium tambahan. 
• Anda menghidapi penyakit diabetes kurang daripada 3 tahun. 
• Anda mengalami keadaan yang tidak mengizinkan anda untuk menyertai 
penyelidikan ini mengikut budi bicara penyelidik. 
 
PROSEDUR-PROSEDUR KAJIAN 
Sekiranya anda bersetuju untuk menyertai kajian ini, maklumat peribadi seperti umur, jantina, 
berat dan tinggi badan anda akan dicatatkan. Anda perlu menjalani ukuran tekanan darah dan 
diminta untuk memberi maklumat tentang sejarah kesihatan anda, seperti jangka masa anda 
menghidapi penyakit diabetes, sebarang masalah kesihatan yang anda telah/sedang alami 
dan sebarang ubat/rawatan yang anda telah/sedang ambil.  
Kaedah pembedahan anda memang melibatkan pengeluaran/pembedahan tisu semasa anda 
dibius. Untuk menyertai kajian ini, satu cebisan kecil tisu lemak yang berukuran 2 cm x 2 cm 
yang TELAH dibedah/dikeluarkan tidak akan dibuang, tetapi akan digunakan untuk tujuan 
penyelidikan. Maka, prosedur ini tidak akan menyakitkan anda dan tiada apa-apa risiko 
tambahan disebabkan tiada prosedur tambahan yang diperlukan sekiranya cebisan tisu ini 
diambil.   
  
Pengambilan darah memang diperlukan untuk pembedahan yang akan anda jalankan. 
Dengan menyertai kajian ini, tambahan darah yang beranggaran 2 mls akan diambil serentak 
untuk sekali sahaja untuk mengukur paras vitamin D. Prosedur ini juga tidak akan menyakitkan 
anda atau mendatangkan apa-apa risiko tambahan disebabkan tiada prosedur tambahan 
yang diperlukan. 
 
DARAH DAN TISU YANG DIAMBIL HANYA AKAN DIGUNAKAN UNTUK TUJUAN 
PENYELIDIKAN YANG DINYATAKAN DI ATAS SAHAJA. IA TIDAK AKAN DIGUNAKAN 
UNTUK TUJUAN-TUJUAN LAIN.  
SETELAH PENYELIDIKAN DISELESAIKAN, SEMUA DARAH DAN TISU ANDA TIDAK 
AKAN DISIMPAN TETAPI AKAN DILUPUSKAN MENGIKUT PROSEDUR-PROSEDUR 
YANG SEDIA ADA.  
 
RISIKO 
Memandangkan penyelidikan ini hanya melibatkan tisu yang akan dibedah/dikeluarkan 
daripada tubuh anda mengikut kaedah pembedahan yang sedia ada, maka TIDAK ada apa-
apa risiko yang mungkin terjadi ke atas tubuh anda sekiranya anda bersetuju untuk menyertai 
penyelidikan ini, selain daripada risiko yang sedia ada untuk pembedahan. Jika apa-apa 
maklumat penting yang baru dijumpai semasa kajian ini yang mungkin akan mengubah 
persetujuan anda untuk terus menyertai kajian ini, anda akan diberitahu dengan secepat 
mungkinnya. 
 
MELAPORKAN PENGALAMAN KESIHATAN 
Jika anda mengalami apa-apa kecederaan, kesan buruk, atau apa-apa pengalaman kesihatan 
yang luar biasa semasa kajian ini, pastikan anda memberitahu jururawat atau Dr. Sahran 
Yahaya (MMC: 47033) atau Prof. Dr. Aida Hanum Ghulam Rasool (MMC: 31313) di talian 09-
767 6398/6123 atau 019-919 5667 dengan secepat mungkinnya. Anda boleh membuat 
panggilan pada bila-bila masa sahaja, siang atau malam, untuk melaporkan pengalaman 
sedemikian. 
 
PENYERTAAN DALAM KAJIAN 
Penyertaan anda dalam kajian ini adalah secara sukarela. Anda berhak menolak untuk 
menyertai kajian ini atau anda boleh menamatkan penyertaan anda pada bila-bila masa 
sahaja, tanpa sebarang hukuman atau kehilangan sebarang manfaat yang sepatutnya anda 
perolehi.  
Penyertaan anda juga mungkin diberhentikan oleh doktor yang terlibat dalam kajian ini tanpa 
memerlukan persetujuan anda. Sekiranya anda diberhentikan untuk menyertai kajian ini, 
doktor yang terlibat dalam kajian ini atau salah seorang kakitangan akan berbincang dengan 




MANFAAT YANG MUNGKIN [Manfaat terhadap Individu, Masyarakat, Universiti] 
Sebagai peserta dalam kajian ini, anda berhak untuk mendapatkan maklumat tentang 
kesihatan anda daripada pemeriksaan fizikal dan ujian darah yang dilakukan dalam kajian ini 
tanpa kos. Sekiranya anda didapati mengalami masalah kekurangan vitamin D, anda akan 
dirujukkan kepada doktor perubatan untuk rawatan, sama ada perlu mengambil bekalan 
vitamin D tambahan.  
Anda akan menerima rawatan sekiranya komplikasi penyakit dikesani. Walaupun anda tidak 
akan menerima sebarang pampasan untuk menyertai kajian ini, namun sebarang keperluan 
berkaitan dengan penyertaan anda dalam kajian ini akan diberikan. 
Walaupun masih tidak ada rancangan untuk memperkembangkan produk kesihatan secara 
komersial daripada hasil kajian ini buat sementara ini, hasil/maklumat kajian ini diharapkan 
dapat membantu penyelidik untuk mengenalpasti sama ada kekurangan vitamin D akan 
mempengaruhi fungsi salur darah kecil yang seterusnya akan membawa kepada komplikasi 
penyakit diabetes. Penemuan ini diharapkan dapat memberi manfaat kepada pihak penaja 
iaitu USM, para penyelidik dan pesakit pada masa yang akan datang.  
 
PERSOALAN 
Sekiranya anda mempunyai sebarang soalan mengenai prosedur kajian ini, sila hubungi: 
 
1. Dr. Sahran Yahaya (MMC:47033) - Penyelidik utama   
Jabatan Ortopedik 
Pusat Pengajian Sains Perubatan 
Universiti Sains Malaysia, Kampus Kesihatan 
16150 Kubang Kerian, Kelantan. 
No. Tel: 09-767 6398 
 
2.  Prof. Dr. Aida Hanum Ghulam Rasool (MMC: 31313) - Penyelidik bersama 
Jabatan Farmakologi 
Pusat Pengajian Sains Perubatan 
Universiti Sains Malaysia, Kampus Kesihatan 
16150 Kubang Kerian, Kelantan. 
No. Tel: 09- 767 6123 
 
Sekiranya anda mempunyai sebarang soalan berkaitan dengan kelulusan Etika atau sebarang 
pertanyaan dan masalah berkaitan kajian ini, sila hubungi: 
 
  
En. Mohd Bazlan Hafidz Mukrim 
Setiausaha Jawatankuasa Etika Penyelidikan (Manusia) USM 
Pusat Inisiatif Penyelidikan - Sains Klinikal & Kesihatan 
Universiti Sains Malaysia, Kampus Kesihatan. 
No. Tel: 09-767 2354 / 09-767 2362 
Email : bazlan@usm.my/jepem@usm.my 
 
KERAHSIAAN 
Maklumat perubatan anda akan dirahsiakan oleh doktor dan kakitangan kajian. Maklumat 
tidak akan didedahkan secara umum melainkan jika dikehendaki oleh undang-undang. Data 
yang diperolehi daripada kajian ini yang tidak akan mengenalpasti anda secara perseorangan 
mungkin diterbitkan untuk tujuan memberikan pengetahuan baru kepada masyarakat.  
Rekod perubatan anda yang asal mungkin akan dilihat oleh pihak penyelidik, Lembaga Etika 
kajian ini dan pihak berkuasa regulatori untuk tujuan mengesahkan prosedur dan/atau data 
kajian klinikal. Maklumat perubatan anda mungkin akan disimpan di dalam komputer dan 
diproses. 
Dengan menandatangani borang persetujuan ini, anda membenarkan penelitian rekod, 
penyimpanan maklumat dan pemindahan data seperti yang dihuraikan di atas. 
 
TANDATANGAN 
Untuk dimasukkan ke dalam kajian ini, anda atau wakil sah anda mesti menandatangani serta 













Borang Keizinan Pesakit/ Subjek 
(Halaman Tandatangan) 
 
Tajuk Kajian:  KAJIAN KESAN KEKURANGAN VITAMIN D KE ATAS FUNGSI SALUR 
  DARAH KECIL DI KALANGAN PESAKIT DIABETES 
Nama Penyelidik: Dr. Sahran Yahaya (MMC: 47033) 
Prof. Dr. Aida Hanum Ghulam Rasool (MMC: 31313) 
Untuk menyertai kajian ini, anda atau wakil sah anda mesti menandatangani mukasurat ini. 
Dengan menandatangani mukasurat ini, saya mengesahkan yang berikut: 
§  Saya telah membaca semua maklumat dalam Borang Maklumat dan Keizinan 
Pesakit ini termasuk apa-apa maklumat berkaitan risiko yang ada dalam 
kajian dan saya telah pun diberi masa yang mencukupi untuk 
mempertimbangkan maklumat tersebut. 
§  Semua soalan saya telah dijawab dengan memuaskan. 
§  Saya secara sukarela, bersetuju menyertai kajian penyelidikan ini, mematuhi 
segala prosedur kajian dan memberi maklumat yang diperlukan kepada doktor, 
para jururawat dan juga kakitangan lain yang berkaitan apabila diminta. 
§  Saya boleh menamatkan penyertaan saya dalam kajian ini pada bila-bila masa. 
§  Saya telah pun menerima satu salinan Borang Maklumat dan Keizinan Pesakit 
untuk simpanan peribadi saya. 
 
 
Nama Pesakit (Dicetak atau Ditaip)   Nama Singkatan & No. Pesakit 
 
No. Kad Pengenalan Pesakit (Baru)      No. K/P (Lama) 
 
Tandatangan Pesakit atau Wakil Sah           Tarikh (dd/MM/yy) (Masa jika perlu) 
 
Nama & Tandatangan Individu yang        Tarikh (dd/MM/yy) 
Mengendalikan Perbincangan Keizinan (Dicetak atau Ditaip) 
 
Nama Saksi dan Tandatangan     Tarikh (dd/MM/yy) 
 











APPENDIX D: CASE REPORT FORM 
 
 
1- Subject's Data 
1. Name 
2. Date of Birth ___ ! ! __ _ 
3. Age 
4. Gender Male I Female 
5. 1/C Number 
R/N 
6. Race 
7. Contact Number 
8. Weight (kg) 
9. Height (em) 
10. BMI (kg/m2 ) 
11. Concurrent medications 
12. Other medical problems 
13. Duration of Diabetes 
  
2- Patient's Characteristics 
1. Systolic Blood Pressure (mmHg) 
2. Diastolic Blood Pressure (mmHg) 
3. Total Cholesterol (mmoi/L) 
4. Triglyceride (mmoi/L) 
5. HDL Cholesterol (mmoi/L) 
6. LDL Cholesterol (mmoi/L) 
7. Serum Creatinine (llmoi/L) 
8. Fasting Blood Glucose (mmoi/L) 
9. HbA1c (%) 
3- Samples 
1. Sites of sample 
2. Sample taken by 
3. Date taken 
4. Time taken 
5. Time of experiment 
6. Diagnosis 
7. Types of operation procedure 
  
APPENDIX E: CHI-SQUARE TEST FOR CONCURRENT MEDICATIONS OF DIABETIC PATIENTS 
 
Categorical data were expressed in number (%). 
[DNP: vitamin D non-deficient diabetic patients; DDP: vitamin D-deficient diabetic patients] 
Parameters Group DNP 
(n = 10) 
Group DDP 
(n = 13) 
X2 (df) p value 
Insulin 6 (60.00) 10 (76.92) 0.765 (1) 0.382 
Oral Hypoglycaemic Agent 7 (70.00) 7 (53.85) 0.619 (1) 0.431 
Angiotensin-converting enzyme (ACE) Inhibitor 3 (30.00) 2 (15.38) 0.306 (1) 0.400 
Angiotensin II Receptor Blocker 2 (20.00) 3 (23.08) 0.031 (1) 0.859 
Calcium Channel Blocker 5 (50.00) 8 (61.54) 0.720 (1) 0.580 
Beta-blockers 1 (10.00) 3 (23.08) 0.673 (1) 0.412 
Lipid Lowering Drug 8 (80.00) 8 (61.54) 0.910 (1) 0.340 
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Vitamin D status and oxidative stress in diabetes mellitus 
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lnti"'dlletion 
Diabetes me.Uilld 
J>iabe1..t$ mellitus (OM) is a I'M'tabolic di:sordu, 
elw'atutrittd by eJevatt-d blood glucose k'\.'\".ls ewer a 
ptol01ttgN period. t\':Slllti.n& from defective insulin p~ 
duetion andlot itlsulin adion ( I). There are lhl\_~ 1:najor 
rypes of D~t: 
I. T)'pt I di:tbe.tcs (TI D~f) is due to im.mune-
med:iattd dt's:uuctioo of p3S'I.ttcatic 1}-«Us that &eads to 
insufficient insulin productioa: 
2. T)'pt fl diabetes (T2DM) is due to etllulaf inro· 
lin. r'd:iuaDCe. Yo1lcreby tbe wgettd tissutS are unable to 
property tei'pond to i.Dsu.JiB; and 
3. GtStational mabttts (GDM). which is &JlliCOISe 
ituOlt:raftCe during ptegnaney (2). 
The woddwidt J'ft:\'all.'ftoe of D~i inataSeS u-em~ 
doosly during tbt pas.1 dtea&s. lt~~tematiooal Diabetes 
Federation (IDF) ~pont<! that tbt global pn.waknce o f 
OM hat inaeased from 28S millioa (6.6%) in )'t at 2010 
(3) to 42S nlillion (8.8%) in year 2 0 17. The figurt ii 
enimattd to uee~ 629 m illioa. (9.9%) in ~ 2045. 
IDF has aha reponed lhat diabetes eaDSts &3th o f 4 
million individuals globally ( I 0. 7% of global aU-c:ause 
morulity), atld lht ttcatmeru eos:e fot disbttcs Ol)flS;litu· 
to.--d 727 billion USO (12 .S% o f global btihb c:xpen.di· 
rure) in yev 2017 (4). 
In Malaysia. tbe pft'\'alenot of D~i inerease:s from 
11.6% itt. yt:3t 2006 (S) to 16.9% (3.S millioo d.i31betie 
potisus) iJ> y<as 2017 (4). 11 is pn:dielt:d ro rise ~ ro 
2 1.6 % in )·ear 2020 witb 4..5 million itldr.•idua.ls h'"•irtg 
di3bctes (6). AMual expendirurt fOil' diabeus ueatmtnt 
in Malaytia W bttn reponed to be as bigh as R.M20.9 
b illion in year lOIS (7). T his c:oftSrirures a lwg_e pot· .. 
lion of tbt Malays:ian nations) healt.bc:ttte budget. Ia 
sb011, high pr't'Valen.ce of OM toaSWn.ti lar&e amount 
of global t.xpCDditure and will advcne:ly impGel oa the: 
nation •.s eeoaomy. 
Loog term augn~~enacd blood g,luc:osc level lalo"''ft 
as ehtonie hypetsJy«mia. upous an indi .. •i<klal 'ol.i th 
OM to tbe signifkat!.t risk of specific diabd.es-rdatOd 
mkro- and maero\'ast'Ulat oomplieation.i.. Mierovaseu· 
Jar ~omplications include diabetic aephtopatby (kid· 
ney damagt), diabetic aeuropathy (acini <tan.~) and 
dia~tie retinopathy (eye d3J'lU&~). On tbt Olb« haod. 
matto .. ·asculat eomplic3tioas comprise of coronuy 
bet111 diseas.t, peripheral vascular d.Uetit aDd ettebto-
vaoculat di,.... (SirOioe) (8). 
Boc:h micnr a:nd maerovas:euJat oom.plk:uions 
oonu ibutr signi6eaa.tly to tbe r3lcs of morbidity and 
mortality in: OM (9), witb approxim3lcly 6S-7S% of 
dia~tie deaths bei.og dot to eatdiovaiCUbt diseas;:s 
{CVD) (10·1 1). Henet. the pm.'tntion of diabetic.fda· 
ted complications becomes the m:Un objccth;oe itt. mana· 
gmg OM (9). 
Vascular oxidati \·e s1rus., in additiot1. to ehtorUc hy· 
fW:rg;lyetmia it tepontd to be a key OOOO'ibutot in the: 
pa~i:s of OM and its secondary oom.plica~ions 
(12). In OM, augn'lt:nttd oxid3live Slr"'!SS is due to the 
en.hsneed fret radical.g_en.tratiag prOCd':S ( I ;.14) and/or 
impairtd c:apaeity of lhe a.ntioxidan1 de.ftt~Sc systtm to 
sea\·tnge l.bt ex~ ft« radicals wttieh att Ulduoed by 
chronic hytW:tg)yotmia (IS). 
Vua.min D dafici't'ir!C)' "'at rtponcd to be closely as· 
soei:ated v.•itb enhaneed VtiCUiat oxidative strtSs aftd in.· 
<::rttitd rUk: of major CVD ill diabetic: populations ( 16). 
This MView aims to explore the as!I;OCiation ~'et:ft 









possible benodidal eJftetS ofvit:lmi.n. D suppk-menw:iocl 
ia oo~ any vitamin D insuftlciency k:ading to im· 
provc:~neal ill vascubr oxidath~ .ure.u. aDd the ability 
110 reduce rist of di3bnes and cardiovasrulat eomplic:a· 
tioM ate also discussed. 
O.ddatln ltniS 
Oxichtivt-wcu is a conditioa. eaused by the ovcrpro-. 
dbetion of rtaetive s.pttits, ~"' as pro-<tX.idants lAd 
Eht ineapthitity of the antiox.idaat defta.S~t S)'Sttm 10 
SCI\'«lg.t dae species (17). Hi&h)y reacth't' .specili!S are 
DOtmally tenmted as a by-product of aerobic mn:Jbo.. 
lism in the body ( 18). These t'detive sp«iesl at a cmaitl 
tn'IO\U'lt is a.fkn ~ to maintain I'IIOtma.l mn:Jbo.. 
lie processes ( 19). Howewr, the exce5S iD tadieal s:pt:· 
c:ies produ«d is likdy to bring deleccriow e.lfcro: 10 
lht htun3.D body (20);; mus !.bey mcd to bt .s.ufficimdy 
remcwtd by the body's antioxicWI.t dcfCI!SlC sysu:m. 10 
ma.imajn. dl.t bomeclliWis of tbt body system (I S). 
In di~ chrorUc hyperglytt1nia i:nduces tuU· 
sh·e formation. ofdle:se rcactiYt species tba might dim.i· 
cisb antioxidant acti\ily, leading to the dominatioa of 
oxidath·e scrcss (17.21). Oxid31ive sttess tht-:n funbtr 
~gates the production of mc::tn!· reactive spt:Cies. 
subscqunldy eausio& the devdoptuent of patbolog,ietl 
conditions in OM 3l'ld its sccoada.r)• eomplieations (12). 
Hlghly rHdiw Jp«<n flntl/r« ratll~b 
In g~:ntal, hig;bly reaetin species cu be dassi6od 
iato rtactivt' oxygen 59t'Cies (ROS) and lUdi\'C niuotell 
species (JLl!.lS}. Bocb Slp«icstft'divided ialo free r1dietl 
or tl(ll'Hadioeal species. Free ndieal ROS 001npr~ of 
superoxidt att.ion (..0;). peroxyf (•ROJ. hydroxyl nrdi· 
cal (-Qll)aod bydropa"Oxyl (•IIR0.1 wbik non·r.l<fical 
ROS in.dude hydtodlloroUi acid ~OCI) and hydrogel~. 
peroxide tll:OJ. Fru- radical R.N'S indude nitric oxide 
(·NO) and mtrogcn. dioxide (•N0~1 wberca:s DOn-radiea.l 
R:.~S comprise of citrous oxide (HNOJ. peroxynilrite 
(ONO<n aod alkyl p<t<>Xl"'i"""' (R0!-100) (22·23). 
n.e classi6eatiol'l ofbi&hJy rc:active species is listtd itl 
Figure I. 
Free radiea.Js att ddined as atty cltcmieaJ entiti.:s daat 
contain unpa.ired .:kctron.s in aa atomic «bitaa. Thty are 
rtlariw:ty UftSlable and highly reacth•e- with short htlf· 
life (24). 'J1t,ey bcbavt' as oxidaau or rOOuetants b«aust ---
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tbcy tend 10 either IIC«pt an dedron from: or d003U an 
cleccron 10 other molecules fO aebicn saablc tknroo 
...,;guru;.. (25). 
In dUhctts-~ eardicwasculat complicariofts, 
..0; . ·OH and ·N'O arc amoa& tbc fitt radicals lhat 
ui widely addressdl itl lhe liu::rarure (26). ·O; is pro· 
duced by ODC- t lcctroo reduction <lf mckc:ulat. OX)"'tctl 
(OJ in oxncn mnabolism (Figure. 2). It is lhe initiaJ 
SOUI'(:IC that ptopG.glle$ the 6u radical c:hai:n rtaeriol'l. 
Hydrogc paoxidt. H,O, wbic:b is ptoduc>ed from -o; 
during disnunation. m die pft$tl'l00 of tntnSition eLt~ 
ments such as ooppcr and itoa. might ~ eon\'trud to 
.OH (2'7). ·OH is hitbJy ttacti\•e and dtc n)()SI: p<llcn'l 
oxidant to attack most biological molccuks, futthtr pro· 
. II>< ba. . -Q . I llso npidl pagalll'lg e tn rc:acuon. ; ttug't .. ..,, y 
with •NO 10 prodlltt C)10otoDc ONOCY. This pedlolo· 
&ical J'I:'IOdifkation impairs tbt role of ·NO to act as tbe 
mcdiaror of vucu!ar tone sad inhibiu ilS ami-prolifc. 
ratiw propt:rty, leadin& to tbe patbogttlltSis of vascular 
dysllulctioo(22). 
Metabolic abtlomuliti.:s of DM it!IOOce mitooebon· 
drial ovuprod:uctiol of ·0 ;. ltadil'lg 10 un.conuolkd 
clevation of ftc.: nrdieab (28). Frc.: nrd.ieak mack 
ir:npo.ttac1 maci'OI'l:'dtcuJcs itt. me body, k:ading to cd· 
lular damage and homoos.taric disruptiocl (29). Free 
radicals also lead 10 foam ceO formatioa and atberoi· 
clerotic plaque by stimulating ibt Jow-dc:Dsity lipcpro· 
tcin (LOL) oxidatioe (30), caus.iog it to bt taken up by 
scavenger rttcptors of macropba&es (26). Besides tbe 
uneotlU'Otkd propagation of f:ttt radical chain ttaeriol'l, 
free radieal:t also iti.~'Otvc in dtc altctarion of eft2)U&· 
tic aotioxidant defmst S)'lltc.D lly impa..irin& glutath.ioae 






(I). The ttdueed hwel of antioxidant makes the. cell s:nd 
tissrue more prone fO oxidative st:re~ causing oxidative. 
damage, furlber exaocrbatil'lg diabetes C<lmplications 
(31). 
Antlo:dillml d~/c>~ts' S!'tc>."' ani/ ll~tflo:cldants 
Antioxidana defense system plays a piv01al role to 
scavenge. exc.css radical species and l'lCUtraliu lbe.ooxi-
city ~riQin.a (rom tbe elevt.!ed :uuounl o( telk'tive Q.,C-
cies. The system is generally divided into eodogeooUi 
and exogenous 3ntioxidants (32). Enzy1natic endoge-
nous antioxidants inc-lude. superoxide disn1utalle, cata· 
lase and glutatbiooe (oxidiudlrod:uced) while. exoge-
nous 3ntioxidants can be acquired from diet and supple-
ments. The antioxidant defense mechanism is simpli6cd 
in Figure 2. Vitamin C and vitamin B ate an'IOng tbe. 
most das:!lic natural.ly occurring antioxidants 1bat regu-
late oxidath•e sttess in tbe. patbos_enc!lis of diabetes-re-
lated ' 'asc.ulat romplieatioos. 
SujJero:tide diJmuUJSc' (SOD) 
SOD is an imponant anaiox:id3nt C:n:l)'lne in tbe regu-
latiol'l of oxidative. !lttess in 0~1 (16). h acts all a tit!lt 
line. defense. against rca clive species to reduee oxidative. 
st:res:s and ~n~bscqucl'llly reduee the risk of cellular 3:nd 
hilltolo&kal il'ljuty (33). The dilferena: forms of SOD, 
man.ganese. !l'llpcroxide dis1ntu:ase (Mn-SOD) in 1be mi-
tochondria and COP'J)f!r superoxide disn1u1ase-(C\1-SOD) 
in 1bc cytosol catalyze the disnMation of-<>; into lcs:s 
toxic 0 and H,O, (27). Aheratiol'l in tbe-metabolic Slate. 
of D~t1eads tO a iminisbed ac.tivity and k vcl of SOD 
in diabetic otgan!l. tis~>UC and blood (34-3S). Reduced 
SOD lwei elevates the production of reacth•e. species, 
leading to augmcnted Vtitular ox.idath•e stress a:nd in-
.::ro:.ucd CVD ti~ i.n J i.abcti .:;:r.. 
Cataltue (CA1) 
CAT is another important enzyme that mc13bolill.:$ 
f\Ol inro Hp and Ol in lysosome (26). Chtonic b)•per-
gl)•ttmia i:nd:uces lbe. augmented fl)t!nation ofH,O,s:nd 
down-regulates tbe gene cxprcs!lion l)f CAT (3~),- lca­
ding to tbe. decteased production of Ibis C'll2)'mc. As tbe. 
major regulator in H,O, metabolism, CAT enzyme. 006-
ciel'lty causes cdl in]u.Y mediated by tbc accumulatic>n 
of HP: in diabetic modeL 
Glutalhitme (GSH) 
GSH acts as direct Sl:a\'el'lget and co-substrate for 
tbe. C'll2)'1nc s,lutatbione. peroxidase (GSH-Px). GSH-Px 
is Ol'le· of the antiox:id3nt C!tt)•mcs in H,O, mctabolism 
that metabolizes H.O. into H,O and 0 , fn m.itoohondria 
(26). Reduced GSA-JSx ex:prCssioo baibeen reponed in 
most diabetic models (31-3.8). 
Yitamll'l.t 
It is well established that vitamin C and Bare. non-
enzymatic exogel'lous antioxidants agai:nsc oxidative. 
st:res:s in the prevention l)f diabetes and its rompliea-
tion!l. Tbc!le antii)Xidana vita:mins ncutrali.ze free radi· 
cals directly and al!l<> inretact in recycling protts!rlts to 
tegencrate. reduced fomu or vltamll'ls for r\lnl'let an-
tioxidant actio.u (39). 
The. molccubr structute-of vitamin CotTers electron 
donatil'lg and accepting po.tential tl) be-in\-olved in redox 
" 
reac:tiol'l, thus it acts as a reducing agel'lt in free radical· 
mediattd oxidation prooell!rltll to elfidemly St-a\'el'lge. 
free l)xygen radicals (40). Vitamin E is a fat·!l<>luble. 
vitamit1 1bat can protect: edl membrane from l)x:idath•e. 
da:nlagf by discontil'luinga potentially destruelive series 
of oxiduh-e cbain reactions on the !Oiru(:tutal and func-
tional <ompo.nents of cells and vessel walls (41). Vita· 
min Elias proved to be. effecch•e in prt:\'tnting s,lucose. 
-indu«d lipid p;:roxi&ation U~d otl.o:r ftee rsd:io:~J.<ftoivcn 
oxidati·te events. It can ako prevent LDL oxidation and 
reduce oxidi.zed lDL uptake. wbicb will ~n~b$cquel'ltly 
lead to foam ocll and athcrosclerocic plaque formatiol'l, 
by dO'AI'lregulating tbe protein expres!lion of scavenger 
rettpt~ (42). 
Tbesrup.plenlena:at.ion of ' 'i1amil'l E (alone or in 001'11· 
binatkn) produces a lligl'li6cant impact on tbe parame-
tm l)f waioxid3nt st:atus, particularly in plasma antii)Xi· 
d3nt Cl'f'lacity and el'leyn1e· concentratiol'ls. Unlike vita· 
min ~vitamin C oontributcs in nellltflli.zing the radical 
(l)tm of l)tbct antioxidanas to tegain tbcir anOOxidant 
ability. Henc.c, il'ltervenli<>n using vitamin C did not 
sbow i•lpactful outcome. compared to those. using vita· 
min E. HOWC\>tr, inter.'tnti<>n using the combil'lation of 
vitamit1 C and E sbowed promi11ing rt!llllts in inel\.'asing 
GSH aad SOD activity (43·44). 
Con~iderablc etTons have. bttn J)lll il'lto scudying 
1be. antoxidant action of vita:nl in D in the past decade. 
Vitamin D may be. regarded as 3n antioxidant in tetms 
of thciJ boml)logous structute to eoholeslerol. Wisenlan 
e1 al. 11993) demot~S~rated 1bat vitamin 0 acts as a 
men1bnne antioxidant in view of its ability to inhibit 
iron-induced lipid peroxidation l)fbrain JipoSll)mes (4S). 
Morco .. er, vitamin D hti been reponed to attel'luate.I)Xi· 
dative. mess by up-regulating antiox:id3nt enzymes and 
J~upprc.-..'-$ing ~I¢Vo!ed lipid pcroxidlltio-.n (37,•G) . 
OxldtJJ,\·~ sfrn.t blom11rkus 
Tbereactions of free. radicals and anOOxidants occur 
il'lstantaneously; hence. it bcoon'ICs a major ptoblcnl to 
petfom direct mca1n11emem on oxidative. st:res:s (41). 
Thus, fie. indirect way tl) e'•aluate. oxidative !ittess is 
1brougb observable bi<>matkers (4.8). The. effectiveness 
of ana;>x:id3nt defense S)'Stem tl) oountm« elevated 
amounl!i of free radicals can be measuted by tbe levels 
of 1be endogenous antioxidant C'll2)'mC!l. Mcanwbilc, 
excess production offroe. radicals can be determined by 
mea!l'Uling the produets produocd as the re~n~l t of oxida· 
th•e. da~U.ge. caused by tl.cJle. species. 
ox;Jative damage comprises of ocllular protcin gl)'· 
cati<>n, membtane lipid peroxidatiM and tbe. damage. 
to nucleic acids (49). Among tbe. oxidative da:nlagc, 
augmCJ.ted lipid peroxidation bas been reponed to be. 
d()Sely allS<>Ciated with cbrol'lic hypcrglyc.cmia il'l OM 
(SO). OM alters !be. lipid ptl)61e.of tbecells by removing 
bydrogm from lipids tl) produoo •HROt· wbel'l attacked 
by ·RO., furti'ICr propagatil'lg the. fttt radical patbway 
(29). F'Unbermore, the natural presence. l)f multiple. 
bonds in polyunsatursted fatty acids in cell membrane. 
makes them more suscept:iblc tl) free. radicals fl)r lipid 
petl)xilatiol'l. 
·HT<O. can ex en Oirect toxltiry on ll'le-oclts; fl can be. 
deg.radtdio ·OH. or to reatl with transitioo metals (such 
as it on or ooppcr) to foml st:able.aldebydcll (30),~>Ueb as 
maloodialdebydc (MDA) tl) oonsequently damage ttU 
  
ml!fl'lbruei (SI). A stable- MDA has btea doeumeattd 
as a primary biomatter (S2) .., t\'alua lipid peroxi· 
datioa.. mostly studiod with Wobatbituric aeid reac1h'C" 
subs:t3Deet (TBARS) assays (S:3). Elc,·ated T'BARS aDd 
MDA k'\.""eli in pla$tl:'la. serum. atld other tissues india· 
betic patict~ts suuest that peroxidaU..·e iajury may bt 
in\·00.-N in the- dtvdopment of diabdts romplicarions 
( 12.50). 
vt..-o 
Vomin D is das:sicaDy bown for itt role as ~a. 
imponaot hom'lODt itt 1ninetal homeostasis aod tn3.i..ou· 
~of mUieu.loshletal hntm (S4). tfowt,.""er, vita.trllin 
D also pOtS:$CsstS aatioxictat. properties u potcru as.. 
ot tvea btuer thaD the e-13SS.ital atttioxichm \'itam.in £ 
(4S.SS-S7}. Funbrtm~, \'it::amitl D bas also been disco-. 
Vt:rtd 10 be a Pf)lftU hornlont daat txcrts sigrillicant bfo.. 
logieal ae6ons:. :sud! u indu.:tion of teU di:tfettl'ltiatioft. 
ttductioft in inflammation a.t!d imrnul'lomodulation. (SI). 
Vomin D is a fat·solubk vitamin. whrroby I'I!IIOrt 
tha.n. 90% ate obtairublc by CUW'IOOUS production from 
sunli,pa exposlft wbil-t only apptoxii'IUUiy I 0· 20% is 
obcaiord by dieury irttakt. lltert are twO major forms 
of viQIDil\ D. 'Atieb difftt chemically Ollly in 1hrir 
side- tb:aio$. Erg;oeticifcrol (viu.m.in OJ is .syntbesiztd 
by ultmiolct imdiation of plant Sl«oh (etgO!Iurol) 
and iavmebrates •'hlle chokeakifcrol (\itam.in 0 ,) is 
phocosylubes.ittd Uldogenously wbcn solar ultra"io-. 
lct B radiation wilh wa\'el«tgtb of280-320 nm suites 
hum3:!l qtidcm'lis.. lrradiatiOI'l siirmlatc:s ~
phodytic con,·tt'Sioft of pn>-,iwnin D (7-dtb>•dfocbo.. 
lcste:rol) to pre·vitan'lin D. thtrtaftcr UDdergoes tb£r.. 
mal isomctizatioa i:nlo \•it:J.mift Dl (S4)._ Vitamin D* is 
also ar;anually ptt:91tm in food especiaDy from attimaJ 
sour«s. s;ueb as oily fish, fonifled d.aity products aDd 
animal fats. 
Vomin Dis biok,gically iDm and oteds to be biokt-. 
gicaUy activated 'ia 1\'i'O bydroxylatiOC'l pro«sscs ill tbt 
body btfore. bcift& utilized far biological accions:. Va· 
min 0 it absoc1>td itt the sm:tiJ intestitles, tr'8XlSf'IOCUd 
via tht bete-al s:ysatm and t«r\' tycd \'~ the l)•mpltaric 
system into the \"mOUS tireubrion (S9). Vnamin 0 is 
then boutld to vitamin 0-biDditl& prou-iD (DBP), aDd 
is ttanSpOrttd to tbt livct via me blood citwlatiOI'l in 
this bound fotm: (60). ln W li\•er. hcp:Qt ctlls: tral!S· 
form vitamin D do 25-hydra:JcyvitamiD D. !S(OH)D 
( calcidiol) io tilt presence of <i>min D 25-bydroxybsc 
eltt)'l'lQe. Jn the- t:idDt')'. ! S{OH)O is tbeD metabolittd 
either Uurarenallyby 2S(OH)O-lo.·bydrozylage enz)""'!Dt 
ot intratcllularlyaa atra·UC3:1 sites in • vsridy of «Usl 
tisS'IJtS.., tbe. physiologically ldi\'t vit3Jb:i:ft D, I~· 
bydtoxyvitamin D. 1,.2S{OH).D (talc:iaiol) (S9.61). 
I ,.2S(OH)lD entered the bl~am to act as the pri· 
mary suroid b.ormont. in mitltral al'ld shkton h<>meos:· 
tasis. The pro«s:s of \'itamitt. D synthesis at1d meubo-. 
lism is illuittatcd ia Figure 3. 
v,, ... ;. D slim•• ~~ s~ppi~~"J"tltJtt 
l:nsuad of J,25(0H)JD, serum 2S(OH)D is the l'l'IIOQ 
common detcll'l'liDan.t of viumin D ~I in tbc body 
(62). nu is in ..vw of its klagct dreulatitl.& balf~li!l!' 
of lS dr)'t (63); i1 is abo tbt primary tK"tubting form 
of \'itam.itl D (64). Tbe le\'tl of S>eNm 2S(OH)D reflecu 
the- precise storttt amount of ~tamin D (both by JKibr.. 
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activated t~J~antous procb:aion and lclllg petiod dietary 
iablce) in tbt human body. The swus ofvitamiD D (de~ 
fideaey, insufficiency Md sufficiency) in the body tan 
bt- ckflned aftt:t measurtmen'l of SltnJm 2S(OH}O. The 
Ettdotfinc Soddy ddiMS vitamitt D i.nsuffitieuy as 
sc:rum2.S(OH)D bctwcna50--74l'ltldll., serum 2:S(OH) 
D of les:s: thaD 50 nmoLIL as vitamia. D defleieacy (6S) 
whik \'it:amita D !ruffieimey as SMJm 25(0H)D of at 
leas:I7S nmolll... The oprimaJ range of7S·I25 amol/L 
is ttetdcd to optim.ize i:mrstinsl Cllciu!:'l absorptiocl and 
10 c:owr all pbytiologieat fuflc-tions ofvita:mjn 0 (66). 
HJ7H!rvi111..U.11Sh D 
H)•petYit:l!bino5js 0, or eommoaly known u vita· 
mift D toxicity, oecvrs when tues:t pba.rm:tCOiogic 
doses of \iwnin D is 1:lken, ll'lmSbtit!& to a bfte jn. 
trt:8$1C in circWating 2:S(OH)D COIIIM'ltratioa, that is 
beyond DBP bitldjng t~paC:ity. Exclt:s:s.h·e sun e-xposure 
dots no1le3d 10 hypenir:lminos.is 0 as J'll't·vjlllll'litl D~ 
wiD undcrzo pboto~gnrdation to iftattive sterols in 1be 
skiD (S4). Tbt main elitsical tClns:tqu.meei of ,itunift 0 
uWeity art hypettalotmia and olbtt syntptoms ioe!u· 
dirlg hypen:ak:iuria, ectopic caltitieWons, bypctphos· 
pbalemia,. kidney stones. polyuria aDd polydipsia, h>·· 
pc:mns:iOI'I, $DOC'ttia, GIII:Siel,- \'Omitil!& and ~tioo 
(62). Ah.hou#l it is uncommon. hypen<itaminosis D has 
lt«a reporte-d itt •nul1ipk ag.e groups and from multiple 
ews:ts. inc:luditlg manuf:acruring errors (67). etn:ln in 
milk fortification (68). iac:orTtct dosing from liquid prt~ 
p~n~tions (69) at1d ingesboo of meg~ dMles of viantin D 
~kments (10}. T~ are s:tudies w.itieb lw1 re-poned 
lD itlc:rcast its wocr irridcnt rates JOd 1noru1Iy riW 
a1 both k»w ud high levels ofscrutD 2S(OH)O (71-72). 
Nimtsb «a/.. (201S) rqtOntd tbat a ooe_.year old cbild 
dtvtJoped acue hypenauk>n and SI!'Vere. h)i1)C:ttaJet~ 
mia due 10 m.m.in D toXicity al\tr higb dosfS o-f oral 
c:akittiol supplementa:tice (70). Gallagbtt (20l6) •lso 
showed thai dlot adminisaabon of tn~Ual botus doses: of 
,-amin D at c:on«l'lttatioa of300,000 ru or soo.ooo ru 
t«UUtcd in tbt itlcreastd rid: of falls atld fratnutt (7l). 
'Thertfott. Ulllil further n ·Wknce is available. a ~UO· 
uble uppet lin'lit for 2.S(OH)D levd at 12S nmoVL (SO 
D&hnl-) is suues:tcd jn dckrt)' indj,;dna.Js (7:3). ittfants 
(74) and h<Uhy )'Oung ..milS (15~ 
Vltamlft D s.tatus ud dl:abf.tes mt.llnu 





especially in OM. k>w ' 'itamin D lcrvcl is suggested as 
ooc of tbe. risk factors (59). This is inlll'J)C)rtcd by statis-
t.ies showing high ptevalenc.t. ofvitan)in 0 insrulfidency 
and deficiency Otturrirtg in the diabetic po-pulation; 
9 1.1% in India (76), 73.6% in Saudi Arabia (71) and 
43% in Malaysia (78).Studies bave. shown that higher 
vitamin 0 levels were. ~sSlOCiatcd with 4~A. k>~A<tr ride 
ofT'2D~1 in women while djocts tb:u developed dia-
betes bad lowcr vitamin 0 levels (scrum 1S(OH)D < 5() 
nmoVL)compared co DOn-diabetics (79). This rru.ggcstcd 
that low cireulating vitamin D coDCenCrations played a 
sigrtificant tole in the patlk>gcnc~is of OM. This might 
occur via dccrea~~ed pancreatic insulin release, under-
sooted insrulin resistance. reduced insrulin sertsith•ity and 
deteriorated glucose.col~rance. (80). This is 1nJPI)Oflcdby 
Wang's study, whereby the incidence of ad\"Crse. CVD 
y;•as doubled in individ.uals with low vitan)i:n D lcrvcls 
(~~erum 2S(OH)D <37.5 nm<>l!L) in a 6-)'i!ar-period stu· 
dy(l6). 
Moderate or SC\'erc ' 'iiamin D dcflcicDCy also in-
creases tbe. activities of glutathione-do:pendertt enzymes 
(16), resuhcd in ovi!tJModuction of ROS in diabetics 
(81). Vitamin Dsupplcmerttation might be. an alternative. 
way to improve tbe. \'itamin 0 lcrvcls in tbe. body, wben 
there is irt~n~fficiena: cutanco'US production or dieta:ty in-
take. Vita:min D, rrupple:nlena:ation is 87% more effective. 
in rais ing senuu 25(0H)D le\•el compared to vitamin Dt 
as it is converted SO~A. f3:S(et to cakitti<>l, the. biok>gi-
cally acth<t· homlone.(8.2). Vitamin D, is also tbc natural 
form of vitan1in D pi'O<Woed by our body wbicb is more. 
pocena: in rais ing and 1M in1aining vitamin D conoentta-
tions in the. circulatory system longer, and produces 2-3 
fold greater scorage of ...,itamin D. Be~ ides. the. action of 
vitamin D~ is approximately three times 1nott effective. 
bceause it binds with high affinity 10 DBP in plasma, 
thus it can stay longer in cbc. circulation (59). 
Vltand n 0 status and l)sJdattve streu 
In some. scudics invo.lving hu:m3:n and 3:nimal models 
of diabeu~s or vitamin 0 deficiency, supplementatioo 
with vitamin 0 showed rtd~tetioo in the levels of oxi-
dative. stress (37-38,83-.84). Caleitriol supplen'lentatic>n 
had been shown to imprO\'e SOD ac.tivities and rtd~tee. 
ROS prod~teti<>n in rcoal attcries of hypcncnsiw pa-
tients as well (81). 
In diabetic rats, bigh lcrvcl o( serum 'mAltS was 
significanlly rtd~tecd .warly to control \'alues after the. 
tu:atmeot with vitamin o , (83). In as>•mptomatic vita-
min Q.(l.e6cicnt srubjects. supplementation with vitamin 
D) (300,000 IU mortthly for 3 n'IOnths) significantly de-
creased serum TBARS similar to that of basal TBARS 
in control group (84). I" srubjects with T2DM, treatment 
with vitamin D1forti6ed doogh (SOO IU twice a OA<tck 
for 12 weeks) showed reduction in MDA and inercascd 
GSH lc\-els (37). How...--wvcr, treaunertt with ' 'itamin D~ 
capsules (SO.OOO ru twioo) did not affect the biomar-
ker of oxidative. stress ().1DA and GSH lc\-els) in wo-
men with GDM (85). Similarly, Efterthari e1 fll. (2014) 
reported that thc:re. was no s igrtitlcant change in MDA 
lcrvcls in T2DM subjee>1s after teooiving caleittiol sup-
plementation (0.5 JAg/day for 12 weeks) (86). Another 
scudy in T2DM vitamin 0-dcfieient patiertts reported 
that vitamin D) treatment (S,OOO IU/day fot 11 weeks) 
did noc signifieantly alf~c.t SOD le\•cls (87). .. 
The. difference in 6ndings bet'A<tc:n these studies 
might be due to: I) vitamin D dosage. ~nd study dllta· 
cion; 2) lhe scatus of vitan)in D in cbe . .cbo~~eo diabetes 
populati<>n studies; and 3) the. type of vi ta:min 0 a.nalog 
used in the: srudy. No i:mprovenlcnt to oxidative scrcs:s 
markers was obset\'ed in the. study by Yiu t!r uL (2013) 
despite incretie in ~~erum 25(0H)D lc\-els. The vitamin 
D) dose given for only a sbort duration of treatn)ent ( 12 
wctb) may not be adequate. to sufficiently inotease tbe. 
alteady low baseline scru1n ' 'itamin 0 levels co theta· 
pcut.ic le,<tls in their study srubjocts (87). No eJfe.ct of 
vitamin D) srupplen)entation on oxidative. stress markers 
in women with GD~1 might be. caused by insufficient 
dosage ofvita:min D~giwn 10 tbe. study srubje.cts,. wbicb 
was SO.OOO JU pcr capsrule givcn twioo througho-ut tbe. 
scudy pcriod of 6 weeks (85). Tbc type of vitamin D 
anak>g used for the tl'l.'atment was al!rll) a eritical indi-
cator. Vitamin o , pcrforms bc1ter than \o'ita:min D as an 
clfecch•e. supplemertt because. non-aetive vitamin b me-
iabolitcs mighi f.aec i.m!)Qimwnl in lheit conversion lo 
cbe. acth<t metabolite, especially in patients with kidney 
problenlll. This resrults in rcdll(:tioo of tcrum vitamin D 
concentrations in the. cireulation that is able co improve. 
oxidative stress in diabetics. A limitatic>n 10 the irttcr-
prctation of the: effect of vitan1in D ~n~pplcmentation on 
oxidative scrcs:s is. some. articles did nol report baseline. 
levels of vitan)in 0 and oxidative stress bion1arkers of 
c.1~ol.lcd J)Qliena:s before srup.plenlentation. These para· 
mccm should be. measuted to display better ouroome. on 
cbe. beneficial effect of vitamin D inlppkmcntation, and 
also to eliminate the. impaec of confounding variables 
cb:u might intcrf~'fe with the. results. 
A study reported on the polential of vitamin 0 1 sup-
plen)entation either as a preventive measure or theta· 
pcut.ic strategy in diabetic tats. Diabetic rabl rccci,•ed 
5000 lU/kg bw/day vitan1in D, srup.ple:nlena: by gastric 
gavage before. and after alloxan-induction rospc.ctivcly 
fM 2 months as pi\..'Vtntive. and cberapeutic groups of 
diabc1cs. The rcsrults showed that administration of 
vitamin 0 1 in bolh groups (pNwerttiw and therapeutic 
groups) c:nbanccd l.epatic and renal attivity of SOD, 
CAT and GSH-h. as ~A<tll as reduced lipid peroxidation 
as indicated by decreased TBARS le\•el compared to 
untr..'atcd diabetic rats. Hov;·ever, vitamin D might play 
a better role. in rogulatil'lg oxidative stress ptior 10 tbe. 
dcrvclopmena: or diabetes as s.bown by the bc1ter signi-
ficant impro,•eruent in the: pNwerttive group compared 
co tbc therapeutic group of diabetic tat!lil (38). Tbe.rcla· 
cionsbip bct'Attn vitan)i:n D interventioos and oxidati\'e. 
stress b}omatkers in al'limal and human. studies is swu· 
mari:ud in Table I . 
VJcamlo D status a nd atbt.rosd erosls 
Epidenl iological studies denlonsu-ate chat low le-
vels of vitamin D is a risk factor for development of 
athc:rosclei'O!Iis (88). Vitamin D dctlctency correlates 
with endothelial dysfunC1ion, vascular smooth mu~~ele. 
c.tll (VSMC) prolifcrati<>n and mig.ration, augmented 
syscemic inflammation. iDCreascd inti:ma-media thic-
kness (1~1T) and enhaDCed oxidative ruess in the de-
velopment of atherosclerosis (16,89-91 ). 
Endothelial dysfuntioo is tbe. precursor of ea:tly atlte· 
rosdcro~is development. which is due .o cbe. imbalance. 
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conttaeting factors. Vitamin D exctts diteCI \'UOJ)tOtCC· 
th<t effects agaimt endothelial dysfunction by enhan-
cing eDCJo.tbelial-dcpcDCknt \'Uorelaxation and inhibi· 
ting va!ilOCOntraclion (92-93). Vitamin D imptO\'es tbe. 
bioaw ilabityof eodotbd ial ni tric oxide. (NO), tbe. potent 
V'tiOtdaxing factor and inhibitor of platelet and k uco-
eytc aggregation and adhcsktn. Tbis OCC\l.t$ via dir«:t 
enhancement of transcriptional regulator of endothelial 
nitric oxide. synthase. (eNOS) (94) and/or exert dTeCI <>n 
phosphatidylino!litol 3 kinase in endothelial ocll (EC), 
which acti,•aus eNOS to catalysc the pt<>duetion of NO 
from L-arginine. (95-96). By iDducing NO prod:uction, 
vitamin D able co stimulate. EC proliferation and inhibit 
apoptosis (97). Vitamin D also induces tbe produccioo 
of prostacydin in VS~tC through the t)•dooxyg.enase. 
(COX) pathway, which prevents thrombus (l)tlnation, 
cell adbc!lion and VSMC proliferation (9&-99). Be!lidcs 
tbat, vitamin D interferes witb calcium influx inao tbe. 
EC ( 100), decteascs tbe expression of COX-2 and 
dOW'flf'egulate!l the expression of prost:aglandin recep-
tors to reduoc the. producti<>n of W.SlOCOnslriCiors (101). 
!Mi. wbieb is a teflcccion of atherosclerotic burden 
Yi'U reported to be. negatively tdated to ~~erum 2S(OH)D 
coDCernration (90). Tbero was marked iDCrease. in caro-
tid anery J~IT in T2DM patients with low vitamin 0 
levels compiU'Cd to lbo,.c- with bigbcr vitamin D Jcveb . 
T2DM patients who dcrvclo.pcd carocid plaoque hu s i-
gnificantly lower 2S(OH)D oonc.cnuation compared to 
T2DM patiena:J~ withOoUJ carotid plaoque (102). Vitamin D 
aDd it!! analogue wppre!ls the. mttohanisms that leads to 
incteased J~IT and \'Ucular calcification by inhibiting 
tbe. owr-expres:sion of multiple adhesion tn<>leculcs oo 
EC (91) and tbe. accwnulati<>n of plaoquc lipid in VS~tC 
( 103). 
Vitamin D al!IO bu ami-inftammaiDty prope11ies. 
It may wppre!!s the producti<>n and release of SC\'eral 
pta-inflammatory (91) and iDCI\.'!.Se tbe productioo of 
anti-inflammatory cytokine!l (104). Vitamin D doYi'nte· 
gulates tbc intlammatoty process by limiting the major 
tole ofT-hdpct I in pro-atherogenic response. and shif· 
til'lg the T-een response ftom T·htlper I co T-hclpcr 2 to 
limit tbe. pro-atherogenic re!lp()nse.( l OS). Vitan)in D dis-
plays anti-atherogenic propeniell through an endoplas-
mic reticulum (ER) strc!!!Hkpendcnt meehanis:m. ER 
st:ros:s is a functional switcb that oon~rol!! macrophage. 
differentiation which may ha\•e. a role in atberosdetot.ic 
plaque tegrcs:sion in diabctics ( 106). Vitamin D acts as 
ER stress rctie\•er to ptC\'tl'll foa:m cell fom)ation duting 
macrophage. differo.ntiat.ion, reduoc tnacrophage infll· 
ttation and migration and !itimulate an lll'lti·atberos,cnic 
macrophage. pbcn()type) thus reducing va~~eular intlam-
matJon and compueatJons in Tl.DM patJent!l. VItamin 
D also revinC!l atherogenic cholesterol metab<>tism de-
position by prevcnting the I)(Ogtes~i<>n of macrophage. 
cbolestc.rol uptake. and pron)()ling cholesterol cgtes~i<>n 
in ma.crophagcs from T'2D~1 patiena:J~ ( 107). 
In ordc.r to counteract tbe. dominant effee.t of oxida-
ti\'t· stress in human cnd<>tbelial cell!!, vitamin D analogs 
ace a!! a negath•e endocrine tegulatot of the tel'lin-an-
gioten~in S)'Sittn by reducing tbe renin synthe!lis (108). 
Vitamin D also inhibits tbe aug1nentcd pt<>duction of 
ROS. cs:pecially !rup(:roxidc anion ( 100) thtou.gh tbe au-
tbophagic and survival pathways ( I 09). Vitamin D al!ilO 
imprO\'tS SOD, CAT. GSH·Px in enhancing antioxidant .. 
defense mttohanism and tedutc:s lipid pcroxidatiM tbat 
willle3d to oxidative. cell damage.(37-38,83-84). 
Coocluloo 
The rehtion~hip bclw«:n ''itamin D levels and oxida-
ch•e. strt!IS in diabete!l has been quite. well !Oiudied. Low 
vitamit1 D levels substal'ltially impaired insulin and glu-
cose m:tabolism whkh may comnDutc to tbe pathoge-
nesis and development of OM. Chronic b)•petgl)<ecnl ia 
in OM futther disrupted the homeostasis betYi<tcn the. 
generation of radical specie!! and tbe. elfcctiwnc!lsof en-
zymatic al'ltioxidant defense system (47), prodispo~in.g 
co tbe jevelopment of diabcles-rclated cardk>Vticular 
inciderw!! and its complicatktns. leading to morbidity 
and roottality. 
O{M:i•ml oontrol of blood glucose lcrvcl might be able. 
co dov down diabetes complication!!, although it is 
not: abb to oomplettly prevent diabetes complication!!. 
Thus, (\•icknccs oo tbe ability of antioxidal'ltS to regu-
late oxKiative. strcs:s in diabcte!l ate. compelling and sug-
gests potential additional treatmena: !itJ'ategy to reduce. 
cardiO\IISetdat ri~k and complications in diabetes. In 
view that ''ita:min 0 wpplen)entation is able. to improve. 
many cardiovucular bionlatkers in both diabetic (78, 
110) ard non-diabetic (I l l) population with vitamin D 
ddidu.,;;y, il n).ty be 11 po1cmi.d .U1.\llllun) in «guLuins 
oxidati·te stress undetlying diabetic complications. By 
corrcctng the vitan)i:n 0 kvell! a!! shown by acctunula-
cing eviden«:s in epidemi<>logy !!tudics, enhanced oxi-
dative. damage. and roduc.cd antioxidal'lt activiti t ll might 
be tc\<mcd or at least imprO\'td in diabetic population. 
Even tllou.gtl clinical trials oondue.tcd to date. failed to 
provide adequate. support for the. implementation of 
vitamit1 D !!uppkmcnt il'l diabcte!l treatment, but they 
did shew improvcnlcnt on ocnain biomartcn for car-
diovas<ulat health. Thus. using ''itamin D ~n~pplcmcnt 
in diab!les treallnena:, especially in vitamin 0-deflcicnt 
and in9.1tflcicnt patients, definitely deserves furthet as-
scssn'ltnt and con~ideration. 
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OA06 VITAMIN D DEFICIENCY ATTEl\'UATES 
MICROVASCULAR ENDOTHELIAL FUNCTION IN 
MESENTERIC ARTERIES OF DIABETIC RATS 
Wtt Cbrt Lf!! Siti Safiab Mokbw, Sahran Yahaya, Ai~U Hanum Obulam R.uool 
School of Medical Seieoees, Urti\'tnitl Saizu MaLaysia, 161 S-0, Kota Bbatu, Ktl.afttaft. Malaysia 
Objecth·e: To study the effects of vitamin D deficiency on mjcrovascular 
endorhelial function in streptozotocin-induced diabetic rats. Thereafter, to 
im·estigate the effects of oral calcitriol treatment on endothelial function in 
diabetic rots wilh vitamin D deficiency. ~lethodolo&Y: 30 Sprague Dawley 
rars were induced for diabetes with 50mglkg streptozotocin intraperitoneally. 
They were randomly divided into lhree equal groups (n= I 0). Diabetic control 
group (DC) received normal diet, diabetic \"itamin D-deficient group (DVD) 
received vitamin 0-deficient diet. while diabetic supplementation group (DVS) 
received vitamin ID-deficient diet and started to recei\'e 4 weeks O. lSJJglkg 
calcitriol daily by oral ga\"age from 7" week after diabetes induction. At lhe end 
of 10 weeks., all rats were sacrificed. The mesenteric arterial rings. with and 
without endothe.liwn, were studied for isometric force measurements us-ing wire 
myograph. Results: The study showed significant reduction in endolhetium-
mediated relaxation to acetylcholine (ACh) and significant augmented 
contraction to caJc:ium ionophore (Cal) in DVD group compared to DC group 
(ACh - DC: 53.48±6.316% VS DVD: 30.06±3.042%. P=0.005) (Cal - DC: 
58.78±8.093% vs DVO: 97.55:1:6.578%, P=0.002). By treatment wilh calcitriol, 
DVS group showed significant erlhanced re.laxation to ACh (DVS: 
48.34±2.641 %, P<0.05) compared to OVO group while !here was no significant 
reduction in contra<:tion to Cal between these two groups. There was significant 
reduction in relaxa1ion to sodium nitroprusside in DVD group compared to DC 
group (DC: 67.83:1:6.993% vs DVD: 34.42±2.986%, P=O.OOl), while lhe DVS 
group showed significant impro,·ement (DVS: 52.24±5.071%, p--0.007) 
compared to DVD group. There were no significant difference in relaxation to 
salbutamol and contraction to phenylephrine among lhree study groups. 
Conclusions: Thi$ s.tudy showed that \·itamin D deJiciency in diabetic rats 
attenuates eodothellium and smooth muscle function by reducing relaxation and 
enhancing contracltion. Treatment with calcitriol may be the potential therapy to 

















AuJmented Acetylcholine-Mediated \ "asodilation In Aona Of Diabetic \ "ltamin D-
Delitient Rats Alter Treatment With Caltitriol 
•v._u, .• s. Mot~~L~t ss. 'l..eto we, 'Ab Am ca. Glml.am R.atool AH 
10rrlttJ,onlic DIJitll'f'N1U, H~p::d Liuwnm ~ -~11Cl ~ .c.n.. X.~~ 
'PltllnNitokiD I>tpailvuN.. tl~t.:nntti ~ JI.J~:;icl ~ Kuil:ft. XI:~ ~"Jill 
INTRODUCTION: 
Recent 0\idence SUJ!gests !hat \illlmin D-
d.tiaency 11 USOClated mth endoilielial 
,-U<IIlar d),llmction and mcreued risk of 
eardio,·ueular dt~a5es. The pre>·alence of 
\1tamin D-deficteney ts htgh in diabetes mellitus 
(DM) plltients. It is not well-known whether 
vatamin D supplementatlon in diabetic patients 
\\~th vitamin o .deflciency will cause reduction 
tn endothelial dysfunction. The aim of this study 
at to ev&luate the effect of oral vitamin D 
supplementation on the aortic endothelial 
function of rats with vitamin 0-deficiency. 
MATERIALS & METHODS: 
Diabetic rata (n•24) were induced ,.;th 50 
mgllcg atreptozotocin and were divided into 
three equal groups: diabetic controls that 
received normal diet throughout study duration 
(DC), dtabetie \oitarnin D-deficient rats "ithout 
supplement (DVD), and diabettc \oitamin D-
defieient rata \\ith supplement (DVDS). 
Diabetic vitamm 0 -deficient rats were 
developed by using \oitamin D-deficient diet 
throughout I 0 weeks of study duration. The rats 
m DVDS recel\'0<1 oral gange of 0.15 ~glkg 
ealcttriol supplement for four weeks. At the end 
of I 0 weeb, riiS were s.acrificed and aortic 
rmga \\ith and \\1lhout endotheliwn were 
studted in tissue organ baths for isometric force 
mtasurtment. 
RESULTS: 
Body \\'tight of rats m DVD group were 
sigDiliamtly mcreued compared to baseline 
(\\"eek 10; 332.3&±16.2Sg \"S. Baseline; 
2$3.75>9.16&}, \\iler .. s sho\\'0<1 reduction in 
DVDS (Buehne; 272.2~12.13g , ... Week 10; 
230.2S.t12.53g) (p<O.OS). The endoilielium-
mediated vuodtlabon to aet'!)1choline was 
simtlar in aorta of DC md DVD. Aoetyleholine-
mdueed endotheliurn-medtated ,·uodtlation was 
sigmfiamtly increa5ed m aorta of DVDS 
(89.05:6.093%) compared to those in DC 
(63.47±10.65%) and DVD 8J0UP1 
(61.88±5.06%) (p<O.OS). There wu no 
signifieo.nt difference in \-uodilatlon to aodtum 
nitroprusside and eontnction to either ealaum 
ionopbore or phenylephtine between IQrtu of 
the three study groups. 
DISCUSSIONS: 
This study demonstrates that 'itarnin D-
deficiency does not exacerbate endothelial and 
smooth muscle dysfunction in aorta of dtabeue 
rats. Interestingly, rats !hat re<leh'Od ,;tarnm D 
supplement show significant reduction in body 
n·eight. T reatrnent with ealcitriol unproves 
endothelium-dependent nsodtlaUOn m IAlftl of 
diabetic rm "ith vitamin D-defieieney. 
CO<'iCLUSION: 
Vitamin D em be on adjunct therapy 10 reduce 
cardionscular risks m dt.abellt pallents. Further 
studies to support the use m ehnical settillg •• 
n-.mnted. 
IU.ITRE.i'iCES: 
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Calcltriol Supplementation Ameliorates Microvascular Endothelial Dysfunction 
In Vitamin D-deflcient Diabetic Rats by Upregulatlng eNOS Expression and 
Reducing Oxidative Stress 
Rasool, Aida Hanum Ghulam (s) 1 ; Mokhtar, Siti Safiah'; Singh, Kim pal Kaur 
Banga2 and Wee, Chee Lee'' 
'Department of Pharmacology. 'Department of Microbiology & Parasitology, School 
of Medical Sciences, Universiti Sains Malaysia (Health Campus), t6t50 Kubang 
Kerian, Kelantan, Malaysia. 
• vchillie88@gmail.com 
Background: Vitamin 0 deficiency in diabetics contributes to endothelial dysfunction 
and augmented oxidative stress. Correcting vitamin D status by supplementation 
might be a potential intervention. 
Objective: To evaluate the effects o f calcitriol supplementation in ameliorating 
microvascular endothelial dysfunction and oxidative stress in vitamin 0-deficient 
diabetic rats. 
Methodology: Streplozotocin-induced male Sprague-Oawley rats were divided into 
three groups of tO rats each. Diabetic controls (DC) received tO-weeks normal diet. 
vitamin 0-deficient diabetics (OD) received tO-weeks vitamin D-deficient diet, while 
the supplemented group received t 0-weeks of vitamin 0-deficient d iet with 4-weeks 
oral calcltrlol supplementation (ODS) (O.t5 mcglkg dally. five times a week). starting 
from week 7 o f diabetes induction. At the end of t 0 weeks, microvascular endothelial 
function of mesenteric artery was assessed using wire myography. Endothelial nitric 
oxide synthase (eNOS) expression was determined using western blotting. 
Immunohistochemistry was used to detect the presence and localization of eNOS. 
Tissue superoxide dlsmutase (SOD) and malondlaldehyde (MOA) levels; FBG and 
serum 25(0H)O levels in blood were measured. 
Results: Calcitriol supplementation signifiCantly improved the attenuated 
endothelium-dependent relaxation In mesenteric artery of vitamin 0-deficient diabetics 
(Rmax (DOS: 48.40±8.41% vs OD: 28.45±t 0.70%)]. However, augmented endothelium-
dependent contraction and impaired sodium-nitroprusside-induced endothelium-
independent relaxation in vitamin D-deficient diabetics were failed to be ameliorated 
by calcitrlol supplementation. Besides, calcitriol supplementation in vitamin D-deficient 
diabetics significantly increased SOD and reduced MOA levels; eNOS expression is 
also increased. 
Conclusion: Calcitrlol supplementation ameliorates microvascular endothelial 
dysfunction in diabetics with vitamin 0 deficiency by upregulating eNOS expression 
and improving oxidative stress status. 
Keywords: vitamin D: diabetes meOitus; oxidative stress 
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